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“In the Brain the appearance is so peculiar, and so little capable 
of illustration from other parts of the body, the surfaces are so 
soft, and so easily destroyed by rude dissection, and it is so 
difficult to follow an abstract description merely, that this part of 
Anatomy cannot be studied without the help of Engravings.” 
Charles Bell  
(from The Anatomy of the Brain, Explained in a 
Series of Engravings, 1802) 
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Summary 
 
During the last few decades, in vivo brain imaging has undergone substantial changes. The 
first brain images, obtained using X-ray-computed tomography, could only provide structural 
information. Subsequently, magnetic resonance tomography provided a better understanding 
of the brain’s anatomy. Nowadays, functional information can also be measured, dramatically 
improving the understanding of brain physiology and pathophysiology. It has been 
demonstrated in numerous studies that the ability to capture functional readouts from the 
brain is of considerable benefit in a range of situations. Detecting the accumulation of 
radioactive ligands is one of the most common functional imaging modalities. Among these 
modalities, the most prominent detection method is positron emission tomography (PET). 
When performed with suitably labeled agents, PET allows the detection of biochemical 
processes such as glucose utilization and ligand-receptor interactions, and other 
physiological processes such as blood flow and amino acid transport. In the brain, one of the 
most frequently used radionuclide techniques is the glucose utilization measurement made 
with radiolabeled 2-deoxyglucoses (2-DG). This technique was first used in autoradiographic 
studies using a carbon-14-labeled 2-DG compound in the late 1970s, and then a few years 
later with PET as fluorine-18-labeled fluorodeoxyglucose. Since then, countless studies have 
been performed. The notion that increases in brain activity are tightly linked to the rate of 2-
DG uptake has made it a precious tool for neuroscience. 
Despite extensive use of the method for studying brain energy metabolism, the precise 
mechanisms involved in processing glucose in the brain are not well understood. It is widely 
accepted that glucose constitutes the main exogenous cerebral energy substrate, but the 
exact allocation of the total glucose uptake to different cell types remains uncertain. Neurons 
and astrocytes are the two main cell groups in the mammalian brain. The classic view is that 
neurons adjust their glucose uptake to match their energy needs. In contrast, a concept 
introduced 17 years ago postulates that activity-dependent uptake of glucose occurs mainly 
in astrocytes, leading to increased production of lactate. Lactate is then transported via 
specific monocarboxylate transporters from astrocytes to neurons. In neurons, lactate is then 
used as an energy substrate. This concept is known as the astrocyte-neuron lactate shuttle 
(ANLS) hypothesis, and remains a significant controversy in the literature. One of the main 
reasons for the ongoing debate is the lack of in vivo data, as most of the available evidence 
is derived from in vitro studies, which by their nature do not reflect normal physiology. 
A major focus of my recent research has been exploring different aspects of cerebral energy 
metabolism in the intact animal using a multimodal approach. Using radiolabeled acetate, we 
were able to demonstrate an activity-dependent oxidative metabolism in astrocytes. The 
active involvement of astrocytes in neuroenergetics is a new finding and we were the first to 
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demonstrate the feasibility of using label clearance as a measure of astrocytic oxidative 
metabolism. The radiotracer approach using a PET nuclide allowed us to transfer the 
experiment directly into a human setting and to reproduce the findings obtained in animals. If 
the ANLS hypothesis is valid, it is essential that neurons are able to use lactate as an energy 
source. However, at the time, only limited in vitro data were available that suggested neurons 
were using lactate. In a further study, we demonstrated the ability of lactate to sustain 
neuronal activity in the intact animal. We showed activity-dependent cerebral lactate 
oxidation and a preference for lactate over glucose in the brain. 
Of course, functional imaging is not only used for basic neuroscience but also for clinical 
applications. PET is a powerful tool in the diagnosis of neurological disorders. In particular, 
its use in the diagnosis of glioma has gained considerable interest during the last few years. 
The most widely used radiotracer for brain (tumor) imaging, 18F-fluorodeoxyglucose, has a 
number of limitations, mainly due to the high intrinsic cerebral glucose utilization and the 
consequent difficulty of differentiating normal from pathological tissue. An additional 
shortcoming of 18F-fluorodeoxyglucose is its uptake in inflammatory tissue, which aggravates 
the difficulty of differentiation of e.g. radiation necrosis from tumor recurrence, one of the 
major clinical indications of PET imaging. Therefore, the development of more specific 
radiotracers is a general aim of nuclear medicine research. However, thorough validation is 
required prior to the introduction of a new molecular probe for clinical application. In this 
context, one aim of my work has been to evaluate the tracers 18F-fluoroethyl-L-tyrosine, 18F-
fluorocholine and 18F-fluorodeoxyglucose in several animal models to determine the tracers’ 
specificity for brain tumor imaging, and to quantify the impact of several factors on the 
tracers. We tested the uptake of the three tracers in an experimentally induced radiation 
necrosis model and in cryolesions. Based on these measurements, we showed that the 
amino acid analog 18F-fluoroethyl-L-tyrosine and the choline analog 18F-fluorocholine are 
feasible tracers for the differentiation of radiation necrosis from tumor recurrence. In addition, 
we measured the accumulation of 18F-fluorocholine and of 18F-fluorodeoxyglucose in an 
abscess model to assess the uptake of these tracers in inflammatory tissue. Notably, we 
observed pronounced 18F-fluorocholine accumulation in infectious tissue, which clearly 
reduces the specificity of this tracer for applications in oncology. On the basis of these and 
other studies, 18F-fluoroethyl-L-tyrosine PET is now used in patients who have been treated 
for glioma to discriminate between treatment residuals and recurrent glioma tissue. This 
important distinction allows better treatment decisions. 
Metabolic changes often precede structural alterations. Therefore, we hypothesized that 
tracer imaging may also be helpful for refining therapy monitoring in brain tumor patients. In 
low-grade glioma patients, we observed an early metabolic response to temozolomide 
treatment, which preceded detectable changes in magnetic resonance images, the standard 
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imaging modality for treatment control. By demonstrating that molecular imaging has an 
advantage over structural imaging in low-grade gliomas in terms of the early identification of 
response to treatment, we proposed that PET data could be used to define and adjust the 
duration of chemotherapy. 
 
In summary, my work encompasses a broad range of applications of radiotracer techniques 
ranging from basic brain research purposes, to preclinical radiotracer testing in animal 
models, and finally to clinically relevant problems. In the future, new imaging modalities and 
novel combinations of imaging techniques such as hybrid PET systems (e.g. PET/MR 
scanners) may further enhance the clinical impact of radiotracer techniques. 
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Background 
 
In 1802, the Scottish anatomist Sir Charles Bell portrayed the anatomy of the human brain in 
a famous series of lifelike watercolor plates demonstrating the beauty of our brains (Bell 
1802).  At the time, no one could have imagined that it would be possible in the future to 
image brains in living organisms. Less than a century later, the demonstration of the first 
radiograph by Wilhelm Roentgen in 1895 opened a new window to medical diagnosis 
(Röntgen 1898). His discovery was the starting point for even more amazing advances in 
imaging during the following century. In 1961, William Oldendorf developed the theoretical 
bases for computerized tomography (Oldendorf 1961). Two years later, his idea of a new 
instrument incorporating the principles and hardware eventually used by modern CT 
scanners was patented. However, manufacturers of X-ray equipment were not aware of the 
potential at this time. Only Sir Godfrey Hounsfield acknowledged Oldendorf’s studies in his 
own work which led to the invention of the X-ray CT scanner (and the Nobel Prize for 
Medicine in 1979 (Hounsfield 1973)). Since then, technical advances have been rapid and 
the next milestone was achieved as quickly as the mid-1970s when magnetic resonance 
imaging (MRI) was introduced by the chemist Paul Lauterbur (Lauterbur 1973). The same 
decade also saw the development of positron emission tomography (PET), which became a 
tool for medical diagnosis by the mid-1980s (Phelps et al 1975; Phelps and Mazziotta 1985). 
This impressive progression in the development of neuroimaging methods has continued 
until today. In this regard, in vivo optical brain imaging methods should be mentioned. In vivo 
imaging using light has seen 30 years of intense development and provides sensitivity to 
functional changes and temporal and spatial resolution not so far seen. Currently, a wide 
range of approaches is applied such as intrinsic optical imaging for the detection of variations 
in the oxygenation state of hemoglobin (Dunn et al 2003), voltage-sensitive dye imaging for 
the measurement of neuronal activity using fluorescent dyes bound to neuronal membranes 
that report changes in transmembrane potentials (Petersen and Sakmann 2001), laser 
speckle imaging for cerebral blood flow (CBF) measurements (Dunn et al 2001) and two-
photon laser scanning microscopy with its subcellular resolution (Helmchen and Denk 2005). 
All these developments have started to satisfy the interest in investigating the brain in situ. 
The more traditional imaging methods such as computed X-ray tomography, ultrasound and 
especially structural MRI allow the imaging of the central nervous system with ever-
increasing spatial resolution, allowing the identification of very small structural alterations. 
However, information about the morphology alone is clearly not enough to obtain a complete 
picture of the (patho)physiology of the brain. In this regard, functional imaging methods such 
Imaging Brain’s (patho)physiology 
 
 
 
 
14 
as the nuclear imaging techniques (e.g. PET) and optical brain imaging methods mentioned 
above are playing a significant role. In my work over recent years, I have mainly made use of 
radiotracer techniques which I will focus on in the following sections. 
 
Functional imaging of the brain using PET tracers 
PET measures the accumulation and distribution of radiolabeled biologically active 
substrates in the tissue over time. The radiotracers are injected into the bloodstream at 
micromolar or nanomolar concentrations. These low concentrations have the advantage that 
systemic effects can be excluded. The nuclides used for radiolabeling decay by the emission 
of positrons which combine with nearby electrons (annihilation reaction), leading to the 
emission of two 511 keV gamma rays traveling at 180°. The emitted gamma rays penetrate 
the head allowing detection by the scintillation crystals of the PET scanner. In addition, the 
most commonly used nuclides have short half-lives, minimizing radiation burden. The most 
widely used radioactive nuclides are fluorine-18 (T1/2 = 110 min), which is used as a 
substitute for hydrogen, carbon-11 (T1/2 = 20.4 min), nitrogen-13 (T1/2 = 10.1 min) and 
oxygen-15 (T1/2 = 2 min), which are used to replace natural isotopes of carbon, nitrogen and 
oxygen, respectively. In theory, this affords an unlimited number of biologically active 
substrates which can be labeled (for more details about basic aspects of PET see (von 
Schulthess 2007)). Together with tracer kinetic models that represent mathematical 
descriptions of transport and biochemical reaction sequences, PET images allow non-
invasive access to the local biochemistry of the intact brain. All these properties make PET 
an ideal tool for both in vivo research and clinical imaging. This is reflected by the increasing 
number of brain studies using PET over the last 15 years (Figure 1). 
With the advance of PET, the term molecular imaging has become increasingly important. As 
recommended by a task force of the Molecular Imaging Center of Excellence in 2007 
(Mankoff 2007), molecular imaging includes the “visualization, characterization, quantification 
and measurement of biological processes at the molecular and the cellular levels in humans 
and other living systems in space and over time”. Molecular imaging instrumentation 
comprises tools that enable visualization and quantification in space and over time of signals 
from molecular imaging agents. Apart from radiotracer techniques, MRI, MR spectroscopy, 
optical imaging, ultrasound and other techniques also offer the capability for molecular 
imaging. However, for human use, PET imaging is still one of the most prevalent modalities 
for functional imaging. In addition to its use in research, molecular imaging has enormous 
clinical relevance because it reveals information about the biology of the disease process 
and characterizes specific disease processes in individual patients. By accurately 
characterizing tumor processes or biological processes, molecular imaging may help to 
refine the treatment (monitoring, treatment decisions, etc.) and evaluate prognosis. 
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Figure 1. Brain studies using positron emission tomography. 
Number of brain studies using PET between 1996 and 2010 cited by PubMed (www.ncbi.nlm.nih.gov/pubmed) 
searching for ‘brain positron emission tomography’ (black bars). Gray bars represent brain studies performed 
using radiolabeled fluorodeoxyglucose (PubMed search ‘brain positron emission tomography 
fluorodeoxyglucose’). 
 
 
Aims of my work 
My work can be divided into two fields. One major focus was the application of nuclear 
techniques to investigate fundamental physiological processes in the brain and, where 
possible, to combine them with complementary imaging methods (see the two articles in 
Section 1). We aimed to disentangle the specific processes involved in the energy production 
of the brain and to measure them in the intact brain. Specifically, we intended to demonstrate 
the feasibility of 1-11C-acetate kinetics for quantitative measurements of astrocytic oxidative 
metabolism and then to translate the approach to a human set-up. With this work, we wanted 
to show whether astrocytes also exhibit activity-dependent oxidative energy metabolism as is 
the case with neurons. In the second study submitted with this work, we aimed to measure 
neuronal lactate oxidation with an analogous approach using 11C-L-lactate. This is of general 
interest because of the ongoing debate regarding cerebral lactate oxidation (see below). 
Combining the radiotracer approach with additional imaging modalities, we further tested the 
hypothesis that the intact brain can sustain its electrical activity with lactate as the only 
substrate. 
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The second pillar of my research over the last decade has been the evaluation of new 
tracers for their application in vivo, mainly for brain tumor imaging. In the technically oriented 
part of this work (see Section 2 – Part I (three articles)), we aimed at improving a preclinical 
imaging system, the so-called beta-probe, for radiotracer evaluation in the intact animal. The 
aims were: 1) to test the beta-probe methodology together with 15O-H2O for CBF 
measurements, 2) to evaluate a novel beta-scintillator system for in vivo brain cortex 
measurements and 3) to demonstrate the system’s feasibility for the evaluation of novel PET 
tracers. 
Furthermore, we examined PET tracers already established for other indications in terms of 
their potential for imaging brain tumors (see Section 2 – Part II (four articles)). In the first two 
studies, we aimed to assess the uptake of 18F-fluoroethyl-L-tyrosine, 18F-fluorocholine and 
18F-fluorodeoxyglucose in induced radiation injury and of 18F-fluorocholine in experimentally 
induced abscesses. We wanted to test in detail the tracers’ feasibility for use as brain tumor 
imaging agents, specifically for their ability to distinguish radiation necrosis from tumor 
recurrence. In the next study submitted with this work, we focused on the in vivo 
characterization of microvessel distribution and CBF in low-grade gliomas using PET. A 
better understanding of tumor biology may enable better assessment and planning of 
individual treatment. In the last study, we investigated the time course of low-grade tumor 
metabolism in patients during temozolomide chemotherapy, and compared metabolic 
responses as measured with PET with volume responses as revealed by MRI. 
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Section 1 – 
Understanding brain physiology: example of cerebral energy metabolism 
The importance of functional imaging in clinical situations is continually increasing and will 
further accelerate with ongoing technical improvements and combinations of imaging 
modalities. 
However, apart from clinical applications, the neuroscience field has also profited 
considerably from the technical developments in brain imaging. One field where in vivo 
imaging has accounted for significant new insights is brain energy metabolism. Traditionally, 
glucose metabolism has been used as a surrogate marker for neuronal activity (e.g. glucose 
utilization measurement using 18F-fluorodeoxyglucose (18F-FDG)), due to the close and 
reliable correlation between brain electrical activity and glucose metabolism (Sokoloff 1999). 
Surprisingly, despite its extensive use as an indirect measure of brain activity, the precise 
mechanisms underlying the energy supply of the brain and the coupling of brain activity and 
glucose utilization are still not well understood. However, in order to draw valid conclusions 
from functional imaging signals, it is crucial to understand not only the mechanisms of the 
methods and imaging agents used, but also the exact nature of the underlying physiological 
processes. The brain is a high energy-consuming organ, having a signaling-related energy 
use equivalent to that of leg muscle running a marathon (Hochachka PW cited in (Attwell and 
Laughlin 2001)). While it constitutes only about 2% of the body’s weight, it uses around 20% 
of the whole body glucose consumption (Magistretti 2008). It is widely accepted that glucose 
represents the main exogenous energy substrate for the healthy brain, providing 95% of the 
total energy (Barros and Deitmer 2010). These numbers are well accepted, but exactly how 
glucose is processed in the brain remains heavily debated. The main cell types found in the 
brain are neurons and astrocytes. The classic view of brain energy metabolism assumed that 
each of these cells use glucose directly as an energy substrate in proportion to its demand. 
However, about two decades ago this perspective was challenged by the suggestion of an 
interaction between neurons and glia in brain energy metabolism. The hypothesis proposed 
a tight spatial and temporal interplay between astrocytes and neurons (Magistretti et al 1999; 
Pellerin and Magistretti 1994), and discussed a major activity-dependent astrocytic glucose 
uptake and glycolysis leading to a high lactate production (Figure 2). Most of this astrocytic 
lactate is then released into the extracellular space, and from there it is taken up by neurons 
via specialized monocarboxylate transporters (MCT 2; (Pierre et al 2002)) to serve as a 
neuronal oxidative fuel. The concept was termed the astrocyte-neuron lactate shuttle (ANLS) 
hypothesis, based on the processes involved. 
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Figure 2. Glutamate uptake into astrocytes stimulates glycolysis: a mechanism coupling neuronal activity 
to glucose utilization. 
This scheme was the first representation of the astrocyte-neuron lactate shuttle model postulated by Pellerin and 
Magistretti (1994). Upon neuronal activity, glutamate is released from presynaptic terminals and induces 
glycolysis in astrocytes. Glutamate is co-transported with sodium (Na+), resulting in an increased astrocytic Na+ 
concentration. Increased [Na+]i leads to activation of the Na+/K+ ATPase which is fueled by ATP. The pump 
activates glycolysis, i.e. glucose utilization and lactate production, in astrocytes. The released lactate can be used 
by neurons as an energy substrate after its uptake. Pyr = pyruvate, Lac = lactate, Gln = glutamine, PGK = 
phoshoglycerate kinase, Figure taken from Pellerin and Magistretti (1994). 
 
However, the controversy is still ongoing regarding the validity of the concept (for review see 
(Pellerin and Magistretti 2011)), largely due to a lack of in vivo evidence for the processes 
proposed to be involved. The main reason for this is the difficulty of measuring the 
participating physiological steps with reasonable temporal and spatial (i.e. cellular) 
resolution. 
 
Investigating aspects of brain energy metabolism down to the cellular level 
Only during the last few years have methods emerged that allow measurements of cellular 
processes in the intact animal. The purpose of one of the articles submitted with this work 
was to investigate the feasibility of non-invasively measuring oxidative metabolism 
specifically in astrocytes using 11C-acetate (Wyss et al 2009c). Labeled acetate was chosen 
as a promising candidate for this purpose due to its selective uptake and metabolism in 
astrocytes (Waniewski and Martin 1998). For the first time, this study used label clearance as 
a measure for oxidative astrocytic metabolism in vivo. During electrical nerve stimulation, an 
increase of k2 (the parameter describing radiolabel washout) from 0.014 ± 0.007 min-1 (mean 
± SD) to 0.027 ± 0.006 min-1 was found in rats, supporting the notion of an activity-related 
astrocytic oxidative metabolism. Of note, the experiments were first performed in rats using a 
dedicated beta-probe (see below for further details about this technology) and were 
subsequently translated in a straightforward manner in a human PET study. In healthy 
volunteers, astrocytic oxidative metabolism increased upon stimulation to a similar degree, 
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confirming the animal results. Due to acetate’s cell specificity, with this approach it is 
possible to investigate aspects of brain metabolism on a cellular level despite the use of 
acquisition tools that intrinsically do not reach cellular resolution. 
Using an analogous approach, the aim of the second work of Section 1 was to investigate 
whether neurons are able to oxidize exogenous lactate (Wyss et al 2011). Using 11C-L-
lactate, we tested the hypothesis that k2 (in the one-tissue compartment model applied, this 
parameter reflects lactate oxidation) increases during increased brain activity. Indeed, we 
found an increase of k2 from 0.077 ± 0.009 to 0.105 ± 0.007 min-1 when brain work was 
increased by electrical infraorbital nerve stimulation. Making use of optical imaging in 
combination with voltage-sensitive dyes, we further examined the ability of the brain to use 
lactate as a source of energy. For the first time, we demonstrated in vivo the maintenance of 
neuronal activity measured by voltage-sensitive dye imaging in the presence of lactate as the 
primary energy substrate. The advantages of a multimodal imaging approach were evident in 
this study, as various aspects could be addressed in the same animal model using different 
methods. In summary, we demonstrated for the first time that lactate is capable of 
maintaining neuronal integrity to a large degree in the absence of glucose in the intact 
animal. Furthermore, we found that 1) lactate is preferred over glucose if both substrates are 
available, 2) lactate is readily metabolized by the intact adult brain and 3) its metabolism is 
activity-dependent. 
 
These examples from basic neurophysiology research demonstrate how radiotracer methods 
can provide helpful insights into principle mechanisms. In particular, combining radiotracer 
methods with additional imaging modalities increases the impact of these experiments and 
significantly enhances the interpretation of the findings. 
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Section 2 – 
Evaluation of PET tracers to establish clinical usefulness 
Newly designed PET radiotracers require rigorous testing before they can be used in the 
clinical setting. First, new radioligands are tested in vitro, e.g. binding studies with membrane 
fractions, metabolism studies with (human) plasma and/or hepatocytes, etc. However, the 
predictive value of in vitro experiments remains limited and is not sufficient to evaluate 
whether a new tracer is suited for application in human subjects. For this purpose, in vivo 
experiments are mandatory. 
 
Part I: Establishment and advancements of novel imaging techniques for preclinical in 
vivo radiotracer testing 
Before a PET tracer can be applied in humans, considerable preclinical evaluation in intact 
organisms is required. One of the prerequisites for economical and conclusive testing of 
novel radiotracers is the appropriate in vivo imaging technology. Ideally, such techniques 
should be relatively inexpensive, preferably non-invasive and exhibit good temporal and 
spatial resolution. For a long time, autoradiography was the only established method to test 
radiolabeled tracers in experimental animals. This method is appropriate for the 
characterization of tracer uptake with sufficient spatial resolution and for organ bio-
distribution studies. However, an autoradiographic study is a ‘one-shot method’, yielding the 
distribution of a given radioligand at one time point only. Thus, using this method to obtain 
temporal information concerning a radiotracer’s kinetic behavior requires a large number of 
animals. 
The development of small animal PET scanners (Ambrosini et al 2009; Dupont and Warwick 
2009; Riemann et al 2008) unequivocally helped to close the gap between the evaluation of 
novel tracers in preclinical animal experiments and their final clinical application. These 
dedicated scanners allow imaging of the whole rodent – if necessary, several times in a 
longitudinal design. However, small animal PET scanners are expensive, need considerable 
servicing and have a limited temporal and spatial resolution. Despite significant 
improvements over the last few years with respect to sensitivity, the temporal resolution is 
still a problem for radiotracers exhibiting fast kinetics. Another drawback of small animal PET 
is the requirement of anesthesia, which inevitably alters normal physiology. 
In this regard, the development of so-called beta-probes (Zimmer et al 2002) has added 
additional possibilities to the field of preclinical radioligand testing in small laboratory animals, 
further accelerating the clinical translation of potential tracer candidates. In two of the articles 
submitted with this work, we substantially improved the performance of original beta-
scintillators. First, we developed for the first time completely light-tight systems, which 
improve usability because experiments no longer have to be performed in darkness. 
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Secondly, the system was tested in response to very fast kinetics with 15O-H2O, a tracer used 
for perfusion measurements that has a very short physical half-life (t1/2 = 122 seconds; 
(Weber et al 2003)). To overcome the invasiveness of classic intracortical probes, and with 
them the need for anesthesia, we later developed and introduced a highly sensitive beta-
scintillator for measurements in the intact rodent cortex (Wyss et al 2009b). We 
demonstrated the feasibility of using this device in non-anesthetized, head-fixed rats. 
Remarkable changes in tracer kinetics were detected between awake and anesthetized 
animals, demonstrating the need for methods that can be applied in awake animals to 
overcome the unfavorable effects of anesthetic agents. In addition, the higher sensitivity 
increased the practicability of study protocols with repeated injections in the same animal. 
This is especially helpful in combination with tracers with short half-lives where the 
radioactivity concentration declines quickly (e.g. carbon-11-labeled compounds with T1/2 = 
20.4 min). Apart from the higher sensitivity and the ability to perform experiments in the 
absence of any tissue damage, this device still shares the advantages of a low price and a 
high temporal resolution with the classic beta-probe. 
The justification of this methodology for the testing of novel radiotracers for human 
application is shown in the third article of Section 2 – Part I. In that project, the aim was to 
quantitatively evaluate a novel receptor ligand for the metabotropic glutamate receptor 
subtype 5 (mGluR5), 11C-ABP688, for its application in brain studies (Wyss et al 2007a). In 
antecedent in vitro experiments, it exhibited ideal properties such as high affinity and 
specificity for the target receptor (mGluR5), high stability of the radioligand in plasma and 
brain, and sufficient passage through the blood-brain barrier (Ametamey et al 2006). 
Altogether, the preclinical profile of 11C-ABP688 suggested that the tracer would have 
reasonable potential for in vivo use. However, in the past, numerous candidates passed in 
vitro evaluation but failed in the following testing in the living organism. We demonstrated the 
feasibility of mGluR5 quantification in intact brains of 13 animals using a beta-scintillator 
(Wyss et al 2007a). Directly following from this kinetic validation in rats, the tracer was 
transferred to human use in a straightforward manner. Notably, 11C-ABP688 exhibited very 
similar kinetic characteristics in the human central nervous system as found in the rodent 
experiments (Ametamey et al 2007). This clearly demonstrates the importance of proper 
preclinical imaging for the efficient introduction of new imaging agents into a human set-up 
(‘from bench-to-bedside’). A congruent example, discussed earlier, is the study using 1-11C-
acetate where we also found similar results in healthy volunteers as previously measured 
using the beta-probe in animals (Wyss et al 2009c). 
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Part II: Evaluation of radiotracers for the management of brain tumor patients 
Overall, the labeled glucose analog 18F-FDG is the most commonly used radiotracer in 
clinical PET. FDG is transported and phosphorylated in a similar manner as native glucose 
but it is trapped within the tissue and is not further metabolized after being transformed to 
FDG-6-P by the enzyme hexokinase. The accumulation of the label in the tissue is then 
proportional to the cellular glucose utilization rate. In the daily routine for whole body tumor 
staging, FDG is by far the most often used PET tracer. PET imaging has always played an 
important role in patients suffering from cerebral pathologies, e.g. diagnosis of brain tumors 
was the first oncological application of 18F-FDG PET (Di Chiro et al 1982). However, in these 
patients, the use of 18F-FDG is more problematic (see below for more details). Nowadays, 
18F-FDG is used in only about one fifth of all brain studies (Figure 1). On the other hand, the 
variety of tracers used for brain studies is large and continuously increasing. Already, 
numerous different compounds have been used to target a wide range of processes, e.g. 
blood flow, glucose metabolism, receptor occupancy of various types of receptors, amino 
acid transport, cellular proliferation, etc. Consequently, PET imaging is becoming 
increasingly helpful in the differential diagnosis of numerous neurological conditions such as 
dementias, movement disorders, seizure disorders, perfusion impairments and psychiatric 
disorders. Amongst all these pathologies, glioma patients still form a considerable fraction of 
the routine diagnostic workout of brain PET examinations. 
 
A) Uptake characteristics in various pathologies 
In glioma patients, PET found a major application for the differentiation of tumor recurrence 
from residual tissue lesions due to treatment, such as cerebral radiation necrosis. However, 
as described in one of the articles submitted with this work, and by others, more and more 
studies suggest that PET may find its niche in the monitoring of treatment response in brain 
tumor patients ((Piroth et al 2011; Schiepers et al 2010; Wyss et al 2009a), see also below). 
Over the last 25 years, PET has become a useful diagnostic tool for the evaluation of the 
biologic activity of brain tumors (for review see (Chen 2007; Heiss et al 2011; Waldman et al 
2009)). One of the main indications for PET in brain tumor patients is the differentiation of 
post-therapy radiation necrosis and pseudoprogression from tumor recurrence (Okamoto et 
al 2011; Terakawa et al 2008), as direct diagnosis is crucial for correct patient management. 
Although the usefulness of 18F-FDG in tumor imaging is beyond doubt, there are several 
drawbacks which reduce the accuracy of 18F-FDG in these situations. One problem is the 
high intrinsic uptake of 18F-FDG in normal brain gray matter. A second issue is the wide 
range of 18F-FDG uptake in different brain tumors and third, the significant uptake of 18F-FDG 
by inflammatory cells (Kaim et al 2002a). Collectively, these problems render the 
differentiation of brain lesions difficult and make the separation of radiation necrosis and 
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brain tumor imprecise. Also, conventional MRI and CT often cannot reliably separate these 
two pathologies (Del Sole et al 2001; Mullins et al 2005). 
In this regard, the development of more specific radiotracers with low intrinsic uptake in 
normal brain tissue and no accumulation in inflammatory cells was and still is a major aim of 
nuclear medicine research. Establishment of the validity of a novel tracer in vivo is an 
indispensable prerequisite for later clinical application. Two promising radiotracers, 18F-
fluorocholine (18F-FCH) and 18F-fluoroethyl-L-tyrosine (18F-FET), were introduced about 10 
years ago. Using classic autoradiography, we compared the accumulation of 18F-FCH and 
18F-FET with the accumulation of 18F-FDG in a radiation necrosis model of the rat (Spaeth et 
al 2004). In the same study, we uncovered the effect of a blood-brain barrier disruption on 
radiotracer uptake by using a cryolesion model. 18F-FCH and 18F-FET revealed themselves 
to be superior to 18F-FDG for separating radiation necrosis from tumor recurrence. We found 
that 18F-FET uptake is most likely due to a disruption of the blood-brain barrier and no uptake 
was observed in macrophages. This is in agreement with previous work which also showed 
that 18F-FET is not taken up in inflammatory lesions (Kaim et al 2002b). In contrast, no data 
were available regarding the uptake of 18F-FCH in inflammatory tissue. For each oncological 
tracer, it is crucial to know the uptake behavior in non-tumorous lesions, of which 
inflammatory and/or infectious foci are amongst the most important. In the second article of 
this section, we assessed 18F-FCH uptake using small animal PET imaging in an animal 
abscess model established in our laboratory (Wyss et al 2004). In addition, autoradiographic 
analysis was performed on a subsequent day for exact correlation with histology. 
Pronounced accumulation of 18F-FCH was found in inflammatory infiltrates, with tracer 
uptake three or more times higher than the accumulation in healthy muscle tissue. This 
finding considerably limits the specificity of labeled choline for tumor detection and has to be 
incorporated into the evaluation of clinical PET scans using 18F-FCH. 
 
B) Target tumor biology with the help of functional imaging and estimate merits of 
functional PET imaging for treatment monitoring 
A better understanding of tumor biology may help to better understand the tumor response to 
treatment. For example, low-grade gliomas have long been regarded as resistant to 
chemotherapy; however, several studies have shown remarkable responses to various 
regimens (Hoang-Xuan et al 2004; Peyre et al 2010). Nevertheless, it is difficult to predict the 
outcome of treatment. Adequate delivery of drugs is a main prerequisite for effective 
chemotherapy. On the one hand drug delivery is a function of drug concentration in the 
blood, but on the other hand it depends on blood flow through tumor microvasculature and 
the transport of drugs across capillaries. In another article submitted with this work, we 
investigated the perfusion and the vascular density in low-grade gliomas (Wyss et al 2007b) 
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using 15O-H2O for CBF measurements and 18F-FET as a tracer for amino acid transport. 
Earlier studies using the amino acid analog 11C-methionine demonstrated that amino acid 
PET serves as an indirect measure of the number of microvessels (Kracht et al 2003). 
Together with the notion that 18F-FET and 11C-methionine provide comparable information 
(Grosu et al 2011; Weber et al 2000), it can be assumed that 18F-FET is a surrogate marker 
of the microvascular density. The spatial distribution of the amino acid carrier, which is 
located at the brain capillaries, and tumor CBF were determined in a group of 17 patients. In 
82% of the patients, increased global CBF and FET uptake were determined. The volumes of 
increased CBF and FET uptake spatially coincided (Spearman rank rho = 0.944, p < 0.01). 
However, we found that CBF only started to increase when 18F-FET uptake increased above 
a certain level, suggesting that CBF increases follow the formation of new microvessels. 
Irrespective of increased capillary density, CBF increases were more confined to the tumor 
center. In many patients, intratumoral heterogeneity on the PET scans was also observed. 
The observed variation of CBF and amino acid uptake within single tumors and within the 
whole group did not depend on the lesion size determined from MR tomographies. Taken 
together, these findings may help to better understand the differences in treatment response 
and aid treatment decisions. Based on these findings and the fact that microvascular density 
constitutes a significant independent prognostic factor (Abdulrauf et al 1998; Leon et al 
1996), we initiated a parallel prospective study addressing the effect of chemotherapy on 
amino acid uptake and examining the potential to use PET for the identification of early 
treatment response in low-grade glioma patients (Wyss et al 2009a). 18F-FET PET scans 
were performed at six-month intervals in a homogeneous population of 11 patients with 
progressive supratentorial LGG WHO Il and treated with 75 mg/m2 temozolomide per day 
over three weeks followed by one week off. None of the patients showed blood-brain barrier 
disruption as revealed by gadolinium-enhanced MR (Figure 3). 
Comparing metabolic (PET) and structural (MRI) responses, we observed a mean delay in 
MRI tumor volume reduction of seven months compared to the PET response. Most 
interestingly, with regard to the identification of patients who benefit most from treatment, we 
found that the magnitude of the first 18F-FET volume response correlated with the best MRI 
tumor volume response obtained later during chemotherapy (Spearman rank rho = 0.731, p 
= 0.01). Due to the small sample size, final conclusions cannot be drawn concerning the 
degree to which the magnitudes of the PET and MR responses relate to the subsequent 
clinical course and to the time until tumor progression. However, we clearly demonstrated the 
advantage of having additional molecular information for low-grade glioma patients in terms 
of the time window of identifying treatment response. 
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Figure 3. Metabolic response precedes structural reaction. 
Example of a patient undergoing chemotherapy using temozolomide. Imaging studies were performed before and 
6, 12, 18, 24 months after initiation of treatment. The color scale represents the tumor:cerebellum 18F-FET uptake 
ratio. Figure modified from Wyss et al. (2009a). 
 
Functional brain imaging using techniques from nuclear medicine now has a broad field of 
application, which is exemplified by my work ranging from basic neuroscience research to 
applications for patient management. In the future, with the advance of novel radioligands 
and technical improvements of the measurement devices such as the introduction of hybrid 
systems (e.g. PET/MR systems (Heiss 2009)), the field may further expand. 
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Section 1 – 
Understanding brain physiology: example of cerebral 
energy metabolism 
 
 
1.   Stimulation-induced increases of astrocytic oxidative metabolism in rats and 
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Stimulation-induced increases of astrocytic
oxidative metabolism in rats and humans
investigated with 1-11C-acetate
Matthias T Wyss1, Bruno Weber1,2, Valerie Treyer1, Stefan Heer1, Luc Pellerin3,
Pierre J Magistretti4 and Alfred Buck1
1PET Center, Division of Nuclear Medicine, University Hospital, Zu¨rich, Switzerland; 2Institute of
Pharmacology and Toxicology, University of Zu¨rich, Zu¨rich, Switzerland; 3Physiology Department,
University of Lausanne, Lausanne, Switzerland; 4Brain Mind Institute, E´cole Polytechnique Fe´de´rale de
Lausanne (EPFL), Lausanne, Switzerland
The purpose of this study was to investigate astrocytic oxidative metabolism using 1-11C-acetate.
1-11C-acetate kinetics were evaluated in the rat somatosensory cortex using a b-scintillator during
different manipulations (test–retest, infraorbital nerve stimulation, and administration of acetazo-
lamide or dichloroacetate). In humans a visual activation paradigm was used and kinetics were
measured with positron emission tomography. Data were analyzed using a one-tissue compartment
model. The following features supported the hypothesis that washout of radiolabel (k2) is because of
11C-CO2 and therefore related to oxygen consumption (CMRO2): (1) the onset of
11C washout was
delayed; (2) k2 was not affected by acetazolamide-induced blood flow increase; (3) k2 demonstrated
a significant increase during stimulation in rats (from 0.014±0.007 to 0.027±0.006 per minute) and
humans (from 0.016±0.010 to 0.026±0.006 per minute); and (4) dichloroacetate led to a substantial
decrease of k2. In the test–retest experiments K1 and k2 were very stable. In summary, 1-
11C-acetate
seems a promising tracer to investigate astrocytic oxidative metabolism in vivo. If the washout rate
indeed represents the production of 11C-CO2, then its increase during stimulation would point to a
substantially higher astrocytic oxidative metabolism during brain activation. However, the
quantitative relationship between k2 and CMRO2 needs to be determined in future experiments.
Journal of Cerebral Blood Flow & Metabolism (2009) 29, 44–56; doi:10.1038/jcbfm.2008.86; published online 20 August 2008
Keywords: 1-11C-acetate; astrocytes; b-scintillator; oxidative metabolism; positron emission tomography; washout
Introduction
There is increasing evidence that astrocytes and
neurons constitute a tightly coupled metabolic unit.
Already early studies of brain metabolism using
14C-labeled precursors such as glucose or acetate led
to the concept of two distinct tricarboxylic acid
(TCA) cycle compartments, that is, two separate
pools for glutamate and glutamine (Berl and
Frigyesi, 1969; Cremer, 1970; Minchin and Beart,
1975; Van den Berg et al, 1969). Later histochemical
work on the restricted localization of glutamine
synthetase to glial cells (Martinez-Hernandez et al,
1977; Norenberg and Martinez-Hernandez, 1979)
further supported the idea on the glial and neuronal
site of these distinct pools. Simplification of these
data has sometimes led to the wrong assumption
that the oxidative activity of astrocytes is negligible.
However, studies using mainly nuclear magnetic
resonance spectroscopy have suggested that astro-
cytic energy metabolism indeed contains a substan-
tial oxidative component which may account for up
to 30% of total oxidative metabolism in brain under
resting conditions (for review see Hertz and Kala,
2007; Hertz et al, 2007; Hyder et al, 2006). Recent
transcriptome analysis has revealed a pattern of
gene expression in astrocytes consistent with a
significant oxidative activity (Lovatt et al, 2007).
Another question is how astrocytic metabolism
behaves during activation. A recent study using
ex vivo autoradiography with 14C-labeled acetate at
the carbon 2 position suggested that astrocytic
oxidative metabolism increases with brain activity
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(Cruz et al, 2005). Labeled acetate is a promising
candidate to investigate astrocytic oxidative meta-
bolism in vivo because it is selectively taken up and
metabolized by astrocytes (Hassel et al, 1992; Muir
et al, 1986; Waniewski and Martin, 1998). Earlier
studies in the heart muscle have further revealed
that quantitative measures for oxygen consumption
can be derived from the washout rate of label after
injection of radiolabeled acetate (Buck et al, 1991).
Acetate can be labeled in the 1- or 2-carbon position.
Whole-body studies using 13C-labeled acetate
demonstrated that labeled CO2 is produced during
the second or third turn in the TCA cycle, depending
on whether 1-13C-acetate or 2-13C-acetate was used
(Wolfe and Jahoor, 1990). However, these results
reflect whole-body metabolism, brain-specific reac-
tions cannot be directly derived from them. In brain,
with 1- and 2-labeled acetate there was substantial
labeling of amino acids, such as glutamate, gluta-
mine, and aspartate and further TCA cycle inter-
mediates as shown in older and more recent
literature (Badar-Goffer et al, 1990; Berl and Frigyesi,
1969; Lebon et al, 2002; Tyce et al, 1981; Tyson
et al, 2003; Van den Berg et al, 1969; Van den Berg and
Ronda, 1976). However, the static measurement of
metabolites at single time points yields only limited
information on astrocytic oxidative metabolism.
In this study we applied 1-11C-acetate and
dynamic measurements to investigate astrocytic
oxidative metabolism. Specific questions were (1)
what is the extraction fraction (EF) of the tracer, (2)
what is the kinetic behavior at baseline and during
stimulation, (3) how does dichloroacetate, an agent
that increases the production of acetyl-coenzyme A
(CoA) from pyruvate in the cell, change the kinetics
of 1-11C-acetate, and (4) is the loss of radiolabel
dependent on blood flow. Studies were performed
in rats and humans. In rats data were acquired using
a b-scintillator, in humans we applied positron
emission tomography (PET).
Materials and methods
Automated Radiosynthesis of Sodium 1-11C-Acetate
11C-CO2 was produced by the
14N(p,a)11C nuclear reaction
using a nitrogen gas (N2/0.5% O2) target.
11C-CO2 was
bubbled at room temperature in a mixture of methylmag-
nesium bromide (3 mol/L solution in diethyl ether; Fluka,
70 mL, 0.21 mmol) and dry diethyl ether (3 mL) placed in
the reactor, where the chemical trapping of the 11C-CO2 by
C-carboxylation of the Grignard reagent takes place
instantly. After delivery (10 mins) the reaction was
quenched by automated addition of nearly equimolar
amount of acid (1 mL 0.2 mol/L aqueous HCl, 0.2 mmol
HCl) and the diethyl ether from the bilayer mixture was
removed by evaporation in a stream of nitrogen (100 mL/
min) for approximately 10 mins. The residual water
solution of 1-11C-acetic acid was automatically drawn into
the loop of the preparative chromatograph (Merck-Hitachi
chromatograph equipped with L-4000A UV detector at
254 nm, isocratic pump L-6000A, 5 mL loop, and radiation
detector Radiation Monitor; Eberline Instrument Corpora-
tion, Santa Fe, NM, USA), injected into a semipreparative
reversed phase column (Polymerx, 10 mm, 250 10 mm,
Phenomenex) and eluted with a mixture of sterile salt
physiologic solution as the mobile phase. The fraction
corresponding to the 1-11C-acetic acid (tR = 7 mins) was
collected to give up to 10 GBq activity of no-carrier-added
sodium 1-11C-acetate with over 99% radiochemical purity
and specific activity of approximately 400 GBq/mmol at the
end of the synthesis in 10 mL sterile isotonic, buffered at
physiological pH solution. The radiolabeling was per-
formed in a lead shielded cell using a computer-assisted
homemade automatic apparatus controlled by LabVIEW
software (National Instruments) via Modulink and RS232
interfaces.
Radiotracer Experiments
Experiments were performed in animals using the
b-scintillator and in humans using PET. All animal
experiments were approved by the local veterinary
authorities and were performed in accordance with their
guidelines. The experiments were performed by licensed
investigators. The animals were kept in cages in a
ventilated cabinet with standardized conditions of light
(night/day cycle 12/12 h) and temperature and free access
to food and water. Before the experiment the animals were
fasted overnight. A total of 29 Sprague–Dawley rats (5 for
the EF determination, 24 for the different experimental
paradigms (for details see below)) weighing 310±41 g
(mean±s.d.) were included in the study.
The human study population was composed of 6
healthy male volunteers aged between 24 and 36 years
without any known neurological impairments. All sub-
jects were studied at the University Hospital Zurich.
Informed written consent was obtained from all subjects
before the beginning of the experiment. The protocol was
approved by the Local Ethics Committee.
Magnetic resonance scanning was performed on each
subject (Twin Speed; GE Medical Systems, Milwaukee,
WI, USA) to rule out any cerebral pathologies and for
anatomical coregistration of the PET scan.
Animal Preparation
Surgery was performed under isoflurane anesthesia and
involved the placement of an arteriovenous shunt from the
right femoral artery to the right femoral vein, tracheotomy
for mechanical ventilation, and exposition of the skull
with subsequent thinning of the bone above the primary
somatosensory cortex using a dental drill. The actual
experiment was then performed under urethane anesthe-
sia (1400 mg/kg, i.p.). The arteriovenous shunt was used
for the injection of the tracer, collection of blood samples
for metabolite analysis, the monitoring of arterial blood
pressure, and the continuous measurement of total arterial
11C activity. For the latter purpose, the shunt was run
through a coincidence counter (GE Medical Systems) that
stored the whole blood radioactivity concentration at
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1-sec intervals. The online arterial sampling procedure is
described in detail elsewhere (Weber et al, 2002).
b-Scintillator
The b-scintillator (Swisstrace, Zurich, Switzerland) has
been described in detail earlier (Weber et al, 2003; Wyss
et al, 2007). In short, it consists of a scintillation tip
(Bicron, BF12, Newbury, OH, USA) with a length of 1 mm
and a diameter of 0.25 mm attached to a high numerical
aperture glass fiber. The scintillator was made light tight
by applying a uniform coating of silver particles. The
scintillations were measured using a photomultiplier tube
and counting electronics (Perkin Elmer, MA, USA). The
limited range of b-particles within biological tissues leads
to a limited detection volume centered around the
scintillating tip of the probe. Monte Carlo simulations
demonstrated that for C-11 the distance required to detect
90% of the b-particles around the probe is 2.0 mm (Pain
et al, 2002). The sensitivity of the used b-scintillator was
in the range of 0.036 to 0.047 cps/kBq/cc.
The scintillator was inserted into the cortex using a
stereotactic frame (David Kopf Instruments, Tujunga, CA,
USA). At the insertion point, which was approximately
(according to Bregma) 1 mm posterior and 5 mm lateral,
the thinned bone was removed and the dura was carefully
incised. The scintillator tip was decreased 1.4 mm below
the dura. In the stimulation experiments, the correct
position was verified by Laser Doppler flowmetry (Periflux
System 5000; Perimed AB, Ja¨rfa¨lla, Sweden). This position
was adjusted to avoid large superficial blood vessels. Only
one scintillator penetration was performed per animal.
The count rate was stored on a personal computer using a
bin width of 1 sec yielding tissue time–activity curves.
Positron Emission Tomography
All subjects were scanned on a whole-body PET/computer
tomography-scanner (Discovery ST-RX; GE Medical Sys-
tems, Waukesha, WI, USA). This is a scanner with an axial
field of view of 14.6 cm and a reconstructed in-plane
resolution of approximately 7 mm. Before the positioning
of the subjects in the scanner, a radial artery was
cannulated for timed arterial blood sampling. An addi-
tional catheter for administration of the radiotracers was
placed in the contralateral antecubital vein. At the
beginning of each study, a low-dose computer tomogram
for attenuation correction was performed.
Experimental Protocols
Cerebral blood flow measurements using H2
15O:
First Pass Extraction Fraction: The first pass EF of
1-11C-acetate at baseline was determined according to the
relationship EF = K1/CBF, where K1 is the transport
parameter of the one-tissue compartment model and
CBF is cerebral blood flow. Cerebral blood flow was
determined in five animals using 15O-labeled water
injected before measurement of 1-11C-acetate kinetics. In
the human study CBF was measured in all subjects
10 mins before the 1-11C-acetate injections. The visual
stimulation was interrupted between CBF and acetate
measurements. Approximately 300 MBq H2
15O was
injected intravenously using an automatic injection
device. After the arrival of the bolus in the brain, the
acquisition of a series of 18 frames (10 secs each frame)
was started.
Measurements of 1-11C-Acetate Kinetics During
Different Conditions
In the animal experiments, two injections spaced 30 mins
apart were administered. Data were acquired for 20 mins
after the injection (slow injection over a period of 30 secs)
of 230 to 260 MBq (diluted in 0.5 mL) of radiotracer. This
part of the study included 24 animals, which were
distributed among the following experimental subgroups:
(1) in this group the baseline was followed by electro-
stimulation (bas–stim); (2) the order was reversed (stim–
bas). Groups (1) and (2) were examined with respect to a
potential order effect. (3) To evaluate the reproducibility
two consecutive baseline measurements were performed
(bas–bas). (4) In four animals the effect of acetazolamide
(Diamox, 66 mg/kg), a carbonic anhydrase inhibitor
increasing CBF but not oxygen consumption (CMRO2;
Okazawa et al, 2001), on the kinetics of 1-11C-acetate was
examined. After 20 mins of baseline acquisition, acetazo-
lamide was intravenously injected over 1 min. Ten
minutes later the same amount of 1-11C-acetate was
injected for the second time. In a last group (5) the effect
of dichloroacetate was investigated. Four hours after the
injection of dichloroacetate (50 mg/kg, Sigma-Aldrich
Product No. 347795, Buchs, Switzerland) a baseline study
was followed by electrostimulation (dichloroacetate chal-
lenge). Dichloroacetate was dissolved in physiological
saline and was adjusted to pH 7.4.
To activate the whisker-to-barrel pathway the infraorbi-
tal branch of the trigeminal nerve was electrically
stimulated with two stainless steel electrodes. The
cathode was inserted through the infraorbital hiatus and
the anode was positioned in the masticatory muscle on the
ipsilateral side. The current was adjusted to 2 mA, and
2 Hz stimulation frequency was chosen because previous
measurements using 18F-fluorodeoxyglucose-autoradio-
graphies demonstrated this frequency to be optimal
eliciting a maximal increase in glucose consumption of
70% to 80% (unpublished data). The stimulation started
30 secs before the tracer injections. To check the effectivity
of the applied stimulation and the effect of acetazolamide
in group (4) animals, a Laser Doppler flowmetry probe was
fixed just above the primary somatosensory cortex to
follow regional CBF changes.
In humans, PET was performed under baseline condi-
tions with eyes closed and during visual stimulation using
different video clips presented on a screen (Charlie’s
Angels and Rolling Stones). In three subjects the baseline
examinations preceded the stimulation studies and in the
other three subjects the order was reversed to rule out any
order effect. The visual stimulation was started 20 secs
before scan start and continued during complete PET
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acquisition. After the intravenous injection of 250 MBq
1-11C-acetate, administered as a slow bolus over approxi-
mately 60 s, data were recorded for 20 mins (25 frames:
6 20, 3 40, and 16 60 secs).
Time–activity curves were derived from volumes of
interest defined on three consecutive slices on the
anatomical magnetic resonance scans and subsequently
transferred to the PET data. Volumes of interest were
drawn in the visual cortex as the target region and in the
frontal cortex and cerebellum as references.
Statistics
The Wilcoxon signed rank test for dependent samples
was used to evaluate differences between within-
subject conditions and the Mann–Whitney U-test
was used for group differences. The criterion for
significance was set at P < 0.05. Values are expressed as
mean±s.d.
Data Acquisition and Analysis
The details are described in the appendix.
Results
Animal Studies
Metabolites of 1-11C-acetate in the blood: High-
pressure liquid chromatography identified 11C-CO2
as the only metabolite in blood. The time course of
the fraction of authentic 11C-acetate in arterial
plasma is demonstrated in Figure 1. The pH
and arterial blood gases were all in the physiological
range (pH = 7.35 to 7.45; pCO2 = 35 to 45 mm Hg;
pO2 = 70 to 100 mm Hg). Plasma lactate levels
were also determined as lactate competes with
acetate for the uptake into brain. They ranged
between 1.4 and 2.1 mmol/L. However, no relation-
ship between plasma lactate levels and changes
in the kinetics of 1-11C-acetate could be found.
Only in group 5 (dichloroacetate challenge) there
was a statistically significant difference in plasma
levels between the two different modalities (see
below).
First pass extraction fraction: CBF was measured in
5 baseline experiments and was 56±16 mL/min/
100 g. The first pass EF of 1-11C-acetate calculated in
these experiments was 18%±5%.
Reproducibility of the 1-11C-acetate measurements:
The reproducibility of the time–activity curves and
of the parameters K1 and k2 is demonstrated in the
top graphs of Figures 2 and 3. In contrast to
trigeminal nerve stimulation, the tissue time–
activity curves in the two sequential baseline
experiments look identical. The difference of the
mean K1 (K1 experiment 2K1experiment 1) was 0.001, and
for k2 the difference was 0.002 per minute.
1-11C-Acetate kinetics during infraorbital nerve
stimulation: The electrical infraorbital nerve stimu-
lation increased the washout of 1-11C-acetate as
shown in the middle graph of Figure 2. The order of
the experiments (baseline–stimulation or stimula-
tion–baseline) had no significant effect on the
changes of the kinetic parameters (Figures 3C and
3D). Therefore the two groups (1) and (2) (bas–stim
and stim–bas) were pooled. During stimulation,
k2 increased by 93% from 0.014±0.007 to
0.027±0.006 per minute (P < 0.01) in the primary
somatosensory cortex. In parallel, K1 increased from
Figure 1 In the upper panel the time course of 11C radioactivity
in whole blood (K), plasma (&), and brain tissue (.) acquired
over 20 mins is shown. In addition the model fit is demons-
trated (straight line, K1 = 0.085 mL/min/mL tissue, k2 = 0.015
per minute). The goodness-of-fit is demonstrated by the random
distribution of the residuals, demonstrated in the insert. In the
lower panel the fraction f of true 1-11C-acetate in plasma in
animal and human studies is plotted. The filled circles represent
data points from animal studies (anesthetized rats) and the
solid line is the corresponding fit of the function f = 100-
a(1exp(mt)). Least squares fitting yielded a= 93% and
m= 0.11 per minute. In the human study (open circles;
conscious humans), a and m were taken from previous
experiments which had yielded very similar values (a= 91%,
m= 0.13 per minute) (Buck et al, 1991).
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0.080±0.015 at baseline to 0.095±0.017 (P < 0.01).
The efficacy of the stimulation was confirmed by the
increase of the laser Doppler flowmetry signal by 20
to 25% (data not shown).
To check for a delayed onset of the radioactivity
washout, the first 5 mins of data were refitted
with only k2 as a free parameter. In this dataset,
k2 decreased from 0.014±0.007 to 0.001±0.002
in the baseline experiments and from 0.027±0.006
to 0.003±0.004 in the stimulation experiments.
An example of a 5 mins fit is illustrated at
the bottom of Figure 2. The low k2 of 0.001 fits
the initial data well, then the washout is clearly
increased.
Effect of acetazolamide on k2: In the 4 experiments
k2 was 0.016±0.002 at baseline and 0.016±0.002
per minute 10 mins after acetazolamide injection.
Laser Doppler flowmetry showed a signal increase
of 61.1%±8.1%.
Effect of dichloroacetate on k2 during baseline
and stimulation: Dichloroacetate pretreatment
decreased arterial plasma lactate from 1.5±0.1 to
1.25±0.2 mmol/L (mean±s.d.; P < 0.05) but exerted
no change of arterial blood gases which stayed in the
physiological range. Four hours after intravenous
dichloroacetate administration, k2 was less at base-
line and during stimulation, compared with the
experiments without dichloroacetate. At baseline
the values were on average 36% less (0.009±0.002
compared with 0.014±0.007), however, this differ-
ence failed to reach significance (n = 5; P = 0.15).
During stimulation k2 was 26% less (n = 5; P < 0.05)
than that in the experiments without administration
of dichloroacetate (0.020±0.004 compared with
0.027±0.006). There was still a significant 122%
increase of k2 from baseline to electrostimulation
(from 0.009±0.002 to 0.020±0.004; n = 5; P < 0.05;
Figure 3E).
Relationship of the tissue activity and changes
of the washout rate k2: This relationship is a
measure of the parameter identifiability. A larger
change of the tissue activity with a unit change of k2
is associated with a better parameter identifiability.
The sensitivity analysis demonstrated that at
20 mins, a 10% change in k2 led to a 2.1% change
in tissue activity at baseline (k2 = 0.014 per minute)
and to a 3.8% change during stimulation (k2 = 0.027
per minute). Furthermore, the activity change in
tissue was linear in the investigated range 0 to 30%
k2 change.
Human Studies
1-11C-Acetate kinetics present the same character-
istics as in animal studies: In all subjects the
blood gas parameters were always in the physio-
logical range (pH = 7.35 to 7.45; pCO2 = 35 to
45 mm Hg; pO2 = 70 to 100 mm Hg). An illustration
of the effect of the visual activation on the kinetic of
1-11C-acetate is demonstrated in Figure 4 and the
quantitative values are shown in Figure 5. The
calculated EF of 1-11C-acetate in visual cortex was
19±4% at baseline and 13±3% during stimulation.
The visual stimulation increased mean CBF in
visual cortex by 64% (P < 0.05). In the control
regions, ‘cerebellum’ and ‘frontal cortex,’ no sig-
nificant change of the CBF was noticed. In visual
cortex mean K1 and k2 values of 1-
11C-acetate were
11% and 62% (P < 0.05 for both) higher during
stimulation as shown in Figures 5F and 5I. No
significant changes of K1 or k2 were noted in frontal
cortex and cerebellum. However, in frontal cortex K1
and k2 data are somewhat distorted by a single
subject, which showed a decrease of the values in
this region in response to visual stimulation.
Figure 2 The top and middle graph demonstrate time–activity
curves of 11C activity in rat brain tissue normalized to injected
activity per g bodyweight yielding standardized uptake values
(SUV). The curves represent mean data from five experiments.
In the baseline–baseline experiments (top panel) the curves
appear identical. In contrast, the washout of 11C activity is
remarkably larger during stimulation (middle panel). The
bottom panel illustrates the residuals between fit and data if
only the first 5 mins of data are fitted. Such a short fit yields
substantially lower initial washout rates than a 20 mins fit,
demonstrating that the onset of the washout of radiolabel from
tissue is delayed.
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Discussion
It was previously suggested that the astrocyte-
specific substrate acetate allows to measure meta-
bolism in human brains in vivo (Hosoi et al, 2004;
Muir et al, 1986). However, to our knowledge this is
the first study using label clearance from brain after
1-11C-acetate administration for the investigation of
astrocytic oxidative metabolism in vivo. Labeled
acetate was already used in various studies to
illuminate certain aspects of astrocytic metabolism.
Some groups used autoradiographical determination
of 14C-acetate uptake (Cruz et al, 2005; Muir et al,
1986), other groups measured the metabolic fate of
acetate by measuring the appearance of labeled
compounds as the label traveled through the TCA
cycle (e.g., Badar-Goffer et al, 1990; Berl and
Frigyesi, 1969; Lebon et al, 2002; Van den Berg
and Ronda, 1976).
Our study demonstrates for the first time the
changes of 1-11C-acetate kinetics during stimulation
in vivo, which are thought to be correlated with the
changes of astrocytic oxidative metabolism.
Although total cerebral CMRO2 can be successfully
measured in vivo using PET and inhaled 15O2
(Mintun et al, 1984; Yee et al, 2006), a direct in vivo
measurement of CMRO2 in astrocytes alone is not
available.
K1 and Extraction Fraction
Compared with the heart where 1-11C-acetate is
almost 100% extracted, the cerebral EF is approxi-
mately 5-fold less. Nevertheless, brain uptake is
large enough to allow quantification. One conse-
quence of the lower EF is the blunted increase of K1
compared with CBF during stimulation. In the
Figure 3 Summary of animal data. Panels (A and B) demonstrate the reproducibility of parameters K1 and k2. There was no
significant change of K1 and k2 between sequential baseline experiments. Panels (C and D) show the increase of K1 and k2 during
infraorbital nerve stimulation. The values of k2 after the administration of dichloroacetate (DAC, 50 mg/kg) at baseline and during
infraorbital nerve stimulation are demonstrated in panel (E). The P-values were calculated using the Wilcoxon signed rank test.
Values are given as mean±s.d.
Figure 4 Time–activity curves of 1-11C-acetate uptake in the
human visual cortex normalized to injected activity per kg
bodyweight yielding standardized uptake values (SUV). The
curves represent mean data from all six human experiments.
During visual stimulation the clearance of 11C activity is larger
compared with baseline. Note also the modestly faster wash-in
of radioactivity during stimulation.
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human study K1 increased 11% compared with a
64% increase in CBF (visual cortex).
Quantitative Relationship Between k2 and Astrocytic
CMRO2
In the following discussion about the meaning of the
rate constant k2 we provide arguments that k2 may
be strongly related to CMRO2. However, it is clear
that a direct proof is not given and would be difficult
to establish, as there is actually no data available to
prove this conclusion directly. One major reason is
that a direct measurement of astrocytic CMRO2 is yet
impossible in vivo.
We hypothesize that k2 is directly related to
CMRO2 in the astrocytes as has been demonstrated
in the heart for the myocytes (Buck et al, 1991).
Prerequisites for this hypothesis are (1) the washout
of radioactivity from the volume of interest is indeed
because of the loss of 11C-CO2 and (2) the rate-
limiting step determining k2 is the production of
11C-CO2 and not its removal.
Prerequisite (1): There seems to be no doubt that at
least part of the radioactivity loss is because of
11C-CO2, because the production of labeled CO2 from
exogenous 1-14C-acetate has been proven in astro-
cyte cultures (Waniewski and Martin, 1998). How-
ever, a quantitative proof of prerequisite (1) would
be difficult. One theoretical possibility would be the
measurement of the arterio-venous difference of
11C-CO2. However, a first order estimation of this
difference demonstrates that it would be in the order
of 4% of the total blood counts. The conclusive
demonstration of such a small difference would
require a prohibitively large amount of animals.
Prerequisite (2): It is well known that CO2 diffuses
practically freely across the blood–brain barrier
(Paulson, 2002). It could therefore theoretically be
possible that the removal of CO2 by the blood is a
Figure 5 Summary of human data. The change of CBF from baseline to visual stimulation in the three examined brain areas is
demonstrated in the top panels (A–C), the one of K1 and k2 of 1-11C-acetate in the middle (D–F) and bottom panels (G–I),
respectively. The P-values were calculated using Wilcoxon signed rank test. Values are given as mean±s.d.
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limiting factor for the washout of CO2. However, the
lack of a change of k2 after the acetazolamide-
induced blood flow increases demonstrates that the
removal of the radioactivity from the volume of
interest is not a limiting factor.
Other arguments which point at a strong relation-
ship between k2 and astrocytic CMRO2 are (1) the
increase of k2 during stimulation, (2) the delay of
the onset of the label washout and the decrease
of the K1/k2 ratio during stimulation, (3) the behavior
of k2 under dichloroacetate, and (4) reasonable
values of astrocytic CMRO2 can be obtained by
applying the calibration established in the dog heart.
Changes of k2 During Increased Brain Activity
Parameter k2 significantly increased during stimula-
tion. In the animal study, k2 almost doubled from
baseline to infraorbital nerve stimulation, indicating
a substantial increase in oxygen consumption. In the
human study, the increase in the visual cortex was
63%. Although not significant, there also seemed to
be a trend toward higher values in cerebellum and
frontal cortex. In fact, omitting the subject with a
decreased value during stimulation, the increase
became significant, not surprising considering the
connectivity in the brain.
Delay of the Washout Onset and the Decrease of the
K1/k2 Ratio During Stimulation
Another result pointing at 11C-CO2 as the washout
agent is the delay of the washout onset (bottom
graph of Figure 2). Such a delay for the appearance
of labeled CO2 was demonstrated by Waniewski and
Martin (1998) in cultured astrocytes and is
explained by the fact that labeled CO2 is only
produced in the second turn of the label in the
TCA cycle. If the loss of label was substantially
because backdiffusion of labeled acetate, one would
not expect a delay. Furthermore, if backdiffusion of
labeled acetate was the main factor determining k2,
one would expect the same effect of stimulation on
K1 and k2, that is, the ratio K1/k2 would remain
constant. However, the data demonstrate a markedly
lower ratio during stimulation. In the anesthetized
rat studies, the mean ratio dropped 44% (P = 0.08),
in the studies with dichloroacetate the decrease was
53% (P = 0.001) and in the human visual cortex the
ratio dropped 44% (P = 0.048). This behavior sug-
gests that the labeled compounds entering and
leaving the brain tissue are different. The mentioned
points are all consistent with the hypothesis that the
washed out compound is indeed 11C-CO2. However,
we cannot completely exclude that some label loss
is because of release of other labeled substrates,
particularly because of efflux of glutamine, which is
quickly labeled after injection of radiolabeled
acetate (Cremer, 1970). Despite the fact that the
blood–brain barrier is closed for the passage of
glutamate and glutamine from blood to brain, the
reverse direction seems possible. Glutamine is taken
up by endothelial cells and intracellularly converted
by the enzyme glutaminase to glutamate. When the
glutamate concentration within endothelial exceeds
the one in plasma net transport of glutamate takes
place through facilitative transporters (Hawkins
et al, 2006). The high number of steps involved in
this process and the fact that normal plasma
concentration of glutamate is approximately 10
times higher than glutamate concentration in the
extracellular fluid of the brain (Hawkins et al, 2006)
indicate that this process is slow and probably not of
relevance during our acquisition period of 20 mins.
Pharmacological Interventions Using Dichloroacetate
and Acetazolamide
The dichloroacetate experiments are also consistent
with the hypothesis that k2 is related to CMRO2.
This compound activates pyruvate dehydrogenase
(Abemayor et al, 1984) by inhibiting its phospho-
rylation by the PDH kinase (Whitehouse et al, 1974).
As a consequence more pyruvate is converted to
acetyl-CoA and less to lactate and the concentration
of acetyl-CoA is expected to increase. If the rate
constants in the following chain of acetyl-CoA
oxidation, which are expected to be related to k2,
remained the same, the rate of the acetyl-CoA
metabolism would increase and with it most likely
CMRO2. However, as the energetic demand is
unchanged there is no reason why CMRO2 should
increase. Consequently one would expect a decrease
in k2 and this is exactly what was observed, at
baseline as well as during stimulation. A good
candidate for regulation at this stage is citrate
synthase, which condenses acetyl-CoA and oxalo-
acetate into citrate. It has been documented that this
enzyme is inhibited by increased concentrations of
acetyl-CoA (Bayer et al, 1981). This inhibition could
be a major reason for the observed decrease of k2
after dichloroacetate. Furthermore, the suggested
increase of the cold acetyl-CoA concentration under
dichloroacetate is itself indirect evidence for the
ability of astrocytes to completely oxidize glucose,
as is the work by Lovatt et al (2007), which
confirmed significantly higher relative expression
of almost all TCA-cycle enzymes in freshly isolated
astrocytes than neurons and showed that the
oxidative pathways were active in astrocytes.
Analogy with Previous Heart Studies
The idea to use the washout rate k2 of 1-
11C-acetate
as a marker of CMRO2 was inspired by earlier
studies performed in the heart (Armbrecht et al,
1990; Buck et al, 1991; Lindner et al, 2006). In those
studies it was clearly established that k2 reflects
myocardial oxygen consumption in a linear fashion.
One rough indication that this approach may also be
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valid in the brain is derived from the following
estimation. In the dog heart, the relationship
between CMRO2 and k2 was CMRO2 (mL/min/
100 g) = 48.8 mL/100 g k2, (per minute). Applica-
tion of this relationship to this study yields an
astrocytic CMRO2 of 0.7 mL/min per 100 g in rats
and humans at baseline. This amounts to approxi-
mately 20% of whole brain oxygen consumption
(3.4±0.28 mL/min per 100 g in humans (Kety and
Schmidt, 1948)). This value compares favorably to
the published values for the fraction of astrocytic
ATP generation by oxidative processes (Hertz and
Kala, 2007; Hertz et al, 2007; Oz et al, 2004) which
are in the range of 14% to 30%.
Is k2 Specific for Astrocytic Metabolism?
One important observation in this regard is that
labeled acetate is taken up only by astrocytes and
not neurons (Waniewski and Martin, 1998). How-
ever, a fraction of the label will eventually end up in
neurons as labeled glutamine/glutamate (via the
glutamate/glutamine cycle), which was produced
via the a-ketoglutarate-glutamate step in the astro-
cytes. Nevertheless, the transfer of labeled gluta-
mine to neurons is slow relative to the 20 mins
acquisition time of this study. Lebon et al (2002)
investigated astrocytic energy metabolism using
nuclear magnetic resonance spectroscopy and
2-13C-acetate in humans. They concluded that the
labeled glutamine/glutamate observed during the
first 20 mins after the start of the 2-13C-acetate
infusion reflected astrocytic glutamate only. It there-
fore seems reasonable to assume that most of the 11C
activity measured in our study was originating from
astrocytes. Even if a small fraction of labeled
glutamine/glutamate had reached the neurons, the
contribution of neuronal 11C-CO2 production could
be expected to have been small. Hertz et al (1988)
demonstrated in cell cultures, that glutamate oxida-
tion of neurons was at most 25% of the one in
astrocytes. In addition, a recent work found a 4.3-
fold higher expression of the enzyme glutamate
dehydrogenase Glud1 in astrocytes, also suggesting
a substantially higher capacity for astrocytes to
metabolize glutamate (Lovatt et al, 2007).
Comparison of the k2 Method with Autoradiography
Cruz et al (2005) investigated the accumulation of
2-14C-acetate during acoustic stimulation in rats
using autoradiography performed 5 mins after tracer
injection. They reported a 15 to 18% increase of
2-14C-acetate uptake in the stimulated compared
with the contralateral structures. These results are in
line with our experiments. At 5 mins, the uptake of
1-11C-acetate was 14% higher in the stimulation
compared with the baseline experiments (Supple-
mentary Figure S1). This value was calculated by
simulating tissue time–activity curves with a mean
input curve and the mean K1 and k2 values of the
stimulation and baseline experiments. Here, it is
crucial to point to an important difference in the
methodology. By evaluating just one time point as in
autoradiographic studies, it is not easy to determine
to what degree the differential uptake is influenced
by increased blood flow, although this influence
seems to be low for acetate (Dienel et al, 2007), but
probably not negligible as our demonstration of a
small K1 increase during stimulation suggests. To
separate delivery and washout, a kinetic approach
as chosen in this study seems advantageous. How-
ever, autoradiographic studies deliver images and,
when using the long-lived 14C, allow an easier
determination of metabolites.
Figure 6 One-tissue compartment models used in animal and
human studies to analyze CBF using H215O (A) and the kinetics
of 1-11C-acetate respectively (B). K1 describes the transfer of
acetate from blood to tissue whereas k2 corresponds to the flux
of radiolabel from tissue to blood. Labeled acetate in tissue
(Cactiss) is converted to acetyl-CoA, catalyzed by acetyl-CoA
synthetase. Acetyl-CoA then enters the TCA cycle, where the
label can either be transferred to CO2 or metabolites (Cmtiss)
such as glutamine and glutamate which were produced via
a-keto-glutarate. Some labeled metabolites will reenter the TCA
cycle at the a-keto-glutarate level and in this way yield more
labeled CO2. In theory, k2 denotes the backdiffusion of all
labeled species from tissue. However, as discussed in the main
text, we argue that the loss of label is mainly because of
backdiffusion of 11C-CO2, and that the rate of this label loss,
described by k2, is reflecting the production of CO2 and is
therefore closely related to oxidative metabolism.
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Using the short-lived isotope 11C we simply
concentrated on two aspects of the label kinetics,
delivery, and washout. We cannot deliver any data
concerning the fate of the label between these steps,
which may be very complex. An indication of this
complexity is demonstrated in the model of
Figure 6. Previous work by Berl and Frigyesi
(1969) demonstrated (1) that 5 mins after injection
of 1-14C-acetate most label is found in amino acids
and (2) that there is a decline of their concentration
afterwards. This may indicate that most acetate
oxidation happens indirect via amino acids. More
extended information on the fate of the label are
found elsewhere (Dienel et al, 2007; Berl and
Frigyesi, 1969). Nevertheless, still more studies are
needed to identify the contribution of acetate and
TCA cycle metabolites as direct substrates for
oxidative metabolism.
General Remarks
Because of the delay of the onset of the label
washout, k2 is smaller during the first few minutes
after injection. This effect was not taken into
account in the tracer kinetic modeling, for example,
k2 was assumed constant. To estimate the resulting
error we calculated simulated tissue time–activity
curves with k2 = 0 (during the first 5 mins) and 0.027
per minute thereafter. The refit of these curves using
a constant k2 demonstrated only a 1.5% change of k2.
Another point concerns parameter identifiability.
The sensitivity analysis demonstrated that the
dependence of tissue activity on k2 is more pro-
nounced at the higher values, implying that the k2
values during baseline are less reliable than during
stimulation. This aspect and the fact that k2 at
baseline is relatively small may lead to a relatively
large error margin in the ratio k2 simulation/k2 baseline.
We also did not consider the effect of blood-borne
11C-CO2 on K1 and k2. Most of the CO2 in blood is
converted to HCO3
, which does not cross the blood–
brain barrier. Approximately 5% of total HCO3
/CO2
is present as dissolved 11C-CO2 (Brooks et al, 1984)
which freely penetrates the brain. We constructed
simulated tissue time–activity curves using the one-
tissue compartment model and the blood-borne 11C-
CO2 as a second input curve. K1 and k2 values for
this fraction of CO2 were taken from Brooks et al
(1984). These tissue time–activity curves were then
refitted using the standard one-tissue compartment
model not considering blood borne 11C-CO2. The
deviation of the K1 and k2 values was less than 1.5%,
demonstrating that the effect of blood-borne 11C-CO2
on K1 and k2 is negligible.
Summary
1-11C-acetate seems a promising tracer to investigate
astrocytic oxidative metabolism in animals and
humans. If the washout rate indeed represents the
production of 11C-CO2, then its increase during
stimulation would point to a substantially higher
astrocytic oxidative metabolism during brain activa-
tion. However, the quantitative relationship be-
tween k2 and CMRO2 needs to be determined in
future experiments.
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Appendix
Details of b-Probe Experiments
and Human PET Measurements
Blood and Tissue Processing
(1) Physiological blood parameters: Several blood
gas variables (pH, pCO2, pO2) relevant to cerebral
energy metabolism were measured with a pH/blood
gas analyzer (AVL, Compact 3, Roche Diagnostics,
Switzerland) before the start of tracer kinetic
measurements. Plasma lactate levels were deter-
mined before the first tracer injection in 24 animals
(Ektachem DT, Kodak, USA). In animals of group 5
(dichloroacetate challenge) lactate levels were
determined twice, before and 4 h after injection of
dichloroacetate respectively (Ektachem DT,
Kodak, USA). In five animals there were technical
problems with the analyzer rendering a measure-
ment impossible.
(2) Determination of the arterial plasma input
curve: For the CBF measurements arterial blood was
continuously drawn during scanning and the
activity in the catheter was measured in a
coincidence counter (GE Medical Systems), which
was cross calibrated with the b-scintillator and
the PET scanner respectively. During the
1-11C-acetate scan arterial radioactivity was also
measured online for the total scan time in the
animal experiments (for an example of acquired
time–activity curves see Supplementary Figure S2).
In the human study, it was acquired online only for
the first 5 mins so as not to miss the peak of
the arterial input curve, thereafter for the remaining
15 mins 4 single samples were taken manually
at different time points (around 3, 6, 15 and
25 mins) and processed as described below.
Whole-blood activity was then corrected for (1) a
different tracer concentration in whole blood and
plasma and (2) the build up of labeled metabolites.
The ratio ‘11Cplasma/
11Cwhole blood’ was determined in
all animals at different time points (three blood
samples per injection). The data of all animals were
then pooled and the time course of the ratio was
approximated by fitting a quadratic polynomial to
the data. This function was then used to convert
counts in whole blood to counts in plasma. In
humans, the 11C concentration in whole blood (CB)
was first converted to 11C concentration in plasma
(CPL) using the same conversion function as
determined in rats.
Secondly, plasma activity was corrected for the
build-up of labeled metabolites using data from
previous 1-11C-acetate studies in the human heart
(Buck et al, 1991).
(3) Metabolite analysis in blood: Three blood
samples (approximately 400 mL each) were collected
at different time points during each 20-min acquisi-
tion for analysis of authentic tracer and metabolites.
These samples were first centrifuged for 3 mins at
2000g. Proteins were then precipitated with 75 mL
acetonitrile in 50mL plasma. After a second centri-
fugation for 3 mins at 2000g, the composition of the
11C-derived radioactivity in the supernatant (80 mL)
was analyzed by high-pressure liquid chro-
matography on a polymeric column (PRP-1, 5-mm,
250 4.1 mm i.d.; Hamilton, USA) with 3 mmol/L
phosphoric acid in water (pH 2.67) as the mobile
phase (1 mL/min). The amount of authentic tracer
was expressed as a fraction of total plasma
11C counts (f).
The fraction data of all animals was then pooled
and the time-course of the fraction was approxi-
mated by a decaying exponential function of the
form function f = 1a(1exp(mt)). This function
was subsequently used to convert the total plasma
activity to the time course of authentic 1-11C-acetate
( = input curve).
Data Analysis
In the animal and human studies the analytical and
statistical methods were similar as described below.
All calculations were performed using the software
package PMOD (Mikolajczyk et al, 1998; PMOD
Technologies, Adliswil, Switzerland).
(1) Cerebral blood flow measurements: The basis
of the calculation for CBF measurements was the
one-tissue compartment model including a partition
coefficient for H2
15O (see Figure 6A). The change of
the radioactivity concentration in tissue CT is then
defined by the following differential equation
dCT=dt ¼ CBFðCAðtÞ  CðtÞ=pÞ ð1Þ
where CA is the arterial tracer concentration and p is
the tissue partition coefficient, for example, that
fraction of tissue that is permeable for H2
15O. In this
configuration CTISS is the concentration of H2
15O in
1 mL of brain and it is assumed that H2
15O
immediately reaches a homogeneous concentration
in permeable space and no division into a vascular
and a tissue compartment is necessary. The analy-
tical solution of Equation 1 is
CT ¼ CBF expðCBF=p tÞ  CA ð2Þ
where # means mathematical convolution.
Equation 2 was fitted to the data using least
squares fitting (Marquardt algorithm) implemented
in the software PMOD (Mikolajczyk et al, 1998).
Before that data analysis tissue TACs and arterial
input curves were corrected for physical decay
of 15O.
With the human H2
15O PET data we calculated
quantitative parametric maps representing regional
CBF using the integration method described
by Alpert et al (1984). This method yielded
maps of K1 and k2 which represent regional
CBF and regional CBF/p respectively (p = partition
coefficient). Before calculation of the parametric
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maps, the input curve was corrected for delay and
dispersion.
(2) 1-11C-acetate experiments: The investigated
method consisted of standard compartmental
modeling using an arterial input function.
Tracer kinetic modeling was performed using the
one-tissue compartment model depicted in
Figure 6B.
K1 describes uptake of tracer across the blood–
brain barrier. K1 is related to the first pass EF and
CBF through the following equation: K1 = EFCBF.
This equation was used to determine EF in the
animal and human experiments.
k2 represents back diffusion of radioactivity from
tissue to vascular space.
Tracer exchange between the compartments
is described by the following differential
equation:
dCT
dt
¼ K1Cp  k2CT ð3Þ
As the total activity measured in a region is
composed of counts from tissue and blood, all
models contained a parameter (a) correcting for
blood activity.
Cvol ¼ ð1 aÞCT þ aCblood ð4Þ
where CVOI, in the human PET study is the
11C
activity concentration in the defined volume of
interest, in the animal study it is the 11C activity
measured by the tip of the b-scintillator; a, percen-
tage of intravascular space in tissue; CT, activity in
the extra vascular compartment; CB, total blood
activity.
CT was calculated by numerical integration of the
differential equations. The correction for the con-
tribution of blood in the brain (a) was fixed at 0.05.
This value considers that signals originating from
large superficial pial vessels impact the b-scintilla-
tor measurements.
Delay of Onset of Radiolabel Washout
To check whether the start of the radioactivity
washout from tissue was delayed, the first 5 mins
of data after tracer injection were refitted with
only k2 as a free parameter and K1 fixed to the full
length fit.
Supplementary Information accompanies the paper on the Journal of Cerebral Blood Flow & Metabolism website
(http://www.nature.com/jcbfm)
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In Vivo Evidence for Lactate as a Neuronal Energy Source
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Cerebral energymetabolism is a highly compartmentalized and complex process in which transcellular trafficking ofmetabolites plays a
pivotal role. Over the past decade, a role for lactate in fueling the energetic requirements of neurons has emerged. Furthermore, a
neuroprotective effect of lactate during hypoglycemia or cerebral ischemia has been reported. The majority of the current evidence
concerning lactate metabolism at the cellular level is based on in vitro data; only a few recent in vivo results have demonstrated that the
brain preferentially utilizes lactate over glucose. Using voltage-sensitive dye (VSD) imaging, beta-probe measurements of radiotracer
kinetics, and brain activation by sensory stimulation in the anesthetized rat, we investigated several aspects of cerebral lactate metabo-
lism. The present study is the first in vivo demonstration of themaintenance of neuronal activity in the presence of lactate as the primary
energy source.The lossof thevoltage-sensitivedye signal foundduring severe insulin-inducedhypoglycemia is completelypreventedby lactate
infusion. Thus, lactate has a direct neuroprotective effect. Furthermore, we demonstrate that the brain readily oxidizes lactate in an activity-
dependentmanner.Thewashoutof 1-[11C]L-lactate, reflecting cerebral lactateoxidation,wasobserved to increaseduringbrainactivation from
0.077 0.009 to 0.105 0.007 min1. Finally, our data confirm that the brain prefers lactate over glucose as an energy substrate when both
substratesareavailable.Using[18F]fluorodeoxyglucose(FDG)tomeasure the local cerebralmetabolic rateofglucose,wedemonstrateda lactate
concentration-dependent reduction of cerebral glucose utilization during experimentally increased plasma lactate levels.
Introduction
For a long time, it was considered that blood-borne glucose is the
sole energy substrate in the adult healthy brain. However, several
studies have reported a different situation in the developing and
diseased brain. For example, in breast-fed newborns and suckling
rats, the utilization of monocarboxylates, such as lactate, and
ketone bodies is increased (Cremer, 1982; Dombrowski et al.,
1989; Nehlig and Pereira de Vasconcelos, 1993). In addition, a
neuroprotective role for exogenous lactate in pathologic situa-
tions, such as prolonged starvation, diabetes, and cerebral isch-
emia, has been documented on several occasions (Gjedde and
Crone, 1975; Schurr et al., 2001; Mason et al., 2006; Berthet et al.,
2009). However, it is still unclear whether the neuroprotective
effect of lactate is indirect [e.g., via increased cerebral blood flow
(CBF) caused by hyperlactemia (Shackford et al., 1994)] or whether
lactate can serve as a direct neuronal energy substrate.
One of the first indications that lactate is not only a product of
the metabolic chain but also a potentially important alternative
neuronal energy substrate was documented more than two de-
cades ago from the demonstration that lactate is able to support
synaptic function in the absence of glucose in rat hippocampal
slices (Schurr et al., 1988). For the living brain, the situation is less
clear. No information about the capability of lactate to sustain
neuronal action in vivo could be provided. Recently, independent
groups have reported lactate utilization by the brain in humans
(Gallagher et al., 2009; van Hall et al., 2009; Boumezbeur et al.,
2010). There is also evidence that lactate oxidation is preferen-
tially located in neurons. Bouzier et al. (2000) used 3-[13C]lactate
to investigate cerebral lactate metabolism. From the accumula-
tion of labeled metabolites, they concluded that lactate metabo-
lism is located in a compartment devoid of pyruvate carboxylase,
e.g., neurons.
Furthermore, astrocytic production of lactate, which serves as
an energy pool for neurons, was proposed (Pellerin and Magis-
tretti, 1994), but neuronal lactate use has still to be demonstrated
in situ.
In the present study, we followed a multimodal approach.
First, using optical voltage-sensitive dye (VSD) imaging to di-
rectly monitor the synaptic activity in the somatosensory cortex,
we report for the first time that lactate is capable of sustaining
neuronal activity for a time period of hours in the quasi-absence
of glucose in the living organism. Second, applying radiotracer
kinetic measurements of 1-[11C]L-lactate accumulation and clas-
sical cerebral glucose utilizationmeasurements using FDG,wedem-
onstrate that lactate ismetabolized by the intact brain in an activity-
dependent manner.
Materials andMethods
Animal preparation
All the animal experiments were approved by the local veterinary author-
ities and were performed by licensed investigators. In total, 64 animals
(male adult Sprague Dawley rats; weighing 220–350 g) were included in
the study. Before measurements, the animals were fasted overnight to
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standardize plasma levels of glucose. Surgery was performed under 2.5–
3.5% isoflurane anesthesia and involved the placement of an arterial and
a venous catheter and tracheotomy for mechanical ventilation. For the
cortical beta-probe acquisitions, the cranial bone above somatosensory
cortices was thinned to translucency. For the voltage-sensitive dye imag-
ing experiments, a craniotomywas performed. Staining with the voltage-
sensitive dye RH1691 (Optical Imaging) was done through the intact
dura mater for 90 min. Leaving the dura intact reduces the movement
artifact during recording and decreases the risk of cortex irritations (Lip-
pert et al., 2007). After staining, the dye was removed by washing with
dye-free Ringer’s solution. Plasma glucose and lactate levels were
determined periodically (Ektachem DT; Eastman Kodak). The actual
experiments were performed under -chloralose anesthesia (44 mg/kg
bodyweight, s.c.). Several blood gas variables (pH, PCO2, PO2) (AVL,
Compact 3; Roche Diagnostics) and metabolic measures such as plasma
glucose and lactate levels (Ektachem DT; Eastman Kodak), which are
relevant parameters influencing lactate uptake in the brain, were mea-
sured in all animals before the start of measurements. Ventilation was
adjusted to reach physiological blood gas values.
Voltage-sensitive dye imaging
The VSD was excited with 630 nm light from an LED (Aculed; PerkinEl-
mer Life and Analytical Sciences). A custom-built tandem lens system
consisting of two 50mm objectives and dichroic and emission filters was
used. Data were collected with a high-speed CMOS-based camera (Mi-
cam Ultima; Scimedia). Images were collected with 1 ms temporal reso-
lution. Images were analyzed using custom-written Matlab routines and
the software package PMOD (Mikolajczyk et al., 1998). Bleaching of
fluorescence was corrected by subtraction of a best-fit double exponen-
tial. Time courses of fluorescence changes were quantified asF/F0 from
circular regions of interest of constant diametermanually placed over the
activated area. To compare VSD signal from different animals, region of
interests (ROIs)were centered on the location of the earliest responses. In
addition, to estimate the spatial extent of the neuronal activation at the
timepoint of the highest activation (peak amplitude), the area containing
voxels 70% of the maximum within the experiment was determined.
The amplitudes of sensory-evoked responses were calculated as the
change in the VSD signal (F/F0) over a fixed time interval for each
experiment. Finally, the time until peak response was determined as the
time span between stimulation onset and peak amplitudewithin theROI.
Baseline was the 10 ms period immediately before the stimulus.
In VSD experiments, five experimental groups were examined: (1)
effect of hyperlactemia (n 4) on neuronal integrity, (2–4) evolution of
the VSD signal after induction of severe hypoglycemia (insulin at 20
IU/kg, i.p.) and subsequent continuous infusion of saline (n  5), glu-
cose (n 5), or lactate (n 5), respectively, and (5) control experiments
with saline infusion only (n 3).
Radiotracer experiments
Radiotracer synthesis: production of 1-[11C]L-lactate. Racemic 1-[11C]lactic acid
was made by [11C]cyanohydrine synthesis starting from [11C]HCN
(trapped as [ 11C]KCN) and acetaldehyde bisulfite adduct. The quantita-
tively formed 1-[ 11C]DL-lactonitrile was hydrolyzed by reflux in concen-
trated HCl, and the reaction mixture was introduced directly into a
semipreparative polymeric HPLC column (250 10mm, 0.03%H3PO4
as the mobile phase; Polymerx 10; Phenomenex) in which the product
was isolated from the aggressive reaction matrix. Then the collected ra-
cemic 1-[ 11C]lactic acid was automatically introduced into a preparative
chiral HPLC column coated with a penicillamine-derived chiral selector
and eluted with 1 mM CuSO4 solution as the mobile phase in which both
enantiomers were separated by ligand exchange chromatography. The
fractions corresponding to [ 11C]D-lactic acid or [ 11C]L-lactic acid were
passed through anion exchanger Sep-Pak cartridges (Accell Plus QMA,
in CO3
2 form) in which the Cu2 ions (as insoluble carbonate) and the
[ 11C]lactate are retained. The latter was selectively washed out from the
cartridges with 2 mmol/L sodium phosphate buffer, pH 7.4, to obtain
injectable solutions of pureNa-[ 11C]D-lactate and L-lactate enantiomers.
The quality control of the final product was done by chiral ligand ex-
change HPLC. The procedure led to a product of 99% chemical and
enantiomeric purity. The specific activity at the end of synthesis was
400GBq/mol. FDGwas obtained from the daily in-house production
by the Radiochemistry Department of the University Hospital Zurich.
Beta-probe experiments using 1-[11C]L-lactate and FDG. A recently de-
veloped two-channel system with surface probes was used for the mea-
surement of the radioactivity concentration in brain cortices (Wyss et al.,
2009). The used devices consist of scintillator crystals with a thickness of
0.2 mm and a diameter of 3 mm. The beta scintillators were made light-
tight by applying a uniform coating of silver particles. The scintillations
were measured using a photomultiplier tube and counting electronics
(PerkinElmer Life and Analytical Sciences). The limited range of beta
particles within biological tissues leads to a limited detection volume
centered around the scintillating tip of the probe (Wyss et al., 2009). The
sensitivities of the used scintillators were 0.31–0.60 cps/kBq/cc.
For beta-probemeasurements, the arterial and venous lines were con-
nected to form an arterio-venous (av) shunt. The av shunt was used for
continuous monitoring of arterial blood pressure, injection of the radio-
tracers, continuousmeasurement of the total arterial blood radioactivity,
and the collection of blood samples. For the recording of the total blood
radioactivity, the shunt ran through a coincidence counter (GE Medical
Systems) (for details, see Weber et al., 2002). Before the actual experi-
mentalmeasurements for 1-[ 11C]L-lactate, the kinetic properties and the
buildup of metabolites of the novel radiotracer were characterized in 10
animals. In addition, in four of these animals, the first pass extraction
fraction was determined with additional measurements of CBF (see be-
low). All subsequent 1-[ 11C]L-lactate experiments consisted of two ac-
quisitions. For each acquisition, 100–150 MBq of radiotracer was
intravenously injected. First, the change of 1-[ 11C]L-lactate kinetics from
baseline conditions to increased neuronal activity [electrical infraorbital
nerve stimulation (ION): 2 mA, 2 Hz, 1 ms pulses applied during the
whole acquisition period; n  5] and the effect of monocarboxylic acid
transporter blockade using -cyano-4-hydroxy-cinnamate (CIN) (n 
5) was investigated. CIN was injected intraperitoneally (90 mg/kg) 30
min before tracer injection.
FDG was used to determine the local cerebral metabolic rate of glucose
(LCMRglu).ForeachFDGacquisition,50–80MBqof tracerwas injected.All
FDG experiments consisted of two measurements. Accumulation of FDG
was measured at baseline (SAL) and at artificially increased plasma lactate
levels (LAC) (100 mol  kg1  min1 during the first 20 min; thereafter,
50mol  kg1  min1, i.v.) during rest conditions (n 4 for SAL; n 13
for LAC) and during activation (n 2 for SAL; n 5 for LAC).
Characterization of 1-[11C]lactate. The total radioactivity in arterial
blood was continuously recorded over 40min using a coincidence coun-
ter (GE Medical Systems). Whole blood activity was then corrected for
(1) a different tracer concentration in whole blood and plasma and (2)
the buildup of labeledmetabolites. The ratio 11Cplasma/
11Cwhole blood was
determined in all animals at different time points (three to four blood
samples per animal). The data of all animals were then pooled, and the
time course of the ratio was approximated by fitting a quadratic polyno-
mial to the data. This function was then used to convert counts in whole
blood to counts in plasma.
Samples (about 400 l) were collected at different time points after
tracer injection, with a maximum of four blood samples per animal, to
determine the time course of the ratio of the 11C activity in plasma to
whole blood and for analysis of authentic tracer and metabolites. These
samples were first centrifuged for 3 min at 2000 rpm. Proteins were then
precipitated with 75 l of acetonitrile in 50 l of plasma. After centrifu-
gation for 3 min at 2000 rpm, the composition of the 11C-derived radio-
activity in the supernatant (80l) was analyzed by HPLC on a polymeric
column (5 m, 250 4.1 mm inner diameter; PRP-1; Hamilton) with 3
mmol/L phosphoric acid in water, pH 2.67, as the mobile phase (1 ml/
min). The retention times of [ 11C]HCO3
 (3.3 min) and lactic acid (5.1
min) were determined by using aqueous solution of NaHCO3 and DL-
lactic acid as reference compounds, detected by UV absorption at 220
nm. The amount of authentic tracer was expressed as a fraction of total
plasma 11C counts.
The fraction data of all animals was then pooled, and the time course
of the fraction was approximated by a decaying biexponential function.
This function was subsequently used to convert the total plasma activity
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to the time course of authentic [ 11C]lactate (input curve). At the end of
these experiments, the rats were perfused with PBS, and brains were
prepared for measurements with the HPLC system. Each brain was first
homogenized before adding acetonitrile (150%). The subsequent proce-
dure was the same as with the blood samples described above, except that
the amount of supernatant injected into the HPLC system was 200 l.
CBF measurements (used for estimating the first-pass extraction fraction
of lactate). The basis of the CBF calculation was the one-tissue compart-
ment model, including a partition coefficient for H2
15O. The change of
the radioactivity concentration in tissue Ctiss is then defined by the fol-
lowing differential equation:
dCtiss/dt  CBF(Ca(t)  Ctiss(t)/p), (1)
where Ca is the arterial tracer concentration, and p is the tissue partition
coefficient, e.g., the fraction of tissue that is H2
15O permeable. In this
configuration, Ctiss is the concentration of H2
15O in 1 ml of brain, and it
is assumed that H2
15O immediately reaches a homogeneous concentra-
tion in permeable space and no division into a vascular and a tissue
compartment is necessary. The analytical solu-
tion of Equation 1 is as follows:
Ctiss  CBF * e
(CBF/pt )VCa, (2)
whereV representsmathematical convolution.
Equation 2 was fitted to the data using least-
squares fitting (Marquardt algorithm) imple-
mented by the software PMOD(Mikolajczyk et
al., 1998). Before data analysis, tissue time ac-
tivity curves and arterial input curves were cor-
rected for the physical decay of 15O.
Analysis of the radiotracer data
The calculations and parameter fitting were
performed using the software PMOD (Mikola-
jczyk et al., 1998). Data were corrected for
physical decay and multiplied by a calibration
factor taking into account differences in sensi-
tivities of the probe system and the coincidence
counter. Before analysis, data were down-
sampled to obtain a 10 or 30 s resolution for
11C and 18F data, respectively. The investigated
methods consisted of standard compartmental
modeling using an arterial input function.
1-[11C]L-Lactate. Tracer kinetic modeling
was performed using the one-tissue compart-
ment model. The parameters are as follows: K1
describes the uptake of tracer across the blood–
brain barrier and is related toCBF and the first-
pass extraction fraction EF (K1  CBF * EF);
and k2 represents the back-diffusion of label
from the tissue to the vascular compartment.
Label exchange between the compartments is
described by the following differential equation:
dCtiss/dt  K1Cplasma(t)  k2Ctiss(t).
(3)
Because the total activity measured in a region
is composed of counts from tissue and blood,
all models contained a parameter () correct-
ing for blood activity:
CVOI  (1)Ctiss  Cblood, (4)
where CVOI is
11C activity measured by the tip
of the beta scintillator,  is the percentage of
intravascular space in the tissue, Ctiss is activity
in the extravascular compartment, Cblood is to-
tal blood activity, and Ctiss was calculated by
numerical integration of the differential equa-
tions. The vascular fraction  was included as a fit parameter that im-
proved the least-squares fit.
The kinetic model was adjusted in two ways for the analysis of dual-
injection data arising from use of the surface probe. (1) Two sets of rate
constants (K1, k2) were used in the calculation of the operational equa-
tion: the first set for the timeuntil the second injection, and the second set
thereafter. The least-squares fit procedure resulted in estimates for all
four rate constants (K11, k21 and K12, k22) and the vascular
fraction. (2) The correction function to derive plasma activity from
whole blood activity was adjusted to distinguish between the contribu-
tions from the two injections. To this end, the blood activity from the first
injection was extrapolated using an exponential function, which was
fitted to the blood activity 10 min before the second injection.
The interpretation of the 1-[ 11C]L-lactate experiments is based on the
following assumptions, which are discussed in detail below: (1) parame-
ter k2 is reflecting the activity of the enzyme lactate dehydrogenase
(LDH), and (2) the total amount of lactate that is oxidized is the product
of k2 and intracellular lactate concentration.
Figure 1. Lactate is able to sustain neuronal activity in the absence of glucose. A, A single electrical pulse applied to the rat’s
hindpaw evoked a transient increase in VSD fluorescence in the primary somatosensory cortex that was abolished after only 150
min in animals receiving saline after the insulin injection (top row) but remained stable in animals infused with glucose (middle
row) or lactate (bottom row) after 240min. B–D, The time courses of the VSD signal displayed a similar result in animals supplied
with glucose (C; gluc) or lactate (D; lac) with sustained amplitude 240min after insulin injection. In contrast, removal of the signal
was observed in animals receiving saline infusion only (B; sal). In the group supplied with lactate, the signal onset was delayed
(example shown inD). The vertical black line represents the time point of hindpaw stimulation. E, Comparison of amplitudes in all
three groups injectedwith insulin at 0min (mean SE; n 5). F–H, Mean plasma levels of glucose and lactate plotted for saline
(F ), glucose (G), and lactate (H ) animals.
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FDG. FDG data were used for calculating LCMRglu. The procedure for
the quantification of the probe studies followed the [ 14C]deoxyglucose
method described by Sokoloff et al. (1977). A compartmentalmodel with
two tissue compartments and four kinetic rate constants (K1 to k4) was
used. The operational equation, which was fitted to the probe time activ-
ity curve, additionally included a vascular fraction  as a fit parameter.
This improved the least-squares fit compared with a fixed value of  
5%. LCMRglu values were calculated from the fitted rate constants:
LCMRglu  K1 * k3/(k2  k3)Cplasma/LC, where Cplasma represents the
plasma glucose concentration, and LC represents the lumped constant
(LC of 0.437).
The kineticmodel was adjusted in twoways for the dual-injection data
analysis. (1) Two sets of four rate constants (K1 to k4) were used in the
operational equation calculation: the first set for the timeuntil the second
injection, and the second set thereafter. The least-squares fit procedure
resulted in estimates for all eight rate constants and the vascular fraction.
(2) The correction function to derive plasma activity from whole blood
activity was adjusted to distinguish between the contributions from the
two injections. To this end, the blood activity from the first injection was
extrapolated using an exponential function that was fitted to the blood
activity 10 min before the second injection.
Statistics
Results are presented as mean  SD if not otherwise stated. To test
differences between different interventions for inter-individual compar-
isons, the nonparametric Wilcoxon’s signed rank test was applied. A p
value of 0.05 was taken as the significance limit.
Results
Lactate can sustain neuronal integrity as an alternative
energy substrate
Severe glucose deprivation was induced by insulin injection (20
IU/kg, injection at time 0 min) while monitoring neural activity
with VSD imaging. In three experimental groups, infusion of
saline, glucose, or lactate was immediately initiated after the in-
sulin injection. The total recording time for VSD imaging is lim-
ited because of dye washout and excitation light-related
amplitude reductions of the signal (Lippert et al., 2007). There-
fore, imaging commenced with delay,100min after the insulin
injection. In animals infused with saline only, blood glucose lev-
els reached 1.5mmol/L already after 60min. Plasma lactate levels
varied on average between 1.0 and 1.5 mmol/L throughout the
whole experimental period (Fig. 1F). Severe hypoglycemia re-
duced the amplitude of the VSD signal by50% from the base-
line after only 140 min after the application of insulin (Fig.
1A,B,E). Thereafter, the signal was further decreased as a result of
severe glucose deprivation. In animals supplied continuously
with glucose, plasma levels of glucosewere not reduced by insulin
action and remained at normoglycemic values (Fig. 1G). Not
surprisingly, the neuronal signal did not show a significant de-
cline throughout the period of data acquisition [270min after the
insulin injection; n  5; not significant (n.s.) compared with
baseline acquisition at 120 min (Fig. 1A,C,E)]. In the group in
which sodium lactate was infused over the whole time period
(plasma lactate levels between 5.5 and 9.7mmol/L), plasma levels
of glucose also exhibited a rapid decline to values 1 mmol/L
within 60 min (Fig. 1H). Nevertheless, the amplitude of the VSD
signal reflecting neuronal activity remained high (n  5; n.s.
compared with the 120 min time point) (Fig. 1A,D,E). The
spread of activation remained constant in the glucose- and
lactate-treated animals within the 240min after the insulin injec-
tion, whereas the extent of activation in the animals receiving
saline infusion only decreased considerably (data not shown). In
the latter group, four of five animals showed no pixels surpassing
70% of the maximal amplitude after 150 min. In the fifth, the
number decreased by50%. The time course of the VSD signal
revealed an accentuated delay of the signal in animals receiving
lactate infusion compared with glucose-infused rats (Fig. 1C,D).
In the animals receiving glucose infusion after insulin injection
(n  5), the times-to-peak were 21.8  1.6, 21.6  1.9, and
20.7  1.5 ms after 120, 180, and 240 min, respectively. In the
lactate group (n  5), delays at the corresponding time points
were 21.2 0.9, 23.5 4.4, and 36.2 10.7 ms. The difference
after 240min was significant between the two groups ( p	 0.05).
Lactate is oxidized by the brain in an
activity-dependent manner
To directly assess lactate use in the adult rodent brain in vivo, we
synthesized radiolabeled 1-[11C]L-lactate. Characterization of
1-[11C]L-lactate revealed suitable properties for use in brain
studies, allowing cerebral tracer kinetic measurements with high
temporal resolution. An extraction fraction (EF  K1/CBF) of
30  10% (n  4) was calculated, which is sufficient to study
physiological processes in the brain and is in good agreement
with previous studies reporting the uptake of L-lactate to be 25–
50% of that of glucose (Knudsen et al., 1991; Hassel and Bråthe,
2000). Kinetic modeling showed that a one-tissue compartment
model was sufficient for the analysis of 1-[11C]L-lactate data,
yielding K1 and k2 values measuring the uptake and the release of
radiolabel, respectively. The time courses of the fraction of au-
thentic tracer andmetabolites in plasma are shown in Figure 2. As
in brain, the main metabolite detected in blood was [11C]CO2.
After 20min, the fraction of true tracer fell to40%. In the brain,
Figure 2. 1-[ 11C]L-lactate is a suitable tracer to study cerebral lactate oxidation. A, Mea-
sured radioactivity concentration in the brain (open circles), model fit (black line), and arterial
input curve (gray line). The inset displays the residuals of the fitting to a one-tissue compart-
ment model. The absence of any distribution bias supports the adequacy of the applied one-
tissue compartment model. B, Fraction of native radiolabeled lactate over 40 min after
intravenous injection of 1-[ 11C]L-lactate in blood. The filled circles represent data points from
baseline experiments (n7) performed to characterize the radiotracer, and the solid line is the
corresponding fit of a biexponential curve.
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the analysis revealed 58 8% lactate and 42 8% CO2 after 40
min (n  7). Using for the first time 11C-radiolabeled lactate to
measure cerebral lactate oxidation, we observed a noticeable in-
crease of both rate constantsK1 and k2 during increased neuronal
activity (Fig. 3B, Table 1). Delivery of the tracer increased during
electrostimulation of the infraorbital nerve as reflected by an in-
crease of the CBF-dependent K1 from 0.09 0.01 to 0.12 0.03
ml  min1  ml1 tissue (n 5; change n.s.).
In parallel to the elevated delivery, radioactivity washout (k2)
increased from0.077 0.009 to 0.105 0.007min1 (n 5; p	
0.05). In Discussion, we will argue that this is most likely related
to increased LDH activity during stimulation.
There is strong evidence in our and other studies that the label
leaves the tissue as CO2, which is cleaved off during the conver-
sion of pyruvate to acetyl-CoA by pyruvate dehydrogenase
(PDH) (Fig. 3A). In the present study, the metabolite analysis
revealed only lactate and CO2 as labeled metabolites. This is in
line with a study by van Hall et al. (2009). Using 1-[13C]lactate,
they reported that 86 15%of the label was released as CO2. The
situation is completely different, if lactate is labeled at position 2
or 3. In that case, most of the label ends up in metabolites of the
TCA cycle (van Hall, 1999; Bouzier et al., 2000; van Hall et al.,
2009).
Increased uptake of blood-borne lactate and efficiency of
lactate transport during activation
It is possible to calculate cerebral uptake of blood-borne lactate as
the product of K1 and blood lactate concentration (in this group
of experiments, plasma lactate levels ranged from 1.7 to 2.8
mmol/L) (Table 2). Based on these values, baselinemean cerebral
lactate uptake was estimated to be 0.17 mol  g1  min1 and
increased to 0.22 mol  g1  min1 during stimulation.
A detailed analysis of K1 revealed furthermore that the
stimulation-induced increase cannot be completely explained by
an increase in CBF only but must at least be partly attributable to
an increased transport rate for lactate.We estimated this increase
to be in the order of 30% using the following relationships:
K1  CBF * EF, (5)
where EF can be expressed according to Renkin (1959) and Crone
(1963), and
EF  1  ePS/CBF. (6)
Combining Equations 5 and 6 yields the following:
PS  CBF * ln(1 K1/CBF), (7)
where PS is the permeability–surface area product. We per-
formed a simulation assuming a constant PS from baseline to
ION stimulation. In previous experiments, the applied electro-
stimulation of the ION led to amean increase of CBF from0.35 to
0.50 ml  min1  ml1 tissue (Weber et al., 2003). In the present
series of 1-[11C]L-lactate experiments, K1 increased from 0.09
0.01 to 0.12 0.03 ml  min1  ml1 tissue during ION. Insert-
ing these numbers into Equation 7 demonstrates a 32% increase
of PS, from 0.104 to 0.137 ml  min1  ml1. This suggests that
monocarboxylate transporter (MCT) efficiency increases during
increased demand.
Effect of MCT blockade on lactate uptake
Injection of CIN 30 min before [11C]lactate tracer kinetic mea-
surements reduced K1 from 0.13  0.01 to 0.09  0.01
Figure 3. The brain oxidizes lactate in an activity-dependent manner. A, Schematic of the
biochemical pathways involved in the degradation of 1-[ 11C]L-lactate ( 11C-Lac) and the pro-
posed interpretationof the rate constantsK1 and k2 describing thekinetics of the radiotracer (for
details, see Results). Briefly, K1 represents delivery of 1-[
11C]L-lactate (orange arrow), and k2
reflects kinetically the loss of radiolabel after conversion of lactate to pyruvate and of pyruvate
to acetyl-coenzyme A (purple arrows). During activation (B; S; n 5), delivery (K1) and wash-
out (k2) increased,whereas duringMCTblockade (C; CIN;n5), the transfer of 1-[
11C]L-lactate
slowed down in both directions (Pyr, pyruvate; Ac CoA, acetyl coenzymeA; TCA cycle, tricarbox-
ylic acid cycle). *p	 0.05, n.s., not significant.
Table 1. 1-
1 1CL-lactate kinetics
Animal number
K1 (ml min
1 ml1 tissue) k2 (min
1)
Baseline Stimulation Baseline Stimulation
1 0.081 0.091 0.073 0.082
2 0.085 0.111 0.074 0.105
3 0.097 0.101 0.09 0.107
4 0.086 0.12 0.069 0.112
5 0.111 0.128 0.076 0.095
Mean 0.092 0.110 0.076 0.100
SD 0.01 0.01 0.01 0.01
Baseline CIN Baseline 4-CIN
6 0.138 0.076 0.116 0.052
7 0.139 0.083 0.115 0.071
8 0.132 0.107 0.102 0.082
9 0.128 0.091 0.109 0.076
10 0.115 0.08 0.098 0.081
Mean 0.130 0.087 0.108 0.072
SD 0.01 0.01 0.01 0.01
Table 2. Plasma lactate levels and calculated cerebral lactate uptake
Animal number
Plasmalactatelevel(mmol/L)
Calculatedcerebral lactateuptake
(K1*lac;mol g
1 min1
Baseline Stimulation Baseline Stimulation
1 2 2.2 0.162 0.200
2 2 2.9 0.170 0.322
3 2 2.1 0.194 0.212
4 1.7 1.6 0.146 0.192
5 1.5 1.5 0.167 0.192
Mean 1.84 2.06 0.17 0.22
SD 0.2 0.6 0.02 0.06
lac, Plasma lactate level.
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ml  min1  ml1 tissue (n 5; p	 0.05)
and k2 from 0.11  0.01 to 0.07  0.01
min1 (n 5; p	 0.05) (Fig. 3C, Table 1).
CIN has been shown to permeate the
blood–brain barrier and to be effective 30
min after intraperitoneal injection (Schurr
et al., 2001). The reduction in K1 after CIN
administration is most likely attributable to
the reduction of lactate transport by a par-
tial blockade of MCTs. The concomitant
reduction in k2 cannot be reliably inter-
preted without additional biochemical
measurements. The fact that the relative
decrease of k2 is of the same magnitude as
the decrease of K1 (33%) points to the
possibility that k2 under CIN blockade
represents back-diffusion of lactate into
vascular space.
Increased blood lactate reduces the
local metabolic rate of glucose
To address the question of how the brain
processes blood-borne lactate compared
with glucose, we artificially increased the
supply of lactate to the brain by continu-
ous intravenous infusion of sodium lac-
tate (Fig. 4A). This led to a significant
increase of plasma lactate levels (from
1.3 0.6 to 5.8 1.6mmol/L;n 10; p	
0.05). Plasma glucose levels were not af-
fected by the continuous lactate infusions.
In all examined animals, a clear reduction
of LCMRglu was observed at resting con-
ditions (decreases ranging from 25 to
49%; n  13; p 	 0.05) (Fig. 4B). The
reduction of the cerebral glucose utiliza-
tion was attributable to both a decreased
delivery of glucose into the tissue (re-
flected by a change of K1 from 0.16  0.05 to 0.12  0.03
ml  min1  ml1 tissue; n 13; p	 0.05) and a reduced phos-
phorylation by hexokinase (k3 decreased from 0.04  0.02 to
0.03 0.01min1;n 13; p	 0.05). The replacement of glucose
by lactate as an energy substrate occurred in a dose-dependent
manner (Fig. 4C).
Reduction in glucose utilization is balanced by the excess of
lactate consumption
The observedmean reduction in glucose utilizationwas 21mol/
100 g/min (Fig. 4B). Because glucose has a six-carbon skeleton,
this corresponds to 42 mol/100 g/min three-carbon substrates
such as pyruvate. The following estimation demonstrates that the
decrease in glucose utilization is quantitatively matched by an
increase in lactate use. For this purpose, we made the following
assumptions: (1) lactate transport from blood into the brain
equals K1 * plasma lactate concentration ([Lac]), (2) K1 ( 0.09
min1 at baseline) does not markedly change within the range of
lactate concentrations found in our experiments, and (3) all the
lactate, which is taken up, is ultimately oxidized by the brain.
Thus, lactate uptake during baseline conditions in the FDG
experiments was 12 mol/100 g/min ( 0.09 min1 * 1.3
mmol/L; mean K1 determined in baseline 1-[
11C]lactate experi-
ments (Fig. 3B) and mean [Lac] from FDG experiments during
saline infusion) and 52 mol/100 g/min during hyperlactemia
( 0.09 min1 * 5.8 mmol/L; mean [Lac] during lactate infu-
sion). The difference of lactate uptake between baseline and hy-
perlactemia conditions is therefore 40 mol/100 g/min (52
mol/100 g/min 12mol/100 g/min). This matches the above
mentioned reduction of three-carbon constituents derived from
glucose during hyperlactemia.
Reduction of glucose consumption during hyperlactemia is
more pronounced during activation
Our results further demonstrate that the reduction of glucose
utilization is not only dependent on blood lactate levels but also
on the level of activation. As shown in Figure 4, D and E, the
decrease of glucose utilization was more pronounced on the ac-
tivated side, as reflected by the decrease of the ratio contralateral/
ipsilateral in the primary somatosensory cortex (i.e., S1contra vs
S1ipsi). During normolactemia, this ratio was 1.65  0.47, but
during hyperlactemia, it decreased to 1.26  0.37 (n  5; p 	
0.05) (Fig. 4E). In two control animals, in which both acqui-
sitions were performed under saline infusion, the ratio of LC-
MRglu between S1contra and S1ipsi remained the same during
the first and the second acquisition (Fig. 4E). Plasma levels of
glucose and lactate behaved in a similar manner as in the
baseline group.
Figure 4. Lactate is preferred over glucose by the brain. A and D detail the protocol during baseline (A) and stimulation (D)
conditions. Overall, hyperlactemia reduced LCMRglu by on average 38% in a dose-dependent manner (B, C) during baseline
conditions. In activated cortex (S1contra), cerebral glucose utilization was further decreased. The effectiveness of stimulation was
controlled autoradiographically (D). The ratio S1contra/S1ipsi decreased from 1.65 0.47 to 1.26 0.37 (E). 1, Acquisition 1; 2,
acquisition 2; LAC, hyperlactemia; SAL, saline. *p	 0.05, n.s., not significant. n 13 for LAC group, n 4 for SAL group at
baseline conditions, n 5 for LAC group, and n 2 for SAL at stimulation conditions.
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Neuronal activity is not reduced by lactate
To verify that the observed reduction in glucose utilization does
not originate from a reduced requirement for energy of the brain
attributable to impaired neural activity, we performed an addi-
tional series of VSD experiments during hyperlactemia. Under
these conditions, increased lactate levels did not affect neuronal
excitability (Fig. 5).
Discussion
For a long time, no functional role has been assigned to cerebral
lactate. Contrarily, the presence of lactate in the brain has been
interpreted as a sign of cerebral harm and of hypoxia (Siesjo¨,
1981). Over the past few decades, this perspective has changed
and it has been postulated that lactate may also possess physio-
logical functions relevant to the CNS. Important roles have been
attributed to lactate such as the modulation of CBF (Gordon et
al., 2008), as a buffer to sustain neuronal energy supply (Kasis-
chke et al., 2004) and most prominently as a pivotal element in
the neuron–gliametabolic cooperation to regulate energy supply
in an activity-dependent manner (for review, see Pellerin and
Magistretti, 2003; Magistretti, 2006). Furthermore, it has been
shown recently that lactate levels are sensed by a specific type of
neuron (orexin neurons in the lateral hypothalamus) to coordi-
nate the balancing of brain activity and energy supply (Lam et al.,
2005; Shimizu et al., 2007; Erlichman et al., 2008; Parsons and
Hirasawa, 2010). Nevertheless, the details of brain energymetab-
olism in general and of lactate as a cerebral energy substrate in
particular are still highly debated.
Lactate serves as a metabolic source
for neurons
It has been shown in vitro that lactate ox-
idation is able to sustain excitatory synap-
tic activity (Schurr et al., 1988; Rouach et
al., 2008), and there have been reports
about lactate protecting cerebral function
during hypoglycemia (Maran et al., 1994;
King et al., 1998). However, the latter in
vivo studies did not use direct neuronal
readouts to assess synaptic activity, and
glucose levelswere above 2.5mmol/L. The
present study is the first in vivo demon-
stration of the maintenance of neuronal
excitability in the presence of lactate as the
primary energy source. The amplitude of
the stimulation-induced increase in neuro-
nal activitywasmaintainedwhen lactatewas
supplied during severe hypoglycemia (Fig.
1).However, the increased delay of theVSD
signal may indicate that lactate alone may
not quite suffice to completely sustain neu-
ronal functioning. Indeed, it has been
shown that glucose is used by neurons to
maintain their antioxidant status via the
pentose phosphate pathway (PPP), which
cannot be fueled by lactate (Magistretti,
2008; Herrero-Mendez et al., 2009). Be-
cause of the low plasma glucose levels and
subsequent small glucose concentration
gradient, the transport into neurons is in-
adequate (Barros and Deitmer, 2010) and
presumably not enough substrate is avail-
able for the neurons to efficiently stimulate
their antioxidant PPP. Neurons, which
are thought to be especially vulnerable against reactive oxygen
and nitrogen species, might not be capable of completely avoid-
ing oxidative damage, whichmay lead to the observed delay of the
electrical signal in the absence of glucose. Furthermore, this find-
ing supports the important role in functional neuroenergetics
dedicated to glucose because glucose is required by the astrocyte
to pump glutamate (Magistretti et al., 1999). Second, lactate is
transported by MCTs in a cotransport with protons (Hertz and
Dienel, 2005). Lactate elevations as performed in our study may
lead to changes in lactate influx that result in alterations of intra-
cellular and extracellular pH in nerve tissue. These changes of the
proton gradient could disturb the conductance of action poten-
tials along nerve axons and lead to a delayed response.
Physiological meaning of k2
Using 1-[11C]L-lactate, we demonstrated that the brain readily
oxidizes lactate at normal plasma lactate levels in accordancewith
recent work using 1- and 3-[13C]L-lactate (Bouzier et al., 2000;
van Hall et al., 2009; Boumezbeur et al., 2010). Our radiotracer
approach enables the measurement of cerebral lactate oxidation
without altering blood and tissue concentrations of lactate. In
this respect, it is important to consider the physiologicalmeaning
of k2. By definition, it represents the loss of label from tissue (Fig.
3A). Themodel depicted in Figure 3A demonstrates that the label
can be lost by back-diffusion of labeled lactate into vascular space
and as labeled CO2. The latter pathway is more interesting be-
cause it is related to the oxidation of lactate, unless the diffusion
of CO2 across the blood–brain barrier is rate limiting. This is
Figure5. Cerebral integrity is not disruptedduringhyperlactemia.A,B, A single example demonstrating the spread (A) and the
amplitude over time (B) during saline (SAL) and lactate (LAC) infusion is shown. C–E, Mean results of changes in amplitude (C),
spread (D), and time-to-peak (E) (n 4; n.s., not significant compared with baseline).
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unlikely because CO2 back-diffusion does not seem restricted
(Paulson, 2002). Radiolabeled lactate is processed by LDH and
PDHbefore the label is lost as CO2. Parameter k2 can therefore be
related to either of them or to both, depending onwhether one of
these steps is rate limiting. A flux estimation suggests that the
processing by LDH and not PDH is the rate-limiting step.
If k2 represented the conversion of pyruvate to acetyl-CoA, it
would closely be related to the flux of pyruvate (FluxPDH), which
in this model would be expressed as follows: FluxPDH k2 * Cpyr,
or Cpyr  FluxPDH/k2, where Cpyr is the intracellular pyruvate
concentration. Inserting a measured FluxPDH value of 1.13
mol  g1  min1 (Oz et al., 2004) and the mean k2 from our
[11C]L-lactate experiments (0.077min1) yields an unphysiolog-
ical pyruvate concentration of15 mmol/L. Measured pyruvate
concentrations are in the range of 0.1–0.2 mmol/L (McIlwain,
1985).
In analogy, the conversion of lactate to pyruvate by LDH yields
FluxLDH k2 * Clac, where Clac is the intracellular lactate con-
centration. Using the numbersmeasured in humans bymagnetic
resonance spectroscopy [FluxLDH  0.06 mol  g
1  min1)
(Boumezbeur et al., 2010)], the above equation yields an intra-
cellular lactate concentration of 0.06/0.077 0.78 mmol/L. This
is in the same range as the reported number [1mmol/L at plasma
lactate levels of 1.5 mmol/L (Boumezbeur et al., 2010)]. These
estimations suggest that k2 is more related to the activity of LDH
than PDH.
Evidence for increased lactate oxidation during stimulation
The increase of k2 can be seen as a facilitation of the flux of
substrates through the oxidative chain. However, an effective in-
crease of the lactate flux furthermore requires that there is no
relevant stimulation-induced drop in another factor driving lac-
tate oxidation, e.g., the intracellular lactate concentration. How-
ever, such a drop seems unlikely for two reasons. First, the
extracellular lactate concentration has been shown to increase
during stimulation (Hu and Wilson, 1997; Caesar et al., 2008).
Second, there is evidence for a translocation of MCT2 to the
membrane surface during stimulation (Pierre et al., 2009), which
would augment lactate transport and lead to higher intracellular
lactate concentration. Such a translocation could also explain the
increased permeability surface product during stimulation ob-
served in this study.
There is another line of evidence supporting an elevated neu-
ronal lactate oxidation during increased neuronal activity. An
increased conversion of lactate to pyruvate is facilitated by an
increase of the lactate/pyruvate ratio. Besides the increase in the
lactate concentration (see above), a decrease of the pyruvate con-
centration or both causes a drop in this ratio. A reduced pyruvate
concentration is achieved by a reduced glycolytic flux. Indeed,
there is evidence from experiments in cell cultures that glutamate
inhibits neuronal glucose uptake (Porras et al., 2004; Castro et al.,
2009) and that upregulation of glycolysis under stress conditions
is prevented (Herrero-Mendez et al., 2009). Recently, it has been
found in vivo that increased neuronal firing mediates inhibition
of glucose transport in neurons while stimulating astrocytic glu-
cose uptake (Chuquet et al., 2010).
Concluding remarks
The results presented demonstrate in vivo that lactate is metabo-
lized by neurons. Indeed, VSD imaging enabled us to follow a
neuronal readout, which is supported by the supplied lactate dur-
ing the experimental period. Considering the facts that intrace-
rebral glycogen stores are relatively limited and consumed in the
absence of exogenous glucose within a few minutes (Brown and
Ransom, 2007) and that gluconeogenic activity in the brain is
negligible (Nelson et al., 1985), it is evident that the neuronsmust
rely on lactate as an energy substrate under hypoglycemic condi-
tions. In addition, hepatic gluconeogenesis is suppressed by the
insulin action. Thus, it can be suggested that the neuroprotective
effect of lactate observed in previous studies (Gjedde and Crone,
1975; Schurr et al., 2001; Mason et al., 2006; Berthet et al., 2009)
is attributable to direct lactate oxidation in neurons.However, we
cannot exclude astrocytic lactate uptake and oxidation.
It is important to note that the data reported here using radiola-
beled lactate provide evidence for the ability of neurons to increase
lactate use during stimulation. During increased activation, we ob-
servedan increased turnoverof 1-[11C]lactate alsoundernormogly-
cemia. Considering the fact that all the experimentswere performed
under anesthesia, thus reducing theoverallmetabolic rate by a factor
of twofold to threefold (Hyder et al., 2006), it is reasonable to assume
that an even larger contribution of lactate to brainmetabolismmay
occur in the awake animal.
In summary, our multimodal experiments demonstrate that
(1) lactate is capable of maintaining neuronal integrity to a large
degree in the absence of glucose, (2) lactate is preferred over
glucose if both substrates are available, (3) lactate is readily me-
tabolized by the intact adult rodent brain, and (4) its metabolism
is activity dependent.
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Quantitative Cerebral Blood Flow Measurements in the Rat
Using a Beta-Probe and H215O
*Bruno Weber, *Nicolas Späth, *Matthias Wyss, *Damian Wild, *Cyrill Burger, †Ross Stanley,
and *Alfred Buck
*PET Center, Division of Nuclear Medicine, University Hospital Zurich, Zurich, and †Center Suisse d’Electronique et de
Microtechnique SA, Neuchatel, Switzerland
Summary: Beta-probes are a relatively new tool for tracer
kinetic studies in animals. They are highly suited to evaluate
new positron emission tomography tracers or measure physi-
ologic parameters at rest and after some kind of stimulation or
intervention. In many of these experiments, the knowledge of
CBF is highly important. Thus, the purpose of this study was to
evaluate the method of CBF measurements using a beta-probe
and H215O. CBF was measured in the barrel cortex of eight rats
at baseline and after acetazolamide challenge. Trigeminal nerve
stimulation was additionally performed in five animals. In each
category, three injections of 250 to 300 MBq H215O were per-
formed at 10-minute intervals. Data were analyzed using a
standard one-tissue compartment model (K1  CBF, k2 
CBF/p, where p is the partition coefficient). Values for K1 were
0.35 ± 0.09, 0.58 ± 0.16, and 0.49 ± 0.03 mL · min−1 · mL−1 at
rest, after acetazolamide challenge, and during trigeminal nerve
stimulation, respectively. The corresponding values for k2 were
0.55 ± 0.12, 0.94 ± 0.16, and 0.85 ± 0.12 min−7, and for p were
0.64 ± 0.05, 0.61 ± 0.07, and 0.59 ± 0.06.The standard devia-
tion of the difference between two successive experiments, a
measure for the reproducibility of the method, was 10.1%,
13.0%, and 5.7% for K1, k2, and p, respectively. In summary,
beta-probes in conjunction with H215O allow the reproducible
quantitative measurement of CBF, although some systematic
underestimation seems to occur, probably because of partial
volume effects. Key Words: Cerebral blood flow—Beta-
probe—Positron emission tomography.
Beta-probes have recently been introduced to measure
the time course of tracer uptake with high temporal reso-
lution (Pain et al., 2002, 2000; Woody et al., 2002; Zim-
mer et al., 2002). The applications of the method are
widespread. Examples are blocking and displacing ex-
periments with receptor ligands or the measurement of
glucose metabolism using 18fluorodeoxyglucose under
different conditions. Compared to an animal positron
emission tomography (PET) system, they are relatively
cheap, the temporal resolution is much higher and mea-
surements can potentially be performed in the awake
animal. However, simultaneous information can only be
obtained from a few locations, whereas the PET systems
cover the whole brain. In some applications of the beta-
probe, the knowledge of CBF is important. The purpose
of this study was to evaluate a beta-probe with regard to
CBF measurements in conjunction with H215O.
MATERIALS AND METHODS
Animal preparation
The study included eight male rats (Sprague-Dawley) weigh-
ing approximately 300 g. Surgery was performed under isoflu-
rane anesthesia and involved the placement of an arteriovenous
shunt from the right femoral artery to the right femoral vein,
tracheotomy for mechanical ventilation and craniotomy for the
placement of the beta-probe. The actual experiment was then
performed under alpha-chloralose anesthesia. 25 mg kg-1 body
weight was injected in the axillary fatty tissue immediately
after the induction of the anesthesia. After surgery, alpha chlo-
ralose (made soluble at room temperature by mixing it with
2-hydroxypropyl-beta-cyclodextrin (Storer et al., 1997) was
constantly infused at 20 mg · kg−1 · h−1. The shunt was used for
the continuous monitoring of arterial blood pressure, the infu-
sion of H215O, -chloralose, acetazolamide, and lethal dose of
pentobarbital at the end of the experiment, and for the continu-
ous measurement of 15O activity for the arterial input curve.
For the latter purpose, the shunt was run through a coincidence
probe that stored the data at 1-second intervals. The online
arterial sampling procedure is described in detail elsewhere
(Weber et al., 2002).
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Electrical stimulation
For the stimulation of the whisker-to-barrel pathway, the
infraorbital branch of the trigeminal nerve was stimulated with
two stainless steel electrodes. The cathode was inserted through
the infraorbital hiatus and the anode was positioned in the
masticatory muscle. The current of the stimulation was adjusted
to produce whisker movements (pulses of 1-millisecond dura-
tion at 1.2-mA, 2-Hz stimulation frequency, using an isolated
constant-current stimulator). The stimulation started 30 seconds
before the H215O bolus injection and lasted 210 seconds.
Acetazolamide challenge
Acetazolamide is a carbonic anhydrase inhibitor that leads to
vasodilatation and can thus be used to induce a global increase
in cerebral blood flow. Acetazolamide (66 mg/kg) was intra-
venously injected in 0.3 mL saline during a 30-second period.
Automated H215O bolus injection
For the administration of the short-living H215O (half-life,
122 seconds) in high concentrations, a special injection instru-
mentation is mandatory. 15O was produced continuously in the
cyclotron and transferred to the synthesis/injection device.
(More information on this device can be found at
http://www.swisstrace.com.) The injection/synthesis device
continuously delivered H215O at a rate of 60 mL/h in a closed
loop. For the bolus injections, a peristaltic precision pump (Is-
matec SA, Glattbrugg, Switzerland) drew approximately 300
MBq H215O from this loop at a rate of 0.4 mL/min during a
40-second period. This high radioactivity concentration re-
quires careful lead shielding, not only for the experimenters but
also to reduce background counts in the photomultiplier tube
and coincidence counter.
Beta-probe
The beta-probe used is a modification of the sensor devel-
oped by Pain et al (2000) (for further information, see
http://www.swisstrace.com). It consists of a scintillation tip
(Bicron, BF12, Newbury, OH, U.S.A.) with a length of 0.8 mm
and a diameter of 0.25 mm attached to a high numerical aper-
ture glass fiber. The probe was made light-tight by applying a
uniform coating of silver particles. The scintillations were mea-
sured using a photomultiplier tube and counting electronics
(PMT 9131/350B, Package P30CWAD5–08, Electron Tubes
Limited). The main contributions to unwanted counts are (1)
the dark count of the PMT, (2) background light, and (3) Ceren-
kov radiation. Dark counts below 1 cps were achieved with the
system. Background light is a serious problem that can be
eliminated by working in total darkness or by using light-tight
probes. Photons can also be created by fast-moving  particles.
A particle moving through a medium faster than the speed of
light in that medium will radiate light. This light is known as
Cerenkov radiation; its spectrum follows the inverse of the
wavelength, so it appears blue. Cerenkov radiation is created
both in the tissue of the animal and theoretically in the fiber
itself. To overcome the problem of Cerenkov radiation, some
investigators use a double-probe system where the reference
probe has no scintillating fiber and is located close to the scin-
tillating probe so that the contribution from Cerenkov can be
subtracted (Pain et al., 2000). This has the drawback of in-
creased complexity, and increased dark noise. A coated probe
has an advantage in that the Cerenkov light coming from out-
side the probe cannot enter it. To determine the signal not
originating from the scintillating tip, the following experiment
was performed. The probe was lowered into a homogeneous
solution of H215O (50 MBq/mL) to various depths: 2 mm (tipjust covered), 7 mm, and 12 mm. Although lowering the probe
from position a to b increased the count rate by 34.0%, there
was only a 3.5% further increase from position b to c. The first
increase is easily explained by a partial volume effect. If Ceren-
kov radiation is created inside the fiber, the signal should in-
crease linearly with depth. However, the small second increase
demonstrates that this is unlikely and that potential Cerenkov
radiation produced in the fiber is therefore negligible.
After each experiment, position c was also used to cross-
calibrate the beta-probe with the coincidence counter used to
measure the arterial input curve. For this purpose, the shunt
tubing was additionally filled with the same H215O solution and
counted with the coincidence counter. For data analysis, all
data were background corrected, converted to kBq/mL, and
decay corrected to the time point of injection.
The probe was inserted in the brain using a stereotactic frame
(David Kopf Instruments, Tujunga, CA, U.S.A.). The skull was
exposed and a craniotomy was performed using a dental drill.
The dura was carefully incised at the insertion position, which
was (according to bregma) 2 mm posterior and 6 mm lateral for
the barrel cortex and 3 mm posterior and 3 mm lateral for the
combined thalamic/cortical penetrations. This position was ad-
justed to avoid large superficial blood vessels. The probe was
carefully lowered to a depth of 1.4 mm for cortical and 6 mm
for thalamic recordings. Only one probe penetration was per-
formed per animal. The count rate was stored on a personal
computer using a bin width of 1 second.
Experimental protocols
After each H215O injection, 180 seconds of data were re-
corded. Injections were spaced at least 10 minutes apart to let
the activity decay to background level. Each experimental
block started under baseline conditions (barrel cortex, n  8).
Then, measurements were performed during electrical stimula-
tion of the trigeminal nerve (in five animals only). The final
measurements were acquired starting 10 minutes after admin-
istration of acetazolamide. Thalamic experiments were per-
formed in three animals. After measurements in the cortex at
baseline, the probe was advanced to the thalamus leaving the
surface position unchanged. Acetazolamide was then injected
and additional thalamic measurements were taken. The last
measurements were acquired shortly after the probe was re-
tracted to the original cortical depth. Three consecutive injec-
tions were made in each condition.
Model
The basis of the calculation of the CBF measurements
was the one-tissue compartment model including a partition
coefficient for H215O. The change of the radioactivity concen-
tration in tissue Ct is then defined by the following differential
equation:
dCtdt = CBF(Ca(t) − Ct(t)p) (1)
where Ca is the arterial tracer concentration and p is the tissue
partition coefficient (that fraction of tissue that is permeable for
H215O). In this configuration, Ct is the concentration of H215O
in 1 mL of brain and it is assumed that H215O immediately
reaches a homogeneous concentration in permeable space and
no division into a vascular and a tissue compartment is neces-
sary. The analytical solution of Eq. 1 is
Ct = CBF exp (−CBFp t)  Ca (2)
where  signifies mathematical convolution. In a K1, k2 no-
tation, Eq. 2 becomes
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Ct = K1 exp(−k2 t)  Ca (3)
where K1  CBF and k2  K1/p.
Equation 3 was fitted to the data using least squares fitting
(Marquardt algorithm) implemented in the software PMOD
(http://www.pmod.com; Mikolajczyk et al., 1998). Before data
analysis, tissue time–activity curves and arterial input curves
were corrected for physical decay.
Statistical analysis
The means of K1, k2, and p at baseline and after acetazol-
amide challenge were statistically compared using the signed
rank test. Bland-Altman analysis was used to assess the repro-
ducibility (Bland and Altman, 1986). In this method, the stan-
dard deviation of the difference of consecutive experiments (in
this study, experiment 2 and 3 of each block) is a measure for
the reproducibility. The differences were expressed as percent-
age of the mean of the two measurements. A total of 21 dif-
ferences were evaluated. Only the cortical experiments were
included in this analysis.
RESULTS
The high reproducibility of the shape of the input
curves is demonstrated in Figure 1. The peak, which was
reached at 50 seconds was followed by a rapid decline,
lasting until 60 seconds. The further time-course was flat
due to recirculating H215O.
A typical blood and tissue curve and the model fit after
injection of acetazolamide are shown in Fig. 2. The ab-
sence of any bias in the residuals demonstrates the good-
ness-of-fit.
The result of the model fitting is summarized in Table
1. In each animal there was a marked and reproducible
increase of K1 and k2 after acetazolamide challenge. The
percentage increase (mean ± SD) from baseline was 66 ±
27 (T 0; P < 0.01) and 72 ± 22 (T 0; P < 0.01) for
K1 and k2, respectively. All five animals in which tri-
geminal stimulation was performed displayed a pro-
nounced increase of K1 and k2 in the corresponding bar-
rel cortex. Because of the small sample size (n 5), no
statistical analysis was performed. The percentage in-
crease from baseline was 47 ± 29 for K1 and 59 ± 44 for
k2. No significant change in the partition coefficient p
was noticed between the different conditions. In the eight
baseline experiments, p in cortex was 0.64 ± 0.05. In the
three animals with a thalamic measurement, p in thala-
mus was higher than in cortex (18%, 13%, and 8%
higher than in cortex).
The Bland-Altman plots of the reproducibility are
summarized in Fig. 3. The highest reproducibility (low-
est standard deviation between successive measurements
2 and 3) was achieved for p, followed by K1 and k2. For
all parameters, all except one data point were contained
in the range mean ± 2 SD.
DISCUSSION
The purpose of this work was to validate the quanti-
fication of CBF measurements using a beta-probe and
H215O. The validation is focused on three major aspects:
(1) the magnitude of the CBF values; (2) the response to
stimulation; and (3) the reproducibility.
Magnitude of K1, k2, and p
The K1 values seem to systematically underestimate
the true CBF. Compared with 14C iodoantipyrine auto-
radiography data published by Nakao et al. (2001), who
used a similar anesthetic protocol, our values in the bar-
rel cortex are approximately 40% lower (0.35 vs. 0.6
FIG. 1. Decay-corrected arterial input functions measured in the
arteriovenous shunt. The graph displays mean ± SD of all injec-
tions performed in this study. Before averaging, all curves were
normalized to the integrated activity between 0 and 160 seconds
and time-shifted. The peak of the resulting average curve was
then scaled to 1.
FIG. 2. A typical example of a tissue time–activity curve, an ar-
terial input curve, and the model fit of an experiment after admin-
istration of acetazolamide. All data are corrected for 15O decay.
The insert represents the residuals. In this experiment, the values
of K1 and k2 were 0.48 mL · min−1 · mL−1 and 0.71 min−1. Note that
the ratio of counts in tissue and blood at 180 seconds is 0.89,
which is higher than the equilibrium value of 0.68 because equi-
librium is not yet reached at 180 seconds. Exp, experiment.
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min−1). This discrepancy is most likely due to an under-
estimation of the true cortical H215O concentration be-
cause of partial volume effects. The maximum free path
length of a positron emitted from 15O in water is 8.2 mm
and the most probable free path length is approximately
2.7 mm, indicating that most of the signal picked up by
the beta-probe originates from a sphere that is approxi-
mately 5 mm in diameter. During calibration, this sphere
contains a homogeneous radioactivity concentration. Be-
cause the rat cortex is approximately 2 mm thick, the
volume contributing to signal in a probe positioned in the
cortex is heterogeneous and includes not only gray mat-
ter, but also white matter and air above the cortex. This
leads to an underestimation of the true cortical H215O
FIG. 3. Bland-Altman plot of the re-
producibility of K1, k2, and p. The
analysis included eight animals for
baseline and acetazolamide and
five animals for the trigeminal stimu-
lation. In each experimental block
(i.e., baseline, acetazolamide, and
trigeminal nerve stimulation) there
were three consecutive injections
10 minutes apart. The important pa-
rameter for reproducibility is the
standard deviation of the difference
between the second and third ex-
periments (experiment 3 − experi-
ment 2), which is indicated as per-
centage of the mean. The middle
line represents the mean difference;
the top and bottom of the gray rect-
angle are mean ± 2 SD of the
pooled differences of all types of experiments. The respective values (mean ± SD) for K1, k2, and p respectively were 0.6 ± 10.1%, 4.7
± 13.0%, and −1.1 ± 5.7%.
TABLE 1. Summarized results of the model fitting
Animal Location Type
K1
(mLmin−1mL−1)
k2
(min−1)
p (K1/k2)
(mL/mL)
1 ctx base 0.245 0.402 0.611
1 ctx stim 0.485 0.955 0.508
1 ctx ACZ 0.443 0.786 0.564
2 ctx base 0.393 0.687 0.572
2 ctx stim 0.539 0.994 0.547
2 ctx ACZ 0.526 1.008 0.522
3 ctx base 0.347 0.582 0.598
3 ctx stim 0.480 0.806 0.595
3 ctx ACZ 0.591 0.883 0.669
4 ctx base 0.353 0.543 0.650
4 ctx stim 0.491 0.787 0.624
4 ctx ACZ 0.466 0.823 0.567
5 ctx base 0.384 0.533 0.722
5 ctx stim 0.468 0.705 0.669
5 ctx ACZ 0.600 0.998 0.601
6 ctx base 0.309 0.496 0.636
6 ctx ACZ 0.672 1.032 0.651
6 thal base 0.375 0.513 0.754
7 ctx base 0.532 0.738 0.720
7 ctx ACZ 0.933 1.239 0.754
7 thal base 0.837 1.021 0.818
8 ctx base 0.270 0.434 0.622
8 ctx ACZ 0.440 0.728 0.604
8 thal base 0.382 0.565 0.677
n  8 ctx mean (SD) base 0.354 (0.089) 0.552 (0.116) 0.641 (0.055)
n  5 ctx mean (SD) stim 0.493 (0.027) 0.849 (0.121) 0.589 (0.063)
n  8 ctx mean (SD) ACZ 0.584 (0.164) 0.937 (0.165) 0.616 (0.073)
The values represent the mean of three successive experiments.
base, baseline; stim, trigeminal nerve stimulation; ACZ, acetazolamide challenge; ctx, cortex; thal, thalamus.
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concentration and, consecutively, K1. This underestima-
tion would also explain the low value of p (K1/k2, 0.64 ±
0.055 at baseline). One would expect a value in the order
of 0.95 mL/mL (Ginsberg et al., 1982). This reasoning is
supported by the result that K1 and p are higher in the
thalamus than in the cortex. There the gray matter vol-
ume surrounding the probe is larger, leading to smaller
partial volume effects. The situation is considerably
more favorable for 11C and 18F with maximum free path
lengths of 4.1 and 2.4 mm.
While K1 describes the delivery of H215O, k2 is deter-
mined by the washout. The baseline value (0.55 ± 0.11
min−1) is closer to the autoradiographically determined
CBF values reported by Nakao et al. (2001). Considering
the relationship CBF k2 p, one could use k2 multiplied
by an estimated p as an indicator of CBF. If one assumes
a p value of 0.95, the baseline CBF would be 0.52
mL · min−1 · mL−1. This value probably still underesti-
mates true CBF, because k2 is also affected by the partial
volume effects (tissue heterogeneity), although to a
lesser degree than K1 (Blomqvist et al., 1995; Herholz
and Patlak, 1987). In our view, there is no simple way to
correct for the partial volume effects. The problem is the
heterogeneity in the volume contributing to signal in the
probe. The different time course of the counts in the
compartments of this volume render a simple correction
by a constant factor inaccurate.
Response of K1 and k2 to stimulation
The increase of K1 (43%) in the barrel cortex during
trigeminal stimulation is in line with the results of
Nielsen and Lauritzen (2001). Using laser-Doppler flow-
metry in the chloralose-anesthetized rat, they found an
approximately 40% change during trigeminal nerve
stimulation at 2 Hz. These values are somewhat higher
than the 28% increase reported by Nakao et al. (2001).
The discrepancy can be explained by the different stimu-
lation methods (mechanical whisker stimulation vs. elec-
trical trigeminal nerve stimulation). The mean of k2 in-
creased from 0.54 to 0.84 min−1, corresponding to 54%.
All animals also displayed a marked increase of K1
and k2 after acetazolamide challenge; the increase of the
mean was 65% and 70%, respectively.
Reproducibility
The Bland-Altman plots demonstrate that the standard
deviation of two successive measurements is in the order
10%, 13%, and 6% for K1, k2, and p, respectively. A
direct comparison with the hydrogen-clearance method,
the only other quantitative method allowing serial mea-
surements in the same animal, is difficult. However, it is
in line with human (Carroll et al., 2002; Matthew et al.,
1993) and monkey (Iida et al., 2000) H215O PET mea-
surements, for which the reproducibility is in the order of
10%.
The data suggest that K1 and k2 are reasonable mea-
sures of CBF. Compared with k2, K1 is somewhat more
reproducible but underestimates true CBF to a higher
degree.
Comparison with alternative methods
In small animals, probably the most accurate quanti-
tative method for CBF measurement is 14C-iodoanti-
pyrine autoradiography (Nakao et al., 2001; Ohno et al.,
1979; Sakurada et al., 1978). This method also has the
highest spatial resolution. The obvious disadvantage is
the need to kill the animals after one experiment, which
renders serial experiments in the same animal impos-
sible. Other possibilities that allow serial measurements
are the methods based on laser-Doppler flowmetry
(Dirnagl et al., 1989; Skarphedinsson et al., 1988) and
hydrogen clearance (Haining et al., 1968; Moskalenko et
al., 1996; Moskalenko Yu et al., 1995; von Kummer and
Herold, 1986; von Kummer et al., 1986). Laser-Doppler
flowmetry has become very popular, one reason being
that brain tissue is not injured. However, it is not a quan-
titative method. The hydrogen clearance method yields
theoretically quantitative CBF values with high tempo-
ral, but relatively low spatial resolution, as does the beta-
probe. Another method is the use of the newly introduced
animal PET scanners. However, with the present systems
the temporal resolution seems to be too low to allow
CBF measurements with H215O, and studies using other
potential PET flow tracers have not been published.
Applications of beta-probes include neuropharmaco-
logic experiments, blocking and displacing experiments
with receptor ligands, or the measurement of glucose
metabolism using 18fluorodeoxyglucose under different
physiologic conditions and pharmacological interven-
tions. In such experiments, the additional measurement
of CBF may contribute important information. For in-
stance, one important parameter of radioligands is the
first-pass extraction fraction (EF). In compartmental
models the first parameter K1 describes transport of
tracer from blood into tissue; it is determined by the
relationship K1  CBF EF. Thus, EF can be calculated
from K1 and CBF. An important advantage of H215O is
the short physical half-life of 15O of 122 seconds, mean-
ing that experiments can be performed at 10-minute in-
tervals. A disadvantage of the presented method is its
complexity and the requirement of a cyclotron. However,
in centers where the necessary equipment is available, it
offers an elegant technique for CBF measurements, es-
pecially in situations where the beta-probe is used for
other experiments that additionally require the knowl-
edge of CBF. Another disadvantage is the relatively large
diameter of the beta-probe (0.25 mm). It is possible that
new, more sensitive scintillator materials may allow a
reduction in this diameter. Furthermore, because of the
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high radioactivity concentrations used, radiation safety
issues have to be considered. In the present study, mov-
able lead shielding was used.
In summary, the beta-probe and H215O allow quanti-
tative, reproducible, and serial measurements of CBF,
although true flow values in cortex are systematically
underestimated. The reproducibility is comparable to hu-
man H215O PET.
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Surface beta probe
β+-sensitive probes are useful tools for the measurement of radiotracer kinetics in small animals. They allow
the cost-effective development of new PET tracers and offer the possibility to investigate a variety of cerebral
processes. The study's main aimwas the in vivo evaluation of a probe system for cerebral surface acquisitions.
The detector system is a 0.2-mm thick scintillating disk of 3-mm diameter, positioned close to the cerebral
surface. The study consists of 4 subparts: (1) simulation of the detection volume, (2) direct comparison with
the classic intracortical beta probe regarding its capability to acquire kinetic data, (3) test of the ability to detect
local tracer accumulations during infraorbital nerve (ION) electrostimulation and (4) demonstration of the
feasibility to measure tracer kinetics in awake animals. Kinetic data acquired with 18F-fluorodeoxyglucose and
15O-H2O were fitted with standard compartment models. The surface probe measurements were in good
agreement with those obtained using the intracortical scintillator. ION electrostimulation induced a marked
increase in tracer accumulation adequately detected by the surface probe. In the head-fixed animal, a marked
change in FDG kinetics was detected between the awake and anesthetized state. The novel surface probe
system proved to be a valuable instrument for in vivo radiotracer studies of the cerebral cortex. Its main
advantage is the absence of any tissue damage. In addition, serial acquisitions of tracer kinetics in the awake
animal turned out to be feasible.
© 2009 Elsevier Inc. All rights reserved.
Introduction
Despite the rapid development of new functional neuroimaging
tools, radiotracer experiments are still considered the gold standard if
absolute quantification is needed. Radiotracer methods are widely
used for the investigation of physiological and biochemical processes
in the brain, such as receptor binding, hemodynamics, substrate use
and transport processes as well as for studies in early drug
development. The progress of research in these fields during the last
few years is in part due to the advance of methods applicable in small
animals. At present, positron emission tomography (PET) and beta
probemeasurements are the two availablemethods for the acquisition
of tracer kinetics in small animals (Chatziioannou, 2002; Hume and
Myers, 2002; Pain et al., 2000; Pain et al., 2002b; Rowland and Cherry,
2008; Weber et al., 2003; Weber and Bauer, 2004; Wyss et al., 2007;
Wyss et al., 2009). The cost of PET is substantial and the temporal
resolution is still limited, due to which kinetic analysis of animal PET
data is oftendifficult. The recently introduced betaprobes demonstrate
a valuable and cost-effective alternative for the detection of positrons
with high temporal and reasonable spatial resolution. They allow the
precise in vivo evaluation of the kinetics of radiotracers labeled with a
variety of PET nuclides (e.g. O-15, C-11, F-18). A disadvantage of most
available beta detectors is their invasiveness. The systems consist of a
scintillating crystal of 0.25 to 1 mm in diameter, which are introduced
into the tissue, which may lead to tissue irritation or even damage.
In this study, we present a detection system designed for cerebral
surface acquisitions in vivo. The probe is positioned close to the
cerebral surface and thus does not cause any cerebral tissue irritation
or damage. The aims of the present study were: (1) to estimate the
detection volume of the surface probe using simulation, (2) to directly
compare the novel system with the classic intracortical beta probe
regarding its capability to acquire kinetic data, (3) to test the ability to
detect local tracer accumulations during infraorbital nerve (ION)
electrostimulation and (4) to demonstrate the feasibility to measure
tracer kinetics in awake animals.
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Material and methods
Design/specifications of the system
We used a twin probe system (Swisstrace GmbH, Zurich, Switzer-
land) with two photomultiplier tubes (Perkin Elmer, Massachusetts,
USA) allowing simultaneous acquisitions of the radioactivity concen-
tration in two separate brain regions. The detectors were connected
with the PMTs via two high numerical aperture glass fibers. The
detector of the surface probe consisted of organic scintillating crystal
disks (Bicron, BF12, Newbury, OH, USA) with a thickness of 0.2 mm and
a diameter of 3 mm embedded in a brass collimator (Fig. 1A). The
intracortical system consisted of a scintillation tip (Bicron, BF412,
Newbury, OH, USA) with a length of 1 mm and a diameter of 0.25 mm.
The probes were made light-tight by applying a uniform black polymer
coating (thickness of 50–60 μm). The limited range of beta particles
within biological tissues limits detection volume to a small sphere
centered on the scintillating tip of the probe. Monte Carlo simulations
demonstrated that for F-18 the distance required to detect 90% of the
beta particles around the probe is ∼1.0 mm (Pain et al., 2002b).
Measuring the decay of a radioactive phantom containing F-18 over the
course of several hours allowed us to measure the linearity of our
system. Kinetic data was stored on a personal computer using a bin
width of 1 s. In the in vivo experiments acquisitions of radioactivity
count rates began 10–30 s before tracer injection to evaluate dark
counts. Thereafter, mean background counts were subtracted from raw
data before data analysis. PMTs were allowed towarm up at least for 1 h
before each experiment in order to reach stable background counts.
Calibration procedure
Calibrationmeasurements were performed after each experiment. A
homogeneous solution with a known radioactivity concentration
(range: 5.7 MBq/ml to 6.8 MBq/ml for F-18 and 7.1 MBq/ml to
8.0 MBq/ml for O-15) was prepared. For the intracortical probe the
calibration was performed by lowering the scintillating tip 1.5 mm into
the solution. To calibrate the surface probe the solutionwas coveredwith
an ultra-thin plastic foil to prevent adhesion of solution to the detector
surface. For the actual calibration measurement the radioactivity of the
test source was measured with the surface probe in close contact. The
factors obtained by this procedure were used to convert the raw data
reflecting counts per second (cps) to the apparent radioactivity
concentration (kBq/cc) measured in the experiments. Furthermore,
for the surface probe, the fraction of recorded events attributable to
gamma radiationwas estimated by counting the test source additionally
with the interposition of a 4mm thick brass disk sufficient to absorb the
18F positrons but not attenuating 511 keV gamma photons.
Simulation of the detection volume
Since the calibration procedure demonstrated a relatively small
contribution of (gamma) photons to the measured signal (≤15%),
only positrons were considered. We also assumed that positrons only
enter the scintillator through the end surface and not through the side
(metal shielding). For the simulation the space below the scintillator
was sparsed into a 3D grid (Pxyz) and the scintillator surface was
divided into discrete squares (SQx1y1). For each point in space Pxyz, the
probability that a positron emitted at location P would enter square
SQx1y1 on the detector was calculated, yielding Qx1y1 (xyz). This
probability depends on the spatial angle of SQx1y1 as seen from Pxyz
and the probability that the positron reaches SQx1y1. This probability,
which depends on the distance, the material and the emission energy
of the positrons was taken from recently published data derived from
a Monte Carlo simulation (Le Loirec and Champion, 2007). The total
signal recorded from location Pxyz is then the sum of all Qx1y1. We
simulated the situation, in which the scintillator is placed 0.2 mm
from the surface of water containing O-15, C-11 and F-18 (0.2 mm
distance was chosen to match the distance between the scintillator
crystal and the cortical surface in a real experiment). The sum of Qx1y1
(xyz) in the simulated volume was normalized to 100.
Animals and radiotracer production
All animal experiments were approved by the local veterinary
authorities and were performed by licensed investigators. 16 female
Sprague–Dawley rats (18F-fluorodeoxyglucose experiments: n=14;
15O-H2O: experiments n=2; weighing between 220 g to 280 g) were
used for this study. The animals were kept in cages in a ventilated
cabinet with standardized conditions of light (night/day-cycle 12 h/
12 h) and temperature and free access to food andwater. Animals used
for the FDG experiments were fasted overnight.
18F-fluorodeoxyglucose (FDG) was obtained from the daily in-
house production by the Radiochemistry Department of the Uni-
versity Hospital Zurich. For the administration of the short-living 15O-
H2O (half-life, 122.2 s) in high concentrations, O-15 was produced
continuously in the cyclotron and transferred to the synthesis device.
The synthesis device delivered 15O-H2O at a concentration of about
1 GBq/ml into a glass vial from where 0.5 ml were drawn into a
syringe for injection.
Fig. 1. (A) Photograph of the novel detector tip. Scale bar represents 5 mm. (B)
Schematic of the novel probe. Dimensions are given in mm. The scintillation crystal and
the optical fiber are covered by a brass shell. (C) Semi-logarithmic plot of the physical
decay of F-18 detected by the novel surface probe. Linearity of the device is evident from
the high agreement of the measured data (open circles) with the theoretical decay
(black line).
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Animal preparation
Surgery was performed under 2.5–3.5% isoflurane anesthesia and
involved for experiments of Paradigm 1 and 2 the placement of an
arterio-venous shunt from the right femoral artery to the right
femoral vein and tracheotomy for mechanical ventilation. In experi-
ments where the intracortical probe was used, a craniotomy and small
incision of the dura was performed for the placement of the beta-
scintillator. This was not needed for the surface probe measurements,
where the cranial bonewasmerely thinned to translucency. The actual
experiments were performed under α-chloralose anesthesia (44 mg/
kg bodyweight s.c.) according to the protocol of Bonvento et al.
(1994). The shunt was used for continuous monitoring of arterial
blood pressure, the injection of the radiotracers, the continuous
measurement of the total arterial blood radioactivity, the collection of
blood samples and the administration of a lethal dose of pentobarbital
at the end of the experiment. For the recording of the total blood
radioactivity the shunt ran through a coincidence counter (GEMedical
Systems). The online arterial sampling procedure was established
earlier and is described in detail elsewhere (Weber et al., 2002a).
During the experiments arterial blood gases were determined
regularly (AVL, Compact 3, Roche Diagnostics, Switzerland) and
ventilation was adjusted as necessary to keep the animals within
physiological ranges. Blood glucose levels were determined before
and after each 45 min acquisition (Ektachem DT, Kodak, USA). For the
experiment with the head-fixed animal (Paradigm 3), after surgery
and 1 week of recovery, the animal was trained to accept head fixation
(Haiss and Schwarz, 2005). Implantation of a head post for later head
fixationwas undertaken under 3% isoflurane anesthesia. After fixation
of micro skull screws (Medartis, Basel, Switzerland) a base was built
with dental cement for the final fixation of a standard M5 screw.
No dental cement was applied above the right primary somato-
sensory cortex and the cranial bone was thinned at this location using
a dental drill. To prevent bacterial infections after surgery the
chronically implanted animal received oral antibiotic treatment
added to the drinking water for 1 week, starting 1 day before surgery
(Baytril® 10% oral solution, Bayer, Germany, 1 ml/1 l).
Experimental protocols
The experiments were divided into three groups:
Paradigm 1) Comparison of the surface probe with the intracortical
probe to measure cortical time–activity curves
In a total of 8 animals the novel probe system was directly
compared to our classic intracortical system. For this purpose the
surface probe was positioned over the primary somatosensory cortex
on one side (S1; 2 mm posterior and 6 mm lateral according to
Bregma; Paxinos and Watson, 1998). The intracortical probe was
stereotactically positioned in the corresponding contralateral S1 and
lowered 1.5 mm below the dura avoiding large blood vessels. For this
paradigm two different radiotracers were used. In 6 animals local
cerebral metabolic rates of glucose (LCMRglu) were determined using
18F-fluorodeoxyglucose. Only one radiotracer injection per animal was
performed in this group (injected activity: 90–145 MBq). Kinetic data
was acquired for a period of 45min. In 2more animals the quantitative
capability of the novel system was compared to the classical
intracortical device performing cerebral blood flow (CBF) measure-
ments. 180 s of data were recorded after each 15O-H2O injection. In
each animal a total of 4 injections were performed 15 min apart to
allow for sufficient activity decay to background level. After two
acquisitions under baseline conditions the carbonic anhydrase
inhibitor acetazolamide (Diamox®; 66 mg/kg i.v.) was injected.
Acetazolamide leads to vasodilation and thus induces a global increase
in cerebral blood flow. Ten minutes after drug application the last two
measurements were started.
Paradigm 2) Quantification of localized increases of LCMRglu using
the surface probe
In a second group (n=5) the ability of the novel system to detect
local metabolic activations was evaluated. For this purpose a surface
probe was positioned over S1 of each hemisphere. Two subsequent
radiotracer injections were performed in these experiments (injection
1: 25–35 MBq in 0.5 ml saline; injection 2: 80–100 MBq in 0.5 ml
saline). Each data acquisition took 45 min. One of the two acquisitions
of 18F time-course served as the baseline, whereas the other FDG
injection was performed immediately after initiation of electrical
infraorbital nerve stimulation (2 Hz, 2 mA, pulse length 1 ms,
continuous stimulation over 45 min). The order of baseline/activation
conditions was balanced across the animals. An autoradiography was
performed after the second tracer injection as a control for the
effectiveness of the applied stimulation (only in animals with
electrostimulation performed during the second injection; n=3).
Autoradiographic studies were performed as described in detail
earlier (Weber et al., 2002b). In short, brains were removed directly
after the probe measurements, frozen in chilled isopentane and cut in
10 μm slices. Brain slices were subsequently placed on a phosphor
imaging screen (Fuji TR2025). In two additional animals both
injections were performed during baseline conditions to control for
possible drift during the experiment.
Paradigm 3) Surface probe measurement in an awake head-fixed animal
The aim of this experiment was to demonstrate the feasibility of
the system for measurements in head-fixed non-anesthetized
animals. First, the animal was carefully trained to tolerate head
fixation. The training started 1 week after surgery and involved
handling during the first week and habituation to the head holding
device in the second week. In the third week, fixation of the animal in
the head holding device started. Over the following 2 weeks, the
duration of fixation was gradually increased up to 30 min. Finally, the
tracer experiment was performed during head fixation. The acquisi-
tion started at the time of intraperitoneal tracer injection. After about
20 min, anesthesia was induced with sevoflurane 3% in a mixture of
oxygen and air (30%/70%) and data acquisition was continued until
45 min after tracer injection. Two days later the measurement was
repeated in the same animal.
Data analysis
Calculations were performed using the software PMOD (Miko-
lajczyk et al., 1998); PMOD Technologies, Adliswil, Switzerland) and
Matlab (Mathworks, Natick MA, USA).
All time–activity curves (TACs) presented are corrected for
physical decay and multiplied by the calibration factor taking into
account the respective experimental configuration for each probe
(scintillating crystal above cortical surface or scintillating tip inside
cerebral cortex). Data from FDG experiments were resampled before
analysis to obtain 30-second frames, whereas TACs from blood flow
measurements were taken with the 1-second time frame duration.
Calculation of the local cerebral metabolic rate of glucose (LCMRglu)
The procedure for the quantification of the probe studies follows
the [14C]-deoxyglucose method described by Sokoloff et al. (1977). It
employs a compartmental model with two-tissue compartments and
three kinetic rate constants (K1 to K4). The operational equation,
which was fitted to the probe time–activity curve additionally
included a vascular fraction α as a fit parameter which was in the
range of 3 to 9%. This improved the least square fit as compared to a
fixed value of α=5%. LCMRglu values were calculated from the fitted
rate constants by: LCMRglu=(K1⁎K3/(K2+K3))/(LC/Cplasma), where
Cplasma represents the plasma glucose concentration and LC the
lumped constant (LC=0.437).
341M.T. Wyss et al. / NeuroImage 48 (2009) 339–347
Model adjustments for the dual-injection paradigm
The kinetic model was adjusted in two ways for the analysis of the
dual-injection data: (1) two sets of rate constants (K1 to K4) were used
in the calculation of the operational equation, the first set for the time
until the second injection, and the second set thereafter. The least-
squares fit procedure resulted in estimates for all 6 rate constants and
the vascular fraction. (2) The correction function to derive plasma
activity from whole blood activity was adjusted to distinguish
between the contributions from the two injections. To this end,
blood activity from the first injection was extrapolated using an
exponential function, which was fitted to the blood activity 10 min
before the second injection.
Analysis of the two-condition experiment
Relative values for LCMRglu were estimated for the awake and
anesthetized state by applying a standard FDGmodel adapted to allow
the estimation of 2 parameter sets, one for each state. The input curve
was based on measurements in other experiments with intraperito-
neal injections in the awake and anesthetized rat. It was constructed
by taking the first part of the awake state input curve and the tail of
the anesthetized state input curves. This is taken as a first
approximation of the true input curve. This approach yields only
relative values for LCMRglu since input and tissue curve are not truly
scaled. However, it allows estimating the fractional change of LCMRglu
from the awake to the anesthetized state.
Calculation of cerebral blood flow measurements (CBF)
The basis of the calculation using the one-tissue compartment
model included a partition coefficient for 15O-H2O. Before data
analysis, tissue time–activity curves and arterial input curves were
corrected for radioactive decay. Further details of the analysis
procedure were described previously (Weber et al., 2003).
Statistics
Bland–Altman tests were used to assess the agreement of LCMRglu
values obtained by kinetic beta probe measurements using the two
different systems and by the static autoradiographic method (Bland
and Altman, 1986). Values are given as mean±sd.
Results
Performance characteristics of the new probe system
The agreement of the decay of F-18 monitored with the beta probe
and a monoexponential function as shown in Fig. 1B demonstrates the
linearity of the detector response. This is in accordance to previous
reports showing linearity for scintillating plastic and LSO crystals
(Pain et al., 2002b; Woody et al., 2001). The mean sensitivity of the
novel surface probe system was 0.83±0.04 cps/kBq/ml. The back-
ground (dark counts) ranged from 2–8 cps. Stopping the positrons
using the brass disk between the 18F source and the detector tip
reduced the count rate to 14.7±4.4% of the initial value. Accordingly,
the contribution of gamma radiation (originating from positron
annihilation) to the total acquired count rate was about 15% for the
new probe system.
Simulation of detection volume
The simulation yielded the detection volumes depicted in Figs.
2A–C. For F-18, 95% of the signal was detected from within an
isosurface with a maximum depth of about 1 mm. This range is
considerably larger for C-11 and O-15, due to the higher positron
Fig. 2. Results from the detection volume simulations. (A)–(C): Detection fraction from a plane representing the sum projection along the Y-direction for F-18 (A), C-11 (B) and O-15
(C). The thin black lines represent the 95% isolines. The sum of all values in the simulated volumewas set to 100. (D) The curves depict the normalized detection fraction for sums in
planes along the depth (Z-direction) for the simulated isotopes. The vertical straight lines represent the 95% thresholds.
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emission energy. As can be seen in Figs. 2A–D, the sensitivity rapidly
decays with depth.
Animal experiments
Paradigm 1) Direct comparison of the two probe systems
Local cerebral metabolic rates of glucose consumption (LCMRglu)
based onmeasurements with the two probe systems are shown in Table
1 (n=6). The data of both probes were adequately fitted by the
standard two-tissue compartment FDG model, as the lack of bias in the
residuals indicates (Figs. 3A and B). However, the higher sensitivity of
the novel surface probe system led to a marked decrease in the relative
residual size. The Bland–Altman plot in Fig. 4 shows that all differences
in LCMRglu are in the range defined by the mean±2 SD. Nevertheless,
the values measured with the surface probewere on average 22% lower
than the ones determined with the intracortical probe.
A typical example of FDG time–activity curves recorded simulta-
neously with the 2 probe systems is demonstrated in Fig. 5. In order to
illustrate the similarity of the shape, the curves were normalized to
the integral of the tissue activity between 0 and 45 min.
Table 1
Rate constants determined using a two-tissue compartment model during baseline.
Animal number K1 (ml min−1 ml tissue−1) K2 (min−1) K3 (min−1) K4 (min−1) LCMRglu (μmol 100 g−1 min−1)
Right somatosensory cortex surface probe 1 0.080 0.196 0.075 0 43.21
2 0.107 0.256 0.070 0.019 45.37
3 0.122 0.304 0.098 0.017 55.88
4 0.111 0.264 0.060 0.009 35.67
5 0.106 0.304 0.108 0.023 61.90
6 0.128 0.269 0.058 0.018 45.89
mean±sd 0.109±0.02 0.266±0.04 0.078±0.02 0.014±0.008 47.99±9.4
Left somatosensory cortex intracortical probe 1 0.081 0.165 0.094 0.010 57.56
2 0.103 0.204 0.069 0.017 51.6
3 0.131 0.266 0.067 0.004 49.26
4 0.089 0.156 0.063 0 45.63
5 0.116 0.270 0.149 0.018 92.13
6 0.173 0.224 0.060 0.014 72.06
mean±sd 0.116±0.03 0.214±0.05 0.084±0.03 0.011±0.007 61.37±17.69
Fig. 3. Typical examples of tissue time–activity curves acquired by the original intracortical probe (A, C) and the surface probe (B, D) using two different radiotracers, 18F-FDG (A, B)
and 15O-H2O (C, D). The radioactivity concentration in plasma (light gray line) in whole blood (dark gray line) and the model fit (black line) are also shown. The goodness-of-fit is
demonstrated by the random distribution of the residuals (inset). Due to the increased sensitivity of the new system, signal-to-noise ratio is increased leading to an improved model
fit illustrated by the narrower range of variability of the residuals.
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For the CBF measurements (n=2) a typical example of tissue
time–activity curves acquired with the two probe systems is shown in
Fig. 3 (panel C and D). Again the surface probe yielded a considerably
improved signal-to-noise ratio. CBF data are shown in Table 2.
In Fig. 6 the reproducibility of the detection of O-15 and F-18 in the
surface probe measurements is shown illustrating the high stability of
the measurement obtained with this device.
The acetazolamide induced CBF increase was 51% when measured
with the surface probe and 48% with the intracortical probe. As with
FDG, the absolute CBF values were somewhat smaller with the surface
probe.
Paradigm 2) ION electrostimulation
To assess whether the surface probe is able to detect local increases
in metabolic activity in the brain, electrical stimulation of the right
infraorbital branch of the trigeminal nerve (ION) was applied. The
stimulation of the ION caused the expected circumscribed increase of
tracer uptake in the contralateral primary somatosensory cortex (S1)
as shown by the autoradiographic slice in Fig. 7. Only a weak increase
in tracer uptake is noticed on the ipsilateral side. The increase was
correctly recorded by the surface probe in all 5 experiments and was
on average 60.7% at 45 min. The subsequent autoradiographic
evaluation showed a mean increase of 64.9%. A typical example of a
probe acquisition during ION stimulation is presented in Fig. 7. In the 2
animals with two FDG injections during baseline conditions stable
radiotracer accumulation was observed. The difference in LCMRglu
between the first and the second injectionwas 8.7% and−14.9% in the
two animals, verifying the stability of the double-injection protocol.
Paradigm 3) Determination of FDG kinetics in the awake head-fixed rat
The animal was successfully trained for 5 weeks to tolerate the
head fixation for up to 30 min. Fig. 8 shows the constant increase of
cerebral FDG uptake during the first 20 min in the awake animal. After
induction of sevoflurane anesthesia LCMRglu was reduced by 46.8%.
The repetition of the acquisition 2 days later precisely reproduced
these results (data not shown), demonstrating the feasibility to
perform serial experiments in the same animal.
Discussion
An increasing number of molecular imaging studies are performed
with PET scanners. These devices allow imaging of thewhole animal, if
necessary several times in a longitudinal design. However, these PET
scanners suffer from drawbacks, such as a high price and limited
temporal resolution. The latter makes it difficult to use them in a
dynamic imaging design coupled with kinetic modeling. Another
drawback of small animal PET is the requirement for anesthesia,
which inevitably alters normal physiology. The recently introduced
small beta probes for intracortical measurements in small animals
overcame some of these problems (Ginovart et al., 2004; Pain et al.,
2000; Pain et al., 2002b; Weber et al., 2003; Zimmer et al., 2002a;
Zimmer et al., 2002b) and the combination with other methods
turned out to be more straightforward (Desbree et al., 2004; Desbree
et al., 2007). They offer a cost-effective alternative whenever the
measurement at a few locations in the brain is sufficient. They already
found application in blood flow studies (Weber et al., 2003), metabolic
studies (Millet et al., 2004; Pain et al., 2002a), receptor occupancy
studies (Ginovart et al., 2004; Zimmer et al., 2002a; Zimmer et al.,
2002b) and the evaluation of new radiotracers (Galineau et al., 2006;
Wyss et al., 2007; Wyss et al., 2009). All these studies were performed
using thin probes designed for direct acquisition within the structure
of interest. However, a disadvantage of these intracerebral probes is
the potential tissue disturbance caused by their insertion. This was
already noted in a previous study by Pain et al. (2002a) and as a
consequence a beta probe of 1 mm diameter was positioned on the
brain surface. However, no results were shown and no subsequent
publications concerning this issue followed according to our
knowledge.
Fig. 4. Bland–Altman plot to evaluate the agreement of the probe measurements in 6
animals using 18F-FDG. The middle line represents the mean of two measurements in
the same animal using the two different probe systems, the border dashed lines the
mean±2 sd, respectively.
Fig. 5. Time–activity curves of 18F-FDG accumulation in the rat's somatosensory cortex
normalized to the integral of plasma activity between 0 and 45 min. Shown is the
measurement in a single animal acquired on one side with the intracortical system
(open circles) and homotopically on the contralateral hemisphere with the surface
probe system (filled gray circles).
Table 2
Rate constants determined using a two-tissue compartment model during baseline.
Condition Animal
number
CBF (ml min−1
100 ml tissue−1)
Right somatosensory
cortex surface probe
Baseline 1 35.14
1 34.58
2 34.04
2 34.21 34.49±0.5
Acetazolamide 1 50.82
1 50.4
2 53.87
2 54.07 52.29±1.9
Left somatosensory
cortex intracortical probe
Baseline 1 37.38
1 38.92
2 39.53
2 39.20 38.76±0.9
Acetazolamide 1 55.02
1 56.14
2 59.94
2 58.97 57.52±2.3
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The present study demonstrates the suitability of the surface probe
for reliable measurements of tracer kinetics in the rat cerebral cortex
through the thinned skull. The fact that there is no need for
craniotomy facilitates and shortens the surgery and does not cause
any tissue disturbance. The dura and brain remain untouched, leaving
the cortex in a physiological state. However, the design of the probe
system does not allow acquisitions from deep brain areas and
measurements are restricted to superficial structures. This limitation
can be overcome by complementary use of intracerebral beta probes
for non-cortical measurements.
This novel probe system was able to reliably measure kinetic
data using radiotracers labeled with nuclides of different energies.
However, values for LCMRglu and CBF were both lower in the
surface probe measurements compared to the intracortical acquisi-
tions. Several factors could contribute to these differences which
include probe calibration procedures, differences in the geometry
and size of the detection volume. In addition, tissues between the
surface probe and cortical surface, such as dura, cerebrospinal fluid
and thinned bone may affect the signal measured. For the
performed simulations we assumed a gap of 200 μm between
cortical surface and the scintillator surface. This gap is mainly filled
by cerebrospinal fluid. Dura mater and bone add at maximum 50–
100 μm. Therefore the assumption of water instead of bone
absorbing the positrons in our simulations will lead only to a
minor error. Gamma radiation may be yet another source for error
(Pain et al., 2000; Pain et al., 2002b; Weber et al., 2003). In the
case of the here presented surface probe the contribution of
511 keV gamma rays was evaluated to be about 15% in the cali-
bration experiments. The exact contribution depends on factors
such as geometry of the volume containing radioactivity and the
temporal and spatial distribution in that volume. This factor is
difficult to assess quantitatively.
The reason we used F-18 and O-15 was the different emission
energy of the positrons and that FDG and 15O-H2O display a very
different kinetic behavior. The higher emission energy of O-15 leads to
a different geometry and size of the volume of the detected positrons,
as is demonstrated in Fig. 2C. Furthermore, the kinetic of 15O-H2O is
much faster than that of FDG. It was therefore relevant to demonstrate
the suitability of the surface probe for both tracers. One of the most
Fig. 6.Mean tissue time–activity curves normalized to the integral of plasma radioactivity between 0 and 210 s for 15O-H2O (n=4) and between 0 and 45min for 18F-FDG (n=6). The
narrow range of standard deviations supports the high reproducibility of the measurements.
Fig. 7.Decay-corrected tissue time–activity curves acquired by the surface probe system
during electrical infraorbital nerve stimulation in one animal are demonstrated. As
shown in the autoradiogram, contralateral to the stimulation site (arrow, gray squares
in the graph) accumulation of 18F-FDG was increased compared to the ipsilateral
hemisphere (open circles in the graph). The radioactivity concentration in plasma (gray
line) and in whole blood (black line) is also shown.
Fig. 8. Acquisition in the awake, head-fixed animal. Tissue accumulation of FDG clearly
slowed down after induction of sevoflurane anesthesia (gray arrow). Shown are
measured tissue activity (circles), the model fit to the actually measured data (black
line) and the putative model fit if the curve was continued using the same rate
constants from the period before anesthesia induction (dotted black line). LCMRglu
decreased by 46.8%. The inset shows the two mean input curves obtained in awake
(n=4) and in sevoflurane anesthetized animals (n=4) from which the applied input
curve was constructed (see Materials and methods).
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critical issues with regard to absolute quantification is the precise
calibration of instruments. The calibration procedure should also
adequately mimic the in vivo situation. It can be assumed, that this is
somewhat more difficult in the case of the surface detector as
compared to the intracortical probe, mainly because the position of
the surface detector cannot be perfectly reproduced from experiment
to experiment (e.g., due to the thinning of the bone, angle and
distance of the probe relative to brain surface). Therefore the accuracy
of the surface probe is expected to be inferior to the one of the
intracortical probe regarding absolute quantification. However, in
many situations it is the change following some kind of intervention,
which is of more interest than absolute values, and that is where we
see themajor application of the surface probe. This is illustrated by the
stimulation experiments where the surface probe registered a similar
percentage change as the autoradiography.
Besides beta sensitive probes, alternative radiotracer probes were
developed in the past. The principle of detection of gamma probes is
either excitation (scintillator) or ionization (semiconductor) and their
major application is intra-operative radio-guided surgery (Classe et
al., 2005; Zanzonico and Heller, 2000). Their spatial resolution is
however at least one order of magnitude poorer as compared to beta
probes (Haigh et al., 2000), which severely limits their applicability in
small animal research.
Finally, another valuable feature of the surface system is its use in
awake animals. This clearly broadens the applicability of the device
given the fact that an increasing number of studies are performed in
awake animals to avoid the disturbing effect of anesthetics on brain
function (Austin et al., 2005; Lindauer et al., 1993; Martin et al., 2006;
Nakao et al., 2001). Our preliminary data acquired in one animal at
two different days demonstrates a marked effect of sevoflurane
inhalation on brain metabolism and shows the feasibility of serial
experiments. However, no arterial input curves were measured in
these experiments, which would be mandatory to obtain reliable
absolute values.
Summary
In this work, we demonstrated the feasibility of a surface probe
system for the measurement of radiotracer kinetics from the cerebral
cortex of the rat. The system yielded reproducible results in the
anesthetized rat. Its potential use in the awake animal was demon-
strated in preliminary experiments. The surface probe is thus a
valuable tool for tracer kinetic experiments where data from only a
few cortical locations are needed. The major advantage of the system
in comparison to intracortical probes is that the brain tissue is not
injured or disturbed.
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In this study we assessed the new glutamatergic ligand 11C-ABP688
with regard to the following characteristics: (A) brain distribution, (B)
first pass extraction fraction, (C) suitable model to describe tracer
kinetics and (D) specificity for the mGlu5 receptor. These parameters
were assessed using autoradiography and a beta-scintillator positioned
in the striatum. The study included 13 male rats. In 2 animals cerebral
blood flow was measured using H2
15O. The 11C-ABP688 data were
analyzed using compartmental modeling. A two-tissue compartment
model turned out to fit the data more adequately (parameters: K1, k2V,
k3V, k4, total distribution volume DVtot=K1/k2V (1+k3V/k4) than a one-
tissue compartment model. The autoradiographic studies revealed high
uptake in hippocampus, striatum and cortex and low accumulation in
thalamus and cerebellum. The uptake was markedly reduced following
blockade with the mGlu5 antagonist M-MPEP. The first pass
extraction fraction exceeded 85%. Baseline DVtot was 15.16±2.67 ml
plasma/ml tissue and decreased by 56, 67 and 72% following blockade
with 1, 2 and 6 mg/kg M-MPEP, respectively. These results show that
11C-ABP688 is a promising PET ligand for the quantification of mGlu5
receptors in humans and animals. It readily crosses the blood–brain
barrier and binds with high specificity to the mGlu5 receptor. The
study furthermore demonstrates the usefulness of a beta-scintillator, if
necessary in connection with autoradiography, to evaluate new
receptor tracers.
© 2007 Elsevier Inc. All rights reserved.
Keywords: Autoradiographic study; Beta-scintillator; Metabotropic gluta-
mate receptor subtype 5
Introduction
Since the cloning of the first metabotropic glutamate receptor
(mGlu1) in 1991 (Masu et al., 1991), seven additional subtypes of
this receptor (mGlu2–8) have been cloned. Based on their amino-
acids sequence, pharmacology and second messenger coupling
these receptors have been classified into three groups (I–III) (Pin
and Duvoisin, 1995). Group I includes mGlu1 and mGlu5
receptors, Group II includes mGlu2 and mGlu3 receptors, and
Group III includes mGlu4, 6, 7 and 8 receptors. For the mGlu5
receptor subtype, based on the wide and consistent effects of
selective non-competitive allosteric antagonists such as MPEP (2-
Methyl-6-(phenylethynyl)pyridine) in animal models for anxiety
(Gasparini et al., 1999; Kuhn et al., 2002), it has been hypothesized
that this receptor could be a valuable target for the treatment of
anxiety related disorders (Spooren et al., 2000; Tatarczynska et al.,
2001; Spooren and Gasparini, 2004). Although a number of mGlu5
receptor antagonists have been successfully used in vitro to label
mGlu5 receptors (Gasparini et al., 2002; Patel et al., 2003), the
development of a PET tracer proved difficult (Hamill et al., 2003).
Only recently a series of PET ligands, allowing the in vivo imaging
in rhesus monkeys, has been described (Hamill et al., 2005). We
have synthesized and profiled a series of derivatives using the
prototypic antagonist MPEP as template. Unfortunately none of
these derivatives proved to be a promising candidate for human
PET imaging (Kokic et al., 2001; Ametamey et al., 2003).
Recently, we identified a very promising ligand: 11C-ABP688 (3-
(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-[11C]-methyl-
oxime). This compound is a highly selective allosteric antagonist
of the mGlu5 receptor in vitro, and initial studies have
demonstrated a high specificity for mGlu5 receptors in vivo
(Ametamey et al., 2005). The major purpose of this study was to
www.elsevier.com/locate/ynimg
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further investigate the suitability of 11C-ABP688 as a radiotracer
for the study of mGlu5 receptors. Issues of interest were (A) the
brain distribution of the tracer, (B) the first pass extraction fraction,
(C) suitable models to describe tracer kinetics and (D) specificity
for the mGlu5 receptor. These issues were addressed using
autoradiographic studies and a beta-scintillator positioned in the
rat striatum.
Materials and methods
Synthesis of 11C-ABP688
The synthesis of 11C-ABP688 has been described in detail
elsewhere (Ametamey et al., 2005). Briefly, desmethyl ABP688
was reacted with 11C-methyl iodide produced from the GE PET
trace system at 90 °C for 5 min. The product was purified by semi-
preparative HPLC using a reversed-phase column. Formulation of
11C-ABP688 for in vivo administration into animals was
accomplished using 0.15 M phosphate buffer and ethanol. The
specific activities at the time of injection ranged from 11 to
437 GBq/μmol. The amount of stable ABP688 which was injected
is indicated in Table 1.
Animal preparation
The beta-scintillator study included 11 male rats (Sprague–
Dawley) weighing approximately 300 g (range: 266–366 g).
Surgery was performed under isoflurane anesthesia and involved
the placement of an arterio-venous shunt from the right femoral
artery to the right femoral vein, tracheotomy for mechanical
ventilation and craniotomy for the placement of the beta-
scintillator. The actual experiments were performed under urethane
anesthesia (1.4 g/kg bodyweight i.p.). The shunt was used for the
continuous monitoring of arterial blood pressure, the injection of
the radiotracers, the continuous measurement of the total arterial
radioactivity and the administration of a lethal dose of pentobarbi-
tal at the end of the experiment. For the recording of the total blood
radioactivity, the shunt was run through a coincidence counter. The
on-line arterial sampling procedure is described in detail elsewhere
(Weber et al., 2002).
Experiments
Beta-scintillator
The beta-scintillator is in detail described elsewhere (Weber et
al., 2003; www.swisstrace.com). In short, it consists of a
scintillation tip (Bicron, BF12, Newbury, OH, USA) with
0.8 mm length and 0.25 mm diameter that is attached to a high
numerical aperture glass fiber. The probe was made light tight by
applying a uniform coating of silver particles. Following each
experiment the beta-probe was calibrated in a vial containing a
known concentration of 11C activity. The sensitivity ranged from
0.035 to 0.044 cps/kBq/ml. For data analysis all data were
background-corrected (range of background count rates: 0–1 cps),
decay-corrected to the time-point of injection and converted to
kBq/ml. The scintillator was placed in the striatum using a
stereotactic frame (David Kopf Instruments, Tujunga, CA, USA).
The skull was exposed and a craniotomy was performed using a
dental drill. Then the dura was carefully incised and the probe was
carefully lowered to a depth of 5.5 mm for striatal recordings. Only
one probe penetration was performed per animal.
Determination of the arterial plasma input curve
The total radioactivity in arterial blood was continuously
recorded using the coincidence counter. Whole blood activity was
then corrected for (a) the relative concentration of 11C-ABP688 in
plasma versus whole blood and (b) the concentration of labeled
metabolites. The ratio “radioactivity concentration plasma/radio-
activity concentration whole blood” was determined in 6 separate
animals in a preceding pilot study at different time-points (2–4
blood samples (∼100 μl) per animal). The data of all animals
were then pooled and the time-course of the ratio was
approximated by fitting a quadratic polynominal to the data.
This function was subsequently used to convert radioactivity
concentration in whole blood to radioactivity concentration in
plasma.
In the same 6 animals, metabolite analysis was performed. For
this purpose, 500 μl blood samples were taken at different time-
points (a maximum of 4 samples per animal). In each sample the
fraction of authentic 11C-ABP688 in plasma was determined as
described below. The data of all animals were then pooled and the
Table 1
Fitting results calculated with the two-tissue compartment model and fixed values for K1/k2 (1.6) and k4 (0.05 min
−1)
Baseline Blockade with MMPEP Blockade with cold ABP (3 mg/kg)
Animal
#
Cold
ABP,
pmol/g
α,
ml blood/
ml tissue
K1,
ml/
min/
ml
k3,
min−1
DVtot,
ml plasma/
ml tissue
M-MPEP Cold
ABP,
pmol/g
α,
ml blood/
ml tissue
K1,
ml/
min/
ml
k3,
min−1
DVtot,
ml plasma/
ml tissue
α,
ml blood/
ml tissue
K1,
ml/
min/
ml
k3,
min−1
DVtot,
ml plasma/
ml tissue
1 0.90 0.09 0.93 0.55 16.21
2 1.05 0.12 0.55 0.44 15.66
3 0.79 0.15 0.88 0.47 16.62
4 1.88 0.14 0.98 0.52 18.28
5 2.10 0.12 0.68 0.38 13.61
6 0.64 0.01 0.41 0.51 18.00
7 0.84 0.02 0.67 0.34 12.60 1 mg/kg 7.47 0.05 0.63 0.12 5.55
8 0.64 0.13 0.91 0.26 9.98 2 mg/kg 2.24 0.01 0.87 0.05 3.32
9 4.51 0.01 0.98 0.47 15.48 6 mg/kg 14.3 0.07 0.74 0.09 4.41
Mean 0.09 0.78 0.44 15.16 Mean 0.04 0.75 0.09 4.43
SD 0.06 0.21 0.09 2.67 SD 0.03 0.12 0.04 1.12
10 3 mg/kg 0.07 0.68 0.07 3.74 0.01 0.87 0.08 4.29
11 3 mg/kg 0.06 0.54 0.07 3.95 0.13 0.67 0.07 3.92
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time-course of the fraction of authentic tracer was approximated by
a decaying biexponential function starting at value 1 at time zero.
This function was then used to convert the total plasma activity to
the time-course of authentic 11C-ABP688. Metabolite data acquired
at baseline were also used for the blocking studies assuming that
the blocking drug did not alter peripheral metabolism of the
radioligand.
Metabolite analysis
To separate authentic tracer and metabolites in plasma, solid
phase separation with extraction cartridges (Waters Sep-Pak®
tC18) was performed. Plasma samples of 100 to 200 μl were
diluted with 2.5 ml aqua and passed through the Sep-Pak®
cartridges. In a second step the cartridges were eluted with 5 ml
aqua and cleared with air to wash out the remaining metabolites,
leaving only the adsorbed tracer in the cartridges. Both components
were measured in the gamma counter, yielding the fraction of
authentic tracer. The Sep-Pak® method had previously been
validated with high-performance liquid chromatography (HPLC)
as demonstrated in Fig. 1.
Experimental protocols
In 2 animals (nr5 and nr9), baseline cerebral blood flow (CBF)
was determined using H2
15O and the methodology described
previously (Weber et al., 2003). Briefly, 150–200 MBq H2
15O
was injected into the shunt and data were recorded for 3 min. The
striatal time–activity curve and the arterial input curve were then
used to calculate quantitative CBF values. The analysis was based
on a one-tissue compartment model (Fig. 2A). In these two
animals the CBF values were then used for the calculation of the
first pass extraction fraction EF of 11C-ABP688 (EF=K1 /CBF).
In 6 (nr1–nr6) animals the time-course of 11C-ABP688 was
measured at baseline alone. In another 5 animals (nr7–nr11) the
experiments involved a pharmacological intervention. In 3 animals
(nr7–nr9) the baseline experiment was followed by blockade of the
mGlu5 receptors using increasing doses of M-MPEP (1, 2 and
6 mg/kg), a selective allosteric antagonist of the mGlu5 receptor
(Gasparini et al., 1999). In each case (1.2 and 6 mg/kg
respectively) the drug was intravenously injected 20 min after
first 11C-ABP688 injection and 10 min before the second
radiotracer injection. Both injections were done sequentially using
the same radiotracer synthesis. In 2 (nr10–11) animals it was
investigated whether 11C-ABP688 binds specifically to another site
which cannot be blocked by M-MPEP. For this purpose the mGlu5
receptors were blocked with 3 mg/kg M-MPEP administered
intravenously 10 min prior to a first tracer injection. Twenty
minutes later, 3 mg/kg stable ABP688 was injected, and 10 min
later another injection of 11C-ABP688 was performed and data
were recorded for another 20 min.
Injected activities were in the range of 41–108 MBq throughout
all experiments and the injected mass of ABP688 was 0.64–
14.30 pmol/g body weight (Table 1).
Model
The models used in this study are illustrated in Fig. 2.
CBF measurements
The basis of the calculation of the CBF measurements was the
one-tissue compartment model including a partition coefficient for
H2
15O (Fig. 2A). The change of the radioactivity concentration in
tissue Ctiss is then defined by the following differential equation
dCtiss=dt ¼ CBFðCbloodðtÞ  CtissðtÞ=pÞ ð1Þ
where Cblood is the arterial blood tracer concentration and p is the
tissue partition coefficient, e.g. that fraction of tissue that is
permeable for H2
15O. In this configuration Ctiss is the concentra-
tion of H2
15O in 1 ml of brain and it is assumed that H2
15O
immediately reaches a homogeneous concentration in permeable
space and no division into a vascular and a tissue compartment is
necessary. The analytical solution of Eq. (1) is
Ctiss ¼ CBFexpðCBF=ptÞ⊗Cblood ð2Þ
where ⊗ signifies mathematical convolution.
Eq. (2) was fitted to the data using least squares fitting
(Marquardt algorithm) implemented in the software PMOD (http://
www.pmod.com; Mikolajczyk et al., 1998). Before fitting all data
were corrected for decay and the input function for delay.
Fig. 1. High performance liquid chromatography (HPLC, BondClone, C18;
3.9×300; 5 μm; mobile phase, acetonitrile: 0.1% phosphoric acid [65:35];
flow late, 0.4 ml/min). The HPLC was performed to validate the Sep-Pak®
method to separate authentic tracer from more polar metabolites. The
peak in the ethanol phase (used to wash out the adsorbed compound) and
in the water phase are clearly separated and there was only one peak per
phase. A second experiment demonstrated that the ethanol peak represents
11C-ABP688. These data demonstrate the suitability of the Sep-Pak®
method.
Fig. 2. One- and two-tissue compartment models used to analyze cerebral
blood flow (CBF) using H2
15O (A) and the kinetics of 11C-ABP688 (B, C),
respectively.
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11C-ABP688 experiments
In the experiments with 2 successive tracer injections the data
following the second injection were confounded by counts from
the first injection. This was corrected by the following procedure,
illustrated in Fig. 3. The tissue data 20–30 min following the first
tracer injection were fitted with a monoexponential which was then
extrapolated to the end to the study (solid line). The value of the
extrapolated exponential was then subtracted from the counts
measured after the second injection. The same procedure was
applied for the correction of the total arterial radioactivity
concentration. All data were decay-corrected to the time-point of
the first injection and expressed in kBq/ml and background
corrected before this procedure.
Tracer kinetic model
The investigated methods consisted of standard compartmental
modeling using an arterial input function. Tracer kinetic modeling
was performed using the models depicted in Fig. 2. They contain
one and two tissue compartments. The notation using primes is
borrowed from Koeppe et al. (1991). The meaning of the
parameters is as follows:
K1: Describes uptake of tracer across the blood brain barrier and is
related to blood flow (CBF) and the first pass extraction fraction
Ef (K1=CBF Ef).
k2ʺ , k2V: Represent backdiffusion from tissue to vascular space in the one-
and two-tissue compartment model respectively
k3V: Describes the transfer of the ligand to the receptor, k3V¼
k3
1þ k5=k6 ¼
kon Bmax V
1þ k5=k6
where k5 and k6 denote the exchange of ligand between the free
and the nonspecific compartment in the full three-tissue compart-
ment model. The term 11þk5=k6 is equivalent to the term f2 used by
Mintun et al. (1984) and others. BmaxV is the density of free
receptors and kon denotes the association constant.
k4: Describes dissociation from receptor (koff)
DVʺ: Total distribution volume of tissue activity calculated with the one-
tissue compartment model (K1/k2ʺ )
DVC1: Distribution volume of compartment C1 (K1/k2V)
DVC2: Distribution volume of compartment C2 (K1/k2V k3V/k4)
DVtot: Total distribution volume of tissue activity calculated with the two-
tissue compartment model (DVC1+DVC2=K1/k2V (1+k3V/k4)
Tracer exchange between the compartments is described by the
following differential equations
dC1
dt
¼ K1Cp  k2Vþ k3Vð ÞC1 þ k4C2 ð3Þ
dC2
dt
¼ k3VC1  k4C2 ð4Þ
dCtiss
dt
¼ K1Cp  k2WCtiss ð5Þ
where Cp is the concentration of authentic tracer in arterial plasma.
Eqs. (3) and (4) describe tracer exchange in the two-tissue
compartment model, Eq. (5) in the one-tissue compartment model.
Since the total activity measured in a region is composed of counts
from tissue and blood, all models contained a parameter (α)
correcting for blood activity.
Cprobe ¼ ð1 aÞCtiss þ aCblood ð6Þ
where:
Cprobe: Radioactivity registered by the beta probe
α: Percentage of the counts originating from intravascular space
Ctiss: Activity concentration in the extravascular compartment; with the
two-tissue compartment model Ctiss is the sum of C1 and C2.
Cblood: Radioactivity concentration in arterial whole blood
Ctiss was calculated by numerical integration of the differential
equations.
Models B and C (Fig. 2) were fitted to the data from the time-
point of injection to 20 min using Marquart's least squares fitting.
The adequacy of the model was judged according to the Akaike
information criterion (AIC) (Akaike, 1974). Model C was
considered superior if there was a decrease in AIC compared to
model B. DVtot was taken as a measure for receptor density.
Autoradiographic studies
This study included 2 male rats (Sprague-Dawley) weighing
approximately 307 and 311 g, respectively. To demonstrate the
native distribution of 11C-ABP688 in the brain and the effect of
blockade with M-MPEP two autoradiographic studies were
performed. Five minutes after the injection of 500 MBq 11C-
ABP688 (specific activities: 104 and 157 GBq/μmol; injected
masses: 8.16 and 15.59 pmol/g body weight) into the tail vein, the
animals were sacrificed by an intravenous overdose of pentobarbi-
tal (Nembutal; Abbott Laboratories, North Chicago, USA), the
brains were quickly removed and frozen in chilled isopentane
(Isopentan; Fluka Chemie GmbH, Buchs, Switzerland). The frozen
brains were cut in 10 μm horizontal slices and thaw-mounted on
glass slides. The slides were put on a phosphor imager screen (Fuji
TR 2025; Fuji Photo Film Co., Ltd., Tokyo, Japan) for 2 h together
with 14C standards for quantification of tracer uptake. In a previous
Fig. 3. Typical experiment with 2 tracer injections. Demonstrated is original
beta-scintillator data (not decay corrected). The solid line represents the
monoexponential fit to the last 10 min of data of the first experiment. The
extrapolation of that fit was used to correct the second experiment for
residual 11C activity from the first experiment.
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calibration experiment, each 14C standard had been assigned a
value in kBq cm−3 of 11C activity. This was achieved by exposing
10 μm sections of porcine brain paste with well defined amounts of
11C activity for 2 h together with the 14C standards. Finally the data
were scanned (Fuji BAS 1900 II, pixelsize 50 μm; Fuji Photo Film
Co., Ltd., Tokyo, Japan) and converted to kBq/ml. Dividing the
tissue uptake by the decay-corrected injected activity per gram of
body weight yielded standardized uptake values (SUVs). In the
blocking experiment, M-MPEP (3 mg/kg i.v.) was injected
intravenously 10 min prior to tracer injection.
Results
Autoradiographic studies
The brain distribution of 11C-ABP688 is illustrated in the left
autoradiograph of Fig. 4. High concentrations are observed in the
striatum, cortex and hippocampus. Lower tracer uptake is seen in
the thalamus and the white matter. The region with lowest uptake is
the cerebellum. Following blockade with M-MPEP, the 11C-
ABP688 distribution pattern is homogeneous and the uptake value
in all structures decreased to the level of the cerebellum. In striatum,
SUV in the untreated animal was 3.15 versus 0.38 in the animal
pretreated with M-MPEP, and SUV in the cerebellum was 0.45 and
0.38 under baseline and M-MPEP conditions, respectively.
Time-course of tracer in arterial plasma
The time-course of the fraction of authentic 11C-ABP688 in
arterial plasma is demonstrated in Fig. 5. Metabolism is rapid, and
at 40 min the fraction of 11C-ABP688 is 20%. The ratio of the 11C-
radioactivity concentration in plasma to whole blood decreased
from 1.2 immediately after injection to 0.95 at 40 min.
Time-course of tracer in tissue and tracer kinetic modeling
An example of the time-course of the radioactivity concentra-
tion in striatum at baseline and following blockade with M-MPEP
is demonstrated in Fig. 6. The model fit is superimposed. At
Fig. 4. 11C-ABP688 autoradiographs demonstrating the 11C distribution
5 min following injection of 500 MBq of tracer. On the left is a baseline
experiment, on the right the animal was blocked with 3 mg/kg M-MPEP
10 min prior to tracer injection. pc: prelimbic cortex, st: striatum, hi:
hippocampus, th: thalamus, ce: cerebellum.
Fig. 5. The larger graph demonstrates the time-course of the fraction of
authentic 11C-ABP688 in arterial plasma. The filled circles are the mean of
the measured data points obtained of 6 animals. In each animal, blood
samples were processed at 2–4 different time-points. The line represents the
biexponential fit to the data (y=0.5 exp(−0.279*t)+0.5 exp(−0.029*t)).
The insert denotes the ratio of the total 11C activity in plasma to whole blood.
Again the filled circles represent measured data from 6 animals. The solid
lines is a quadratic fit to the data (y=0.00016t2−0.01152t+1.15756, t in
minutes).
Fig. 6. Blockade experiment in animal nr9. Data recorded from the striatum
at baseline are presented in the upper panel and following blockade with M-
MPEP (6 mg/kg intravenous) in the lower panel. Washout of tracer is
remarkably faster after blockade with M-MPEP. The dots represent the tissue
time–activity curves, the solid line is the model fit and the broken line
represents the 11C-ABP688 activity concentration in arterial plasma.
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baseline washout of tracer during the investigated 20 min is
minimal. In contrast washout is remarkably faster following
blockade with M-MPEP. The fitting results of all 11C-ABP688
experiments are summarized in Table 1. In 5 of the 9 baseline
experiments, the two-tissue compartment model was more
adequate to fit the data based on a clear decrease in the AIC. In
order to fit all experiments with one type of model, all data were
then fitted using the two-tissue compartment model. To get stable
fits K1/k2 was fixed to 1.6 and k4 to 0.05 min
−1 in both the
baseline and the blocking experiments, corresponding to mean
values of free fitting using two tissue compartments. Using this
procedure we assumed that the blocking drug decreases the number
of available receptors (k3) but not the DV of compartment C1 (K1/
k2V) and k4. Blood flow in the 2 animals with CBF measurement
was 0.63 and 0.69 ml/min/ml respectively. These values together
with K1 from
11C-ABP688 experiments yielded a first pass
extraction fraction of 97 and 87%, respectively. In the baseline
experiments K1 ranged from 0.41 to 0.98 ml/min/ml. The values of
DVtot were generally high, above 12 ml plasma/ml tissue in 8 of
the 9 baseline experiments.
Blockade with M-MPEP
The blocking experiments nr7–9 demonstrate a marked
reduction of DVtot. The percentage reduction from baseline was
56, 67 and 72% for 1, 2 and 6 mg/kg M-MPEP, respectively. The
effect of the blockade on K1 was markedly less pronounced.
Sequential blockade with M-MPEP and stable ABP688
In the 2 experiments (nr10 and nr11) with a double blockade,
there was no further decrease of DVtot following cold ABP688.
Discussion
Qualitative assessment of the general distribution and specificity of
the tracer using autoradiographic studies
Autoradiographic studies are very suitable to investigate the
tissue distribution of a tracer. Spatial resolution is very high, but, as
a disadvantage, only one time-point following tracer injection can
be assessed per animal. It is furthermore important to note that
tracer distribution assessed in a non-equilibrium state, as occurs
after bolus injection, does not reflect receptor density in a
quantitative manner, even if the tracer was 100% specifically
bound. In order for the tracer distribution to reflect receptor density
quantitatively one would have to image while tracer in brain and
plasma are in complete equilibrium. Theoretically that would be
possible using a “bolus and constant infusion” protocol as has been
employed in human studies (Koeppe et al., 2005). However, it
would be very difficult to do a 11C autoradiographic study using
such a protocol. Because of the rapid decay during the time to
equilibration, not enough radioactivity would be available. Never-
theless, the comparison of the autoradiograph in Fig. 4 with
previous studies (Shigemoto et al., 1993; Romano et al., 1995;
Aoki et al., 2004) indicates, that the distribution of 11C-ABP688 is
related to the pattern of mGlu5 receptor distribution. Together with
the blockade experiment, one can also get a first indication of the
amount of specifically bound tracer. Since M-MPEP binds with
high specificity to the allosteric binding site in the transmembrane
portion of the mGlu5 receptor (Gasparini et al., 2002), the
difference between the 2 autoradiographic studies represents
specific binding of 11C-ABP688 to the same site on the mGlu5
receptor.
First pass extraction fraction (EF)
This study demonstrates that the EF is exceptionally high,
although probably somewhat overestimated because of a more
pronounced underestimation of CBF relative to K1. This is due to
the larger free range of 15O positrons leading to a more pronounced
partial volume effect. With a high EF the tracer distribution early
after injection will reflect blood flow. This opens the potential to
assess CBF and receptor density with one tracer injection.
Specificity for the mGlu5 receptor
One measure for the specificity is the amount of tracer tissue
binding which can be blocked by a ligand that binds to the same
site. The allosteric antagonist M-MPEP displays high affinity
binding to the mGlu5 receptor and has no relevant affinity for the
other subtypes of the glutamate receptor family or other known
receptors (Gasparini et al., 2002). The SUV values in the
autoradiographs demonstrate an 88% reduction of 11C-ABP688
binding in striatum following a blocking dose of M-MPEP,
suggesting that this fraction of total tissue activity at the selected
time-point was specific binding. More quantitative information on
specific binding is obtained from the blocking experiments nr7–9.
The reduction of DVtot in the range of 56–72% indicates a high
amount of specific binding. The percentage reduction seems
related to the injected amount of M-MPEP; however, more
experiments would be needed to establish a clear dose-dependence.
The high specificity of 11C-ABP688 for the mGlu5 receptor is
further demonstrated by the successive blockade with M-MPEP
and stable ABP688 in experiments nr10 and 11. While the
reduction of DVtot following blockade with M-MPEP demonstrates
the fraction of 11C-ABP688 bound to the mGlu5 receptor, it does
not exclude binding of 11C-ABP688 to another specific (displace-
able) binding site. This does not seem to be the case, since we
observed no marked further reduction in DVtot following the
injection of stable ABP688.
General remarks
The combination of autoradiographic studies and beta-scintil-
lator proved to be a valuable tool to evaluate important aspects of
new receptor ligands. At this point it could be argued that the use
of small animal PET would be preferable over the beta-scintillator.
The advantage of the small animal PET method is that it is less
invasive and that the tracer distribution can be assessed in the
whole animal and not only at one location. However, there are
points in favor of the beta-scintillator, e.g. it is considerably
cheaper and its temporal resolution is superior. The latter point is
important for quantitative perfusion imaging using H2
15O and the
evaluation of tracer kinetic models.
Another point concerns the mass of injected stable ABP688.
The number of stable ABP688 molecules per volume should be
small relative to the available receptors, otherwise it will markedly
alter the kinetics of the labeled ABP688 molecules due to relevant
receptor binding. To evaluate this problem we took a Bmax value of
83 nM (Hamill et al., 2005) and assumed that all ligands at peak
activity were bound to receptors. This yielded a receptor occu-
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pancy of 6±5% (mean±SD, all baseline experiments). This value
is an upper limit, since not all ligands will be receptor bound.
Another indication that receptor occupancy by stable ABP688 was
low is the lacking correlation between the injected mass of stable
ligand and DVtot in the baseline experiments (Table 1). The
vascular fraction α demonstrated in Table 1 displays quite a large
variation. Part of this is probably noise, but some of it may be
attributed to the location of vessels relative to the probe. A vessel
located close to the probe will contribute more counts than a vessel
1 mm away.
Conclusion
11C-ABP688 is a very promising ligand for the quantification of
mGlu5 receptors in humans and animals. It readily crosses the
blood–brain barrier and binds with high specificity to the mGlu5
receptor. The study furthermore demonstrates the usefulness of a
beta-scintillator, if necessary in connection with autoradiographic
studies, to evaluate new receptor tracers with regard to their
usefulness in human PET studies.
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Differentiation between posttherapy radiation necrosis and re-
current tumor in humans with brain tumor is still a difficult
diagnostic task. The new PET tracers 18F-fluoro-ethyl-L-tyrosine
(FET) and 18F-fluorocholine (N,N-dimethyl-N-18F-fluoromethyl-
2-hydroxyethylammonium [FCH]) have shown promise for im-
proving diagnostic accuracy. This study assessed uptake of
these tracers in experimental radiation injury.Methods: In a first
model, circumscribed lesions were induced in the cortex of 35
rats using proton irradiation of 150 or 250 Gy. After radiation
injury developed, uptake of 18F-FET, 18F-FCH, and 18F-FDG was
measured using autoradiography and correlated with histology
and disruption of the blood–brain barrier as determined with
Evans blue. In a second model, uptake of the tracers was
assessed in acute cryolesions, which are characterized by the
absence of inflammatory cells. Results: Mean 18F-FET, 18F-
FCH, and 18F-FDG standardized uptake values in the most
active part of the radiation lesion and the contralateral normal
cortex (in parentheses) were 2.27  0.46 (1.42  0.23), 2.52 
0.42 (0.61 0.12), and 6.21 1.19 (4.35 0.47). The degree of
uptake of 18F-FCH and 18F-FDG correlated with the density of
macrophages. In cryolesions, 18F-FET uptake was similar to that
in radiation lesions, and 18F-FCH uptake was significantly re-
duced. Conclusion: Comparison of tracer accumulation in cry-
olesions and radiation injuries demonstrates that 18F-FET up-
take is most likely due to a disruption of the blood–brain barrier
alone, whereas 18F-FCH is additionally trapped by macro-
phages. Uptake of both tracers in the radiation injuries is gen-
erally lower than the published uptake in tumors, suggesting
that 18F-FET and 18F-FCH are promising tracers for separating
radiation necrosis from tumor recurrence. However, the com-
parability of our data with the literature is limited by factors such
as different species and acquisition protocols and modalities.
Thus, more studies are needed to settle this issue. Neverthe-
less, 18F-FCH and 18F-FET seem superior to 18F-FDG for this
purpose.
Key Words: radiation necrosis; 18F-fluorocholine; 18F-fluoro-
ethyl-L-tyrosine; 18F-FDG; autoradiography
J Nucl Med 2004; 45:1931–1938
Over the last 20 y, PET has become indispensable for
evaluating brain tumors. Indeed, diagnosis of brain tumors
was the first oncologic application of 18F-FDG PET (1).
Differentiation of posttherapy radiation necrosis from recur-
rent tumor remains a challenging diagnostic problem. Cor-
rect diagnosis obviously has strong implications for disease
management. Attempts with 18F-FDG were only partially
successful (2–5). One problem is the high intrinsic uptake of
18F-FDG in normal brain cortex, often rendering differenti-
ation of lesions from normal brain difficult. Another is the
wide range of 18F-FDG uptake in different brain tumors,
leading to an overlap with the degree of uptake in radiation
necrosis. Also, MRI and CT cannot reliably separate radi-
ation necrosis from recurrent tumor (6–8).
Therefore, the development of more specific radiotracers
is a major aim of nuclear medicine research. Radiolabeled
choline or amino acid analogs such as 18F-fluorocholine
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(N,N-dimethyl-N-18F-fluoromethyl-2-hydroxyethylammo-
nium [FCH]) and 18F-fluoro-ethyl-L-tyrosine (FET) seem
promising for separating radiation necrosis from tumor re-
currence (9–11). The ideal tracer for this purpose would
reproducibly demonstrate a different accumulation pattern
in radiation necrosis from that in tumor, such as no accu-
mulation in radiation necrosis and high accumulation in
tumor—a pattern that has been demonstrated for 18F-FET
and 18F-FCH.
18F-FET is an amino acid analog that is not metabolized
or incorporated into proteins. A specific Na-independent
amino acid transport system, the L-system, is responsible
for high 18F-FET accumulation in tumor cells (12). Wester
et al. introduced this tracer to clinical research (13). Further
studies have demonstrated increased uptake of 18F-FET in
various brain tumors (11,14,15) and lack of uptake by
inflammatory tissue (16,17). This is important, since radia-
tion necrosis may contain inflammatory cells.
Choline is transported into mammalian cells by specific
mechanisms and then phosphorylated by choline kinase. In
a further step, choline is metabolized to phosphatidylcholine
and incorporated into the cell membrane (18,19). The in-
creased choline uptake in tumor cells is explained by up-
regulation of choline kinase (20,21). Initial studies with
11C-choline demonstrated the diagnostic potential of this
substance in different tumors (22–26). Degrado et al. intro-
duced 18F-FCH for brain tumor imaging (27). The major
advantage of 18F-labeled compounds, especially in clinical
use, is the longer physical half-life of 18F (110 min) than of
11C (20 min). The tumor uptake patterns of 11C-choline and
18F-substituted choline analogs are very similar (9). Con-
trary to 18F-FET, 18F-FCH is accumulated by inflammatory
cells (28).
The purposes of this study were, first, to assess uptake of
18F-FET, 18F-FCH, and, for comparison, 18F-FDG in exper-
imentally induced acute radiation injury in the rat brain. The
tracer uptake pattern was assessed by autoradiography and
correlated with histologic findings and disruption of the
blood–brain barrier (BBB) as assessed with Evans blue. A
second purpose was to evaluate the effect of BBB disruption
alone on uptake of 18F-FET and 18F-FCH. For this purpose,
18F-FET and 18F-FCH accumulation was determined in cry-
olesions, which are characterized by a heavily disrupted
BBB but, in contrast to radiation injury, absence of inflam-
matory cells. Finally, this study assessed the pattern of
blood flow in radiation injuries and cryolesions. To this end,
perfusion was determined in another group of animals using
14C-iodoantipyrine autoradiography.
MATERIALS AND METHODS
Animals
This study used 35 male Sprague–Dawley rats weighing 250–
400 g. All interventions were performed while the animals were
under inhalation anesthesia using isoflurane (2–3 vol%, Forene;
Abbott Laboratories). The experiments were approved by the local
veterinary authorities of the Kanton of Zurich, Switzerland.
Radiopharmaceuticals
4-Iodo-N-methyl-14C-antipyrine was obtained from American
Radiolabeled Chemicals, Inc. 18F-FDG was obtained from the
commercial 18F-FDG production of the University Hospital Zu-
rich. 18F-FET was produced using a method analogous to that of
Wester et al. (13). 18F-Fluoride (azeotropically dried with 0.7 mL
of acetonitrile) was reacted with 10 mg of ethylene glycol-1,2-
ditosylate in acetonitrile in the presence of Kryptofix(2.2.2)
(Merck) at 110° to give 18F-fluoroethyltosylate, which was purified
by reversed-phase high-performance liquid chromatography
(HPLC) (LiChrospher 100 RP-18 [Merck], 250  10 mm, MeOH/
H2O  60/40). The product fraction was trapped on a polystyrene
cartridge (LiChrolut EN; Merck), dried with nitrogen, and eluted
with 0.7 mL of dimethyl sulfoxide into a second vial containing 10
mg of L-tyrosine and 7.5 mg of potassium methylate, where it was
reacted for 5 min at 120°. The product was purified by reversed-
phase HPLC (LiChrospher 100 RP-18, 10 m, 250  10 mm,
EtOH/H2O/HAc  8/89.5/2.5, 2.5 g of ammonium acetate per
liter). The product peak was sterile filtered into a bottle containing
1 mL of saline and 0.1 mL of phosphate-buffered saline (0.6
mol/L, pH 4). Quality control was by reversed-phase HPLC over
LiChrospher 100 RP-18, 5 m, 250  4 mm, eluting with EtOH/
H2O/HAc  8/89.5/2.5, with 2.5 g of ammonium acetate per liter.
Radiochemical purity was 99%. In the ultraviolet trace, 18F-FET
was not visible and no quantifiable impurities were visible. Enan-
tiomeric purity was determined by chiral ligand exchange HPLC
over a Luna C18 column (250  4.6 mm, 5 m) coated with
L-penicillamine chiral selector, eluting with 30% methanol in 5
mmol of aqueous CuSO4 per liter. Starting from L-tyrosine as the
substrate, no D-(R)-O-18F-fluoroethyltyrosine was detected.
18F-FCH was produced by the reaction of 18F-fluoromethyltri-
flate with diaminoethanol. 18F-Fluoride (azeotropically dried with
2  0.7 mL of acetonitrile) was reacted with dibromomethane in
acetonitrile in the presence of Kryptofix(2.2.2) at 110° to give
18F-fluorobromomethane (29), which was purified over a series of
4 Sep-Pak Plus silica cartridges (Waters). 18F-Fluoromethyltriflate
was made by passing 18F-bromofluoromethane over a silver tri-
flate/Graphpac GC column (Alltech Associates Inc.) at 180°. 18F-
Fluoromethyltriflate was then used for the N-alkylation of 2-di-
methylaminoethanol immobilized on a Sep-Pak Plus C-18 cartridge (a
solution of 2-dimethylaminoethanol in ethanol [200 L in 600 L]
was put on the cartridge), to quantitatively yield the desired product.
For purification, 18F-FCH was selectively trapped on a Sep-Pak Accel
CM cartridge (Waters), washed with water, removed with saline, and,
via a sterile filter, added to a patient bottle with 4 mL of saline, 0.5 mL
of 10% NaCl, and 70 L of NaHCO3. Quality control was by HPLC
over a cation exchange column (30). Supelcosil LC-SCX (Supelco,
Inc.), 250  4.6 mm, 5 m, eluting with a 0.15 mol/L concentration
of NaH2PO4 in water/pyridine (1,000/0.08 v/v), was adjusted to pH
2.37 by 70% H3PO4. Radiochemical purity was 99%. In the ultra-
violet trace, 18F-FCH was not visible and no quantifiable impurities
were visible.
Proton Irradiation
The rats were irradiated with a thin, collimated proton beam of
3-mm diameter at the Facility for Ocular Tumor Treatment (31) of
the Paul Scherrer Institute. The energy of the protons was adapted
to the required penetration depth of the beams or to the Bragg peak
position. This position was evaluated using radiographs and CT
scans of rats that were of a size typical of the irradiated animals.
To ensure that the Bragg peak was at the same location for each
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animal, a special holder was constructed. This holder was placed
on the patient chair, which could be positioned with high precision.
A laser beam, which marked the proton beam, guided the position
of the irradiation point. The radiation was delivered as a single
dose of 250 (n  18) or 150 (n  5) Gy.
MRI
Weekly sequential MRI examinations after the radiation treat-
ment served for detection of radiation necrosis. MRI was per-
formed on a 1.5-T system (Signa CV/i; General Electric Medical
Systems). To maximize signal-to-noise ratio, animals were placed
with their heads centrally located in a dedicated wrist coil. This
coil was chosen because its design provides an optimal signal-to-
noise ratio in relation to the relatively small diameter of a rat’s
skull. The imaging protocol included the following sequences: an
unenhanced transaxial T1-weighted spin-echo sequence (repetition
time [TR]/echo time [TE], 300 ms/13 ms; slice thickness, 3 mm,
without an interslice gap) and a transaxial T2-weighted 3-dimen-
sional fast spin-echo sequence (TR/TE, 3,000/128; slice thickness,
1.5 mm). In addition, the T1-weighted sequence was acquired in
the transaxial plane after administration of gadopentetate dimeglu-
mine (Magnevist [Schering AG], 0.1 mmol/kg of body weight)
through a tail vein.
Cryolesions
Cryolesions (n  12) were used as a model of pure BBB
disruption without an inflammatory component. They were in-
duced according to the method described by Hermann et al.
(32,33). A liquid-nitrogen-cooled copper probe with a tip diameter
of 2.5 mm and a tip temperature of 150°C was placed stereotac-
tically through a burr hole onto the right parietal dura mater. Then,
the probe was lowered another 200 m to ensure contact with the
cortical tissue and was left for 2 min. 18F-FET and 18F-FCH
injections followed 30 min later.
Autoradiography with 18F-FET, 18F-FCH, and 18F-FDG
After detection of radiation injuries on MRI, autoradiography
was performed (12–20 d after irradiation in the 250-Gy group,
70–80 d in the 150-Gy group). Two hours before tracer injection,
Evans blue was injected into a tail vein. Catheters were then placed
in the right femoral artery to monitor blood pressure and in the
femoral vein to allow intravenous application of the tracers. Fif-
teen (18F-FCH and 18F-FET) or 45 (18F-FDG) minutes after injec-
tion of 150–200 MBq of tracer, the animals were sacrificed using
an overdose of pentobarbital. The brain was removed and instantly
frozen in cooled isopentane. For quantification, 10-m brain slices
(100-m slice distance) were placed on a phosphor imaging screen
together with 14C standards and left for 240 min. Tritium-sensitive
screens (TR2025; Fuji) were used, as their uncoated, thin, sensitive
layer yields higher-resolution 18F autoradiographs than do ordinary
screens. The data were scanned (BAS 1800 II [Fuji]; pixel size, 50
m) and converted to kBq/cm3. For this conversion, the 14C
standards had previously been recalibrated using data from a 4-h
exposure of 10-m slices of brain homogenate containing a de-
fined amount of 18F activity.
For quantitative analysis, the activities were then decay cor-
rected to the time of injection. Dividing these values by the amount
of injected activity per gram of body weight yielded standardized
uptake values (SUVs). Regions of interest were subsequently
placed over the areas with highest and average tracer uptake in the
lesions and over contralateral cortex.
4-Iodo-N-Methyl-14C-Antipyrine Autoradiography for
Evaluation of Perfusion
Two rats of each lesion model (n  4) were injected with
1.85–2.0 MBq of 14C-iodoantipyrine in 1 mL of saline and sacri-
ficed 1 min later. The brain was removed and instantly frozen in
chilled isopentane. Brain slices of 10-m thickness (100-m slice
distance), together with 14C standards, were placed on a phosphor-
imaging screen for 24 h.
Histologic Examination and Evans Blue Fluorescence
Imaging
Frozen sections 10 m thick were fixed with 4% formalin and
stained with hematoxylin–eosin for morphologic analysis. For
Evans blue visualization, slices were fixed with 4% formalin and
stained with 4,6-diamidino-2-phenylindole (Molecular Probes).
Images of the Evans blue distribution were then obtained using a
fluorescence microscope. To assess the grade of gliosis, the brain
slides were immunohistochemically stained with anti–glial fibril-
lary acidic protein (GFAP) (DAKO) and developed with the En-
Vision horseradish peroxidase rabbit system (DAKO).
Statistics
Differences in 18F-FCH and 18F-FET uptake in radiation injury
and cryolesions were assessed using the Student 2-tailed unpaired
t test.
RESULTS
Animals
In the 2 radiation groups, no animal experienced systemic
side effects. Only a small oblong area of alopecia on the
temporal skin corresponding to the beam line was discov-
ered during the time of observation.
Radiation Injury
Development of Radiation Injury. Intracerebral lesions
were detected on the MRI scans 12 and 70 d after irradiation
in the 250- and 150-Gy groups, respectively. The diameter
of the lesions ranged from 2 to 6 mm independent of the
radiation dose.
Typical examples of MRI scans are demonstrated in
Figure 1. The lesion was within the cortex of the right
FIGURE 1. Axial MRI scans of rat brain clearly depict radiation
lesion in frontoparietal right hemisphere. (A) T2-weighted 3-di-
mensional fast spin-echo sequence. (B) T1-weighted, gadolin-
ium-enhanced spin-echo scan indicating disruption of the BBB.
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frontoparietal region and extended into white matter. It
presented as a hyperintense parenchymal signal alteration
on the T2-weighted image. On the enhanced T1-weighted
image after intravenous administration of gadolinium-dieth-
ylenetriaminepentaacetic acid (Magnevist; Schering AG),
the entire lesion enhanced slightly, indicating leakage of the
BBB.
Histology and Disruption of BBB. Images of a typical
radiation injury are shown in Figure 2. Most lesions were
characterized by a center of colliquation necrosis (area 1)
consisting of cell debris, foamy macrophages, and some-
times calcifications. This center was surrounded by a layer
(area 2) consisting of macrophages, reactive astrocytosis
(evaluated by GFAP staining), dilated vessels, edema, and,
occasionally, small hemorrhages.
Extravasation of Evans blue, indicating BBB disruption,
was present in each case. In the example shown in Figure 2,
the largest amount of Evans blue accumulated in parts of the
necrotic center; smaller amounts were present in the sur-
rounding inflammatory layer (area 2). A similar pattern is
found in Figure 3B. In the 18F-FDG example (Fig. 3D), no
clear necrotic center was detectable. The small circum-
scribed area with increased Evans blue accumulation (area
4) did not correspond to the area with highest 18F-FDG
uptake (area 3 in Fig. 3C).
Perfusion Pattern in Radiation Injury. 14C-Iodoantipyrine
autoradiography (n  2) demonstrated reduced perfusion in
the necrotic center. In the inflammatory layer adjacent to the
necrotic center, where 18F-FCH, 18F-FET, and 18F-FDG
demonstrated increased uptake, perfusion was similar to
that in normal cortex.
Uptake of 18F-FET, 18F-FCH, and 18F-FDG. An autora-
diograph demonstrating 18F-FCH uptake is shown in Figure
2E. The highest degree of tracer accumulation was in the
inflammatory layer (area 2) surrounding the central necro-
sis. Examples of 18F-FET and 18F-FDG autoradiographs are
shown in Figure 3. 18F-FET accumulation (Fig. 3A) was
highest in the inflammatory layer (area 2). In the 18F-FDG
example (Fig. 3C), histologic examination revealed no clear
necrotic center. The area with the highest 18F-FDG uptake
(area 3) was histologically characterized by increased mac-
rophage density.
The SUVs of the various tracers are summarized in Table
1. 18F-FDG displayed by far the highest uptake in the
lesions. The SUVs for 18F-FCH and 18F-FET were similar
and considerably smaller than for 18F-FDG. The value of
L/B (ratio of uptake in lesion to that in contralateral cortex)
was highest for 18F-FCH, followed by 18F-FET and 18F-
FDG. This ratio to a high degree reflects the differing
amounts of tracer accumulation in healthy cortex: least for
18F-FCH, followed by 18F-FET and 18F-FDG.
Cryolesions
Histology and Disruption of BBB. Representative pho-
tomicrographs are shown in Figure 4. Cryolesions were
characterized mainly by edema. There were no inflamma-
tory cells or reactive astrocytes. Evans blue extravasation is
demonstrated in Figure 4A. BBB disruption was present in
the entire lesion.
FIGURE 2. Images of radiation injury. (A–D) Hematoxylin- and
eosin-stained histologic samples. The overview in panel A dem-
onstrates the necrotic center (area 1) and the surrounding in-
flammatory layer (area 2). Panels B–D zoom in on layer 2, which
is characterized by infiltration of macrophages and reactive
astrocytosis. Panel D corresponds to the area with highest
uptake of 18F-FCH (arrow in E). The dense infiltrate of macro-
phages is clearly visible. Panel E depicts uptake of 18F-FCH,
which is concentrated in the area adjacent to the central necro-
sis. (F) Corresponding Evans blue fluorescent scan demon-
strates disruption of the BBB.
FIGURE 3. Uptake of 18F-FET (A) and 18F-FDG (C), together
with the corresponding (B and D, respectively) Evans blue flu-
orescence scans.
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Perfusion in Cryolesions. An example of the perfusion
pattern as assessed with 14C-iodoantipyrine is shown in
Figure 4B. Perfusion in the lesion was reduced but not
absent.
Uptake of 18F-FET and 18F-FCH. Typical 18F-FCH and
18F-FET autoradiographs are shown in Figures 3C and 3D.
Accumulation of both tracers was homogeneously increased
in the cryolesion, compared with the adjacent and contralat-
eral normal brain tissue.
Table 2 summarizes the SUVs of 18F-FCH and 18F-FET.
In lesions, 18F-FET SUVs were on the order of 85% higher
than 18F-FCH SUVs. Compared with uptake in radiation
injury, 18F-FCH uptake was significantly lower in cryole-
sions (0.99  0.18 vs. 1.50  0.33, P  0.006). In contrast,
18F-FET accumulation was similar in both types of lesions
(1.85  0.34 vs. 1.63  0.34, P  0.14).
DISCUSSION
The main purpose of this study was to evaluate accumu-
lation of the investigated tracers in an acute model of
radiation injury so as to assess their ability to separate
radiation necrosis from tumor recurrence in humans with
brain tumors. All 3 investigated tracers have demonstrated
usefulness in the evaluation of brain tumors with PET.
18F-FET and 18F-FCH usually display increased uptake in
tumors relative to normal gray matter. Because 18F-FDG is
avidly taken up in normal gray matter, one commonly
relates tumor uptake to white matter. The ideal tracer to
separate tumor recurrence from radiation necrosis would
show high uptake in tumors and no uptake in radiation
necrosis. That ideal is clearly not met by any of the exam-
ined compounds. Three major components determine tracer
uptake in lesions. The first is blood flow, which is respon-
sible for tracer delivery. However, the normal or decreased
blood flow that is found in areas with increased 18F-FET or
18F-FCH uptake indicates that blood flow is of minor im-
portance. One can therefore concentrate on the other 2
factors: crossing of the BBB, which may be mediated by
some regulated process if the BBB is intact or by pure
leakage if the BBB has been disrupted, and accumulation in
cellular elements. Of note with regard to the latter, a major
histologic hallmark of tissue surrounding the necrotic center
in radiation injury is macrophage invasion. Previous studies
have shown that 18F-FET is not taken up by these cells but
is taken up by tissue outside the brain. One of these previous
studies addressed 18F-FET uptake in experimentally induced
abscesses in the rat thigh muscle (16), and the other inves-
tigated 18F-FET uptake in murine lymph nodes (17). Be-
TABLE 1
SUV in Animals with Induced Radiation Necrosis
Animal
no. Tracer
Radiation
dose (Gy) Nec1 Nec2 Ctx Nec1/Ctx Nec2/Ctx
1 18F-FCH 250 2.18 1.38 0.58 3.76 2.38
2 18F-FCH 250 2.62 1.43 0.54 4.85 2.65
3 18F-FCH 250 2.18 1.43 0.53 4.11 2.70
4 18F-FCH 250 2.11 1.12 0.54 3.91 2.07
5 18F-FCH 250 2.44 1.25 0.59 4.14 2.12
6 18F-FCH 150 3.22 1.99 0.60 5.37 3.32
7 18F-FCH 150 2.92 1.92 0.86 3.40 2.23
Mean 2.52 1.50 0.61 4.22 2.50
SD 0.42 0.33 0.12 0.67 0.44
8 18F-FET 250 1.25 0.90 0.73 1.71 1.23
9 18F-FET 250 2.13 1.29 1.20 1.78 1.08
10 18F-FET 250 2.64 1.39 1.56 1.69 0.89
11 18F-FET 250 2.52 1.82 1.70 1.48 1.07
12 18F-FET 250 2.40 1.80 1.27 1.89 1.42
13 18F-FET 250 2.44 1.92 1.08 2.26 1.78
14 18F-FET 150 1.77 1.52 1.57 1.13 0.97
15 18F-FET 150 1.98 1.69 1.54 1.29 1.10
Mean 2.27 1.63 1.42 1.64 1.19
SD 0.46 0.34 0.23 0.36 0.29
16 18F-FDG 250 4.82 3.66 4.29 1.12 0.85
17 18F-FDG 250 4.93 4.35 3.62 1.36 1.20
18 18F-FDG 250 6.59 4.48 4.38 1.50 1.02
19 18F-FDG 250 6.50 5.28 5.07 1.28 1.04
20 18F-FDG 250 6.39 3.93 4.24 1.51 0.93
21 18F-FDG 150 8.01 6.11 4.47 1.79 1.37
Mean 6.21 4.64 4.35 1.43 1.07
SD 1.19 0.91 0.47 0.23 0.19
Nec1  area of highest SUV in necrosis; Nec2  area of average SUV in necrosis; Ctx  contralateral cortex.
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cause 18F-FET is not taken up by macrophages, the in-
creased uptake in radiation injury is most likely due to
leakage of the BBB. This hypothesis was tested in the
cryolesions, which served as a model of severe BBB dis-
ruption without inflammatory cells. The finding that 18F-
FET SUV was similar in radiation injury and cryolesions
strongly supports the assumption that 18F-FET uptake in
acute radiation injury is indeed driven mainly by leakage
across the disturbed BBB. In this context, it is important to
note that blood flow in cryolesions was decreased (Fig. 4C).
Increased blood flow could have been another reason for the
observed increased 18F-FET uptake.
The situation is different for 18F-FCH, which displayed
significantly higher uptake in radiation injury than in cry-
olesions. This finding is consistent with the hypothesis that
18F-FCH uptake in radiation injury is determined by leakage
across the BBB and incorporation mainly in macrophages.
Because macrophages are missing from cryolesions, 18F-
FCH probably diffuses back from tissue into blood in cry-
olesions but is incorporated into macrophages in radiation
injury. That 18F-FCH is indeed incorporated mainly into
macrophages and not other cells is suggested by the finding
that the areas with highest 18F-FCH uptake coincided with
the areas of densest macrophage infiltration. Furthermore,
we already demonstrated in a previous study that 18F-FCH is
taken up by macrophages (28).
There remains the important question of the suitability of
the investigated tracers for differentiating radiation necrosis
from tumor tissue. We address this question by comparing
our data with published data on uptake of 18F-FET, 18F-
FCH, and 18F-FDG in brain tumors. However, a direct
comparison of our data with the literature is limited by
factors such as different acquisition protocols and modali-
ties and interspecies differences.
18F-FET
A direct comparison is possible of our 18F-FET data with
the tumor data of Langen et al., who inoculated F98 glioma
cells into the brains of 13 CDF Fisher rats and evaluated
18F-FET uptake by autoradiography. They reported a mean
L/B of 5.26  1.30 (34). This L/B is markedly higher than
the values for radiation injury (1.19  0.29, average areas)
found by our study.
Weber et al. investigated 18F-FET uptake in 16 patients
with various tumors and radiation necrosis (11). SUV in the
2 patients with radiation necrosis was 1.1 and 0.8, and L/B
was 1.2 and 1.1. These values are smaller than in our study.
FIGURE 4. Examples of cryolesions. Extravasation of Evans
blue, demonstrating disruption of the BBB, is already clearly
visible on native images (A). Perfusion in the lesion is decreased
relative to that in normal cortex but not absent, as is demon-
strated by autoradiography with 14C-iodoantipyrine (B). In con-
trast, 18F-FCH (C) and 18F-FET (D) uptake is increased in the
cryolesion. Hematoxylin–eosin staining (E and F) demonstrate
that edema characterizes the histology. There are no signs of
inflammatory infiltration.
TABLE 2
SUVs in Animals with Induced Cryolesions
18F-FCH 18F-FET
Animal
no. Lesion Ctx Lesion/Ctx
Animal
no. Lesion Ctx Lesion/Ctx
1 1.29 0.71 1.82 6 1.6 1.10 1.45
2 0.84 0.36 2.33 7 1.52 1.10 1.38
3 0.89 0.45 1.98 8 1.88 1.19 1.58
4 0.97 0.40 2.43 9 1.87 1.21 1.55
5 0.98 0.59 1.66 10 2.38 1.69 1.41
Mean 0.99 0.50 2.04 1.85 1.26 1.47
SD 0.18 0.15 0.33 0.34 0.25 0.09
Ctx  contralateral cortex.
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A possible reason is that radiation necrosis in the human
study was of a more chronic type. Furthermore, SUVs
measured with PET tend to underestimate the true values
because of the limited resolution of PET. In the 14 patients
with tumors, the L/B was 2.27  0.65. In other studies, this
value ranged from 2.0 to 3.3 (13–15,35,36). These values
are higher than those found by our study, but there is some
overlap. With regard to SUV, Weber et al. reported values
of 2.67 0.91 and 1.17 0.16 in tumor lesions and normal
cortex, respectively. Direct comparison of SUVs in humans
and rats is limited, since the magnitude of the SUV depends
on the distribution in all tissues that accumulate the tracer,
and this distribution may differ between species. In addi-
tion, PET SUVs tend to be too small. These factors may be
why SUVs in normal cortex were 18% smaller in the human
study of Weber et al. than in our animal study. Considering
all the available data, and especially the rat study by Langen
et al. (34), 18F-FET seems promising for separating radia-
tion necrosis from tumor tissue.
Radiolabeled Choline Analogs
For 18F-FCH, the comparison of our data with the liter-
ature is less conclusive, since no data are available on
18F-FCH uptake in a rat model of brain tumor. Shinoura et
al. measured 11C-choline uptake in C6 glioma cells im-
planted under the skin of rats. Tumor uptake was 3- to
4-fold higher than brain uptake (26). This is higher than the
L/B ratio of 2.50  0.44 found by our study. Although
Shinoura et al. used 11C-choline, the data should at least in
part be comparable, since Hara described similar uptake
characteristics for 11C-choline and 18F-labeled choline com-
pounds (9). Some data are available from human studies.
Degrado et al. also used 18F-FCH and reported an L/B of
10.0 in a single patient with recurrent anaplastic astrocy-
toma (27). Using another 18F-labeled choline analog, 18F-
fluoroethyl-dimethyl-2-hydroxyethylammonium, Hara et al.
found an L/B in the range of 12–21 for high-grade gliomas
(n  8) and 0–4.8 for grade II astrocytomas (n  2) (10).
Ohtani et al. investigated 11C-choline uptake in 20 patients
with different brain tumors and calculated tumor–to–white
matter ratios in the range of 0.98–29.10 (37). The above
studies indicate that 18F-FCH in the radiation injury of our
study is generally lower than in tumors. However, more
studies using 18F-FCH in tumors are needed to settle the
issue.
18F-FDG
In our study, accumulation of 18F-FDG in radiation injury
was generally on the same order as accumulation in normal
cortex (mean L/B  1.07  0.19, average regions). For
comparison, a rat study of Takeda et al. showed a maximum
14C-FDG L/B of approximately 1.2 in intracerebral C6
gliomas (38). This is in the same range as the 18F-FDG
uptake in our study and leads to the conclusion that 18F-
FDG is of questionable suitability for separating radiation
necrosis from tumor.
General Remarks
Some differences between our model and human studies
are important to mention. The dose and type of irradiation
(single dose, 150–250 Gy) used in our study differ from
those used on humans. In addition, our model represents
acute radiation injury. In humans, a more chronic phase of
radiation injury is seen, referred to in the clinical literature
as radiation necrosis. In radiation necrosis, the accumulation
of inflammatory cells and degree of BBB disruption is
probably less pronounced than in acute radiation injury.
Typical alterations include wall thickening, fibrinoid necro-
sis, hyalinization of the vessel walls, and extensive gliosis
adjacent to the necrotic focus (39). Therefore, uptake of all
investigated tracers in such lesions is likely to be smaller.
The low 18F-FET uptake found by Weber et al. (11) for 2
cases of human radiation necrosis points in this direction. A
lower uptake would increase the specificity for diagnosing
radiation necrosis, especially for 18F-FET and 18F-FCH.
However, more studies on 18F-FCH and 18F-FET uptake in
chronic radiation lesions are needed to settle this issue.
CONCLUSION
The presented data elucidate the mechanism of 18F-FET
and 18F-FCH uptake by acute radiation injuries and acute
cryolesions. 18F-FET uptake is determined mainly by dis-
ruption of the BBB, whereas 18F-FCH is additionally
trapped by inflammatory cells. Uptake of both tracers in
radiation injuries was generally lower than published uptake
values in tumors, suggesting that 18F-FET and 18F-FCH are
promising for separating radiation necrosis from tumor re-
currence. However, the comparability of our data with the
literature is limited by factors such as differences in species
and acquisition protocols and modalities. Thus, more stud-
ies are needed to settle this issue. Nevertheless, 18F-FCH
and 18F-FET seem superior to 18F-FDG for this purpose.
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Abstract. For each oncological tracer it is important to
know the uptake in non-tumorous lesions. The purpose
of this study was to measure the accumulation of fluo-
rine-18 choline (FCH), a promising agent for the evalua-
tion of certain tumour types, in infectious tissue. Unilat-
eral thigh muscle abscesses were induced in five rats by
intramuscular injection of 0.1 ml of a bacterial suspen-
sion (Staphylococcus aureus, 1.2×109 CFU/ml). In all
animals, FCH accumulation was measured with high-
resolution positron emission tomography (PET) on day
6. Autoradiography of the abscess and ipsilateral healthy
muscle was performed on day 7 (three animals) and day
11 (two animals) and correlated with histology. In addi-
tion, 18F-fluorodeoxyglucose (FDG) PET was performed
on day 5. Increased FCH uptake was noted in specific
layers of the abscess wall which contained an infiltrate
of mainly granulocytes on day 7 and mainly macro-
phages on day 11. The autoradiographic standardised up-
take values in the most active part of the abscess wall
were 2.99 on day 7 (n=3) and 4.05 on day 11 (n=2). In
healthy muscle the corresponding values were 0.99 and
0.64. The abscesses were clearly visualised on the FCH
and FDG PET images. In conclusion, this study demon-
strated avid FCH accumulation in inflammatory tissue,
which limits the specificity of FCH for tumour detection.
Future studies are now needed to determine the degree of
this limitation in human cancer patients.
Keywords: Soft tissue infection – 18F-choline – 18F-fluo-
rodeoxyglucose – Autoradiography – PET – Tumour im-
aging
Eur J Nucl Med Mol Imaging (2004) 31:312–316
DOI 10.1007/s00259-003-1337-4
Introduction
Whole-body positron emission tomography (PET) has
developed into an invaluable tool for the evaluation of
tumours. By far the largest number of examinations are
performed with fluorine-18 fluorodeoxyglucose (FDG).
However, FDG has several disadvantages. One is the re-
duced specificity for tumour cells due to FDG uptake in
inflammatory lesions. A promising candidate for higher
tumour specificity was 18F-ethyl tyrosine (FET), which
does not accumulate in inflammatory lesions [1] and
which had shown promising potential in the evaluation
of brain tumour patients [2]. Unfortunately, FET proved
to be less sensitive than FDG in whole-body imaging of
certain tumours [3]. Another substantial disadvantage of
FDG is the minimal or lacking uptake in certain tumours,
such as prostate carcinoma, the most common cancer in
elderly men. Promising results for staging patients with
prostate carcinoma have been reported with labelled cho-
line compounds. Some studies have used carbon-11 la-
belled choline [4, 5, 6], whose clinical usefulness is lim-
ited by the short half-life of 11C. This problem is over-
come by 18F-labelled choline (FCH), which has recently
been introduced and has also shown promising results in
the evaluation of patients with prostate cancer [7, 8, 9,
10]. For every tumour imaging compound it is important
to know the accumulation characteristics in non-tumor-
ous lesions, of which inflammatory/infectious foci are
among the most important. Thus, the purpose of this
study was to assess the FCH uptake in infected tissue. As
in our previous studies, we used a rat model with experi-
mentally induced abscesses in a leg muscle [1, 10]. FCH
accumulation was determined using high-resolution PET
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and autoradiography. In addition, FDG PET was per-
formed in each animal.
Materials and methods
Animals and abscess model. This study was performed according
to the guidelines of the National Institutes of Health and the rec-
ommendations of the committee on animal research at our institu-
tion. The protocol was approved by the local institutional review
committee on animal care.
The study included five Sprague-Dawley rats (weight 250–
300 g). All the animals were kept in cages with standardised con-
ditions of light and free access to water and food. Using general
inhalation anaesthesia (isoflurane, Forene, Abbott Laboratories), a
unilateral deep calf muscle abscess was induced by intra muscular
inoculation (25G needle) of 0.1 ml of a bacterial suspension (Sta-
phylococcus aureus, clinical strain 10B, Novartis Pharma, Inc.,
Switzerland). The bacterial concentration (1.2109 CFU/ml) was
measured by optical density (McFarland Standard, bioMerieux,
Inc., USA).
All animals developed a palpable fluctuating mass in the left
calf muscle within 36 h after bacterial inoculation. No systemic in-
fection occurred.
Positron emission tomography with FCH and FDG. Examination
were performed on a high-resolution PET system (16 Module
quad Hidac PET System). The resolution at the centre of the field
of view was 1.0 mm. FDG PET was performed 5 days after the in-
duction of the abscess. Twenty minutes of data were acquired in
list mode starting 40 min following the injection of 10–19 MBq
FDG into the tail vein. FCH PET was performed 1 day later. For-
ty-five minutes of data were acquired immediately following in-
jection of 8–20 MBq FCH into the tail vein. The list mode data
were then rebinned into nine frames of 5 min duration. Injection
and imaging with both tracers were done under isoflurane inhala-
tion anaesthesia. To quantify tracer uptake a 10-ml syringe filled
with an 18F solution of known concentration (0.5–1.5 MBq/ml)
was imaged immediately following the animal examination. The
raw data were reconstructed using the iterative one pass list-
mode–expectation maximisation (OPL-EM) algorithm (0.5 mm
bin size, 200×200×440 matrix size) incorporating resolution re-
covery. Volumes of interest (VOIs) were subsequently placed on
various tissue areas using the software PMOD [11]. The uptake
values were expressed in kBq/ml using the syringe calibration. Di-
viding the tissue uptake by the injected activity per gram of body
weight yielded the standardised uptake value (SUV).
Autoradiography with FCH. Autoradiography was performed 
7 days (three animals) and 11 days (two animals) following induc-
tion of the abscess. For injection of the radiotracer a catheter was
put into the right femoral vein under isoflurane anaesthesia. Ten
minutes following the injection of 100–200 MBq FCH, the ani-
mals were sacrificed by an intravenous overdose of pentobarbital.
Infected calf muscle and ipsilateral normal calf muscle were dis-
sected immediately and frozen in isopentane cooled to −50°C. The
frozen samples were cut (10 µm thickness) and thaw-mounted on
glass slides. The slides were then put on a phosphor imager screen
(Fuji TR 2025) for 4 h together with 14C standards for quantifica-
tion of tracer uptake. The data were scanned (Fuji BAS 1800 II,
pixel size 50 µm) and converted to kBq/mg. For histological ex-
amination the slices were stained using haematoxylin-eosin (H-E).
Quantitative analysis. In a previous calibration experiment, each
14C standard was assigned a value in kBq/ml of 18F activity. For
this purpose, 10-µm-thick slices of tissue homogenate that con-
tained defined amounts of 18F activity (kBq/mg) were exposed on
the phosphor imaging screen together with the 14C standard for
4 h. Using this calibration allowed conversion of the gray values
into absolute uptake values (kBq/ml) at the beginning of screen
exposure. To calculate standardised uptake values (SUVs) the in-
jected activity was also decay-corrected to the same time point.
The SUVs were then obtained by dividing the tissue uptake by the
injected activity per gram of body weight. Regions of interest
were subsequently placed on several tissue areas using the soft-
ware PMOD [11].
Histology. After the autoradiographic measurements with the
phosphor imaging system, the same slices were stained with H-E
for histological examination.
Results
Histomorphological correlation to FCH 
autoradiography
A typical autoradiograph of an abscess formation on day
7 is shown together with the histology in Fig. 1. The
acute abscess formation is histologically characterised
by central necrosis surrounded by a layer consisting
mostly of necrotic granulocytes. Adjacent to this layer is
a zone of granulation tissue with an active inner part and
a more mature outer part. The inner layer contains granu-
locytes, macrophages, myofibroblasts, blood capillaries
and bacteria. The outer part is composed of the same ele-
ments but contains fewer inflammatory cells (granulocy-
tes and macrophages) and more mature collagen. Super-
position of the histological and autoradiographic image
of the identical slice clearly demonstrated that the high-
est FCH concentration was in layer 3; no FCH at all was
noted in layer 2. On day 11, layer 2 was even more ne-
crotic and granulocytes were no longer present in layers
3 and 4.
The SUVs (mean) of layers 3 and 4 are summarised
in Table 1. In the three animals examined 7 days and the
Table 1. FCH SUV determined by autoradiography
Animal Daya Abscess wallb Muscle SUV
Inner Outer
1 7 2.96 2.13 0.85
2 7 2.94 2.02 0.95
3 7 3.07 2.12 1.16
4 11 4.02 2.82 0.61
5 11 4.07 2.95 0.67
a Day of autoradiography following induction of abscess
b Inner: layer 3 in Fig. 1; outer: layer 4 in Fig. 1
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two animals examined 11 days following induction of
the abscess, the mean SUV in layer 3 was 2.99 and 4.05
respectively. The corresponding values for layer 4 were
2.09 and 2.89 and for healthy muscle, 0.99 and 0.64.
FCH and FDG PET
The SUVs of tracer uptake determined with FCH and
FDG PET are demonstrated in Table 2. In animals 1 and
Fig. 1A–F. Histology of the abscess formation on day 7 (H-E stain-
ing, A), FCH autoradiography of the identical slice (B) and superpo-
sition of the two (C). The abscess wall (D) is characterised by a ne-
crotic centre (1), which is surrounded by a layer consisting mainly of
necrotic granulocytes (2; for higher magnification see E). Adjacent is
a zone with granulation tissue, which can be subdivided into a more
active inner (3, for higher magnification see F) and a more mature
outer part (4). The highest concentration of FCH is found in layer 3,
while layer 2 does not take up any FCH. Further details are reported
in the text. The bar represents 400 µm in D and 100 µm in E and F
Table 2. SUV of tracer uptake determined with PET
Animal FCH PET, day 6 FDG PET, day 5
Abscess Normal ipsilateral Muscle contralateral Abscess Normal ipsilateral Muscle contralateral
1 4.12 1.72 2.10
2 1.06 0.45 0.30 4.53 0.95 0.55
3 1.17 0.38 0.28 2.36 0.86 0.42
4 2.36 0.81 0.44
5 1.13 0.35 0.29 3.45 1.29 0.63
Mean 1.12 0.39 0.29 3.37 1.13 0.83
SD 0.06 0.05 0.01 0.99 0.38 0.72
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4, tracer uptake was sluggish owing to partial parave-
nous injection of FCH. SUV values were therefore not
calculated. In the other three animals the mean SUV in
the abscess wall was 2.8 and 3.9 times higher than in ip-
silateral and contralateral normal muscle respectively.
With FDG, the abscess wall accumulated three to four
times more tracer than normal muscle.
A slice of an FCH and an FDG PET scan are shown
in Fig. 2. The abscess wall is clearly delineated with
both tracers. With FCH the highest uptake is present in
the liver and kidney. The time course of FCH concentra-
tion is illustrated in Fig. 3. In the abscess wall and in
muscle tissue there was only minimal change between 
5 and 45 min following injection. In the liver a maxi-
mum SUV of 4.75 was reached after 15–20 min.
Discussion
The most important result of this study is the demonstra-
tion of avid FCH uptake in inflammatory lesions. Such
uptake will potentially limit the specificity of FCH in tu-
mour evaluations. In the abscess wall the autoradio-
graphically measured FCH SUV was 3 and 4 at days 7
and 11 respectively. This is somewhat lower than the
FDG SUV determined with the same methods in one of
our earlier experiments [12]. In that study the FDG SUV
in the abscess wall was 5 and 8 at days 5 and 9 respec-
tively. However, the important issue is how FCH SUV in
infectious lesions compares with FCH uptake in tu-
mours. In a study by Price et al. in patients with prostate
cancer, the FCH SUV was between 2 and 8 in the pros-
tate gland and between 3 and 8 in metastatic lymph
nodes and bone metastasis [10]. Zhang et al. assessed the
usefulness of 11C-choline in separating benign from ma-
lignant lesions in bone and soft tissue tumours in 43 pa-
tients [13]. The SUV was 4.9±2.1 and 2.5±1.7 in malig-
nant and benign lesions respectively. The data of both
studies demonstrate that the SUV in certain tumorous le-
sions is in the same range as the SUV in the infectious
tissue of our study (range 3–4).
Correlation of the FCH autoradiographs with the his-
tology clearly demonstrated that the highest FCH uptake
is found in the active granulation tissue (layer 3). The res-
olution of autoradiography does not allow identification of
which cell types within this area incorporate FCH. How-
ever, since the main difference between the inner and the
outer layer of the granulation tissue is the number of in-
flammatory cells, it seems likely that these cells accumu-
late a major part of the FCH. On day 11, FCH uptake in
layers 3 and 4 is even higher than on day 7, with granu-
locytes no longer present. This suggests that a major part
of the FCH is incorporated in macrophages at that stage,
pointing to an upregulation of choline kinase in these
cells, as has been demonstrated for tumour cells. Choline
is transported into cells by specific mechanisms and then
phosphorylated by choline kinase. In a further step it is
metabolised to phosphatidylcholine and incorporated into
the cell membrane. The increased choline uptake in tu-
mours is explained by upregulation of choline kinase.
It is interesting that the layer with the highest cell
density (layer 2) does not take up any FCH. This may be
because this layer contains only dead cells or because it
is not perfused, or a combination of the two. Another
question is to what degree the observed FCH uptake pat-
tern is determined by blood flow, which may vary in the
different layers of the abscess wall.
Fig. 2. FCH and FDG PET. Shown is a slice with a thickness and
pixel size of 0.5 mm. The abscess (arrows) is clearly visualised
with FCH (on the left) and FDG (on the right). With FCH the
highest uptake is in the liver and kidney
Fig. 3. Time course of the FCH concentration in different struc-
tures (mean of three animals)
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The abscesses were clearly delineated by FCH and
FDG PET. The contrast relative to surrounding tissue
seemed similar for both tracers. Comparison of the
SUVs determined with PET and autoradiography dem-
onstrated an underestimation of the FCH SUVs by PET.
This is most probably due to the limited spatial resolu-
tion of PET and the resultant underestimation of radio-
activity concentration in small structures. Another fac-
tor may be the lack of attenuation correction, which is
not implemented on the present system. Also the FDG
SUVs in the abscess wall at day 5 were somewhat 
lower than the autoradiographically determined values
in our previous study (3.3 vs 5 in the previous study
[12]).
In summary, FCH is avidly accumulated in inflamma-
tory infiltrates. This finding limits the specificity of la-
belled choline compounds for tumour detection. Future
studies are now required to determine the degree of this
limitation in human cancer patients. This includes the
evaluation of FCH uptake in different acute and chronic
inflammatory lesions.
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Many low-grade gliomas (World Health Organization grade II) re-
spond to chemotherapy. Cerebral blood flow (CBF) and micro-
vessel density may be critical for drug delivery. We used PET
with 18F-fluoro-ethyl-L-tyrosine (FET) to measure the spatial dis-
tribution of the amino acid carrier, which is located at the brain
capillaries, and 15O-H2O to measure tumor CBF.Methods: Sev-
enteen patients with low-grade glioma were studied. Region-of-
interest (ROI) analysis was used to quantify tumor tracer uptake,
whichwas normalized to cerebellar uptake (tumor-to-cerebellum
ratio). ‘‘Active’’ tumorwas defined as tumor having a radioactivity
concentration that was at least 110% of the cerebellar activity.
This threshold providedmeasures of active tumor volume, global
and peak tumor CBF, and 18F-FET uptake. Trace ROIs were ap-
plied to create voxelwise profiles of CBF and 18F-FET uptake
across tumor and brain. Standard MRI sequences were used
for spatial correlations. Results: Fourteen of 17 tumors showed
increased global CBF and 18F-FET uptake. Active tumor volumes
ranged between 3 and 270 cm3 for 18F-FET and between 1 and
41 cm3 for CBF. Global 18F-FET uptake in tumors corresponded
to CBF increases (Spearman rank r5 0.771, P, 0.01). The vol-
umes of increased CBF and 18F-FET uptake spatially coincided
and were also correlated (r 5 0.944, P , 0.01). Trace ROIs
showed that irrespective of increased 18F-FET uptake at the tu-
mor periphery, CBF increases were more confined to the tumor
center. Within individual tumors, spatial heterogeneity was pres-
ent. Particular tumors infiltrating the corpus callosum showed
low CBF and 18F-FET uptake in this tumor region. The patterns
observed with PET were not reflected on MRI of the tumors, all
of which presented as homogeneous non–gadolinium-enhancing
lesions. Conclusion: Low-grade gliomas are heterogeneous tu-
mors with regard to the distribution of amino acid uptake and
CBF. Both are coupled in the tumor center. At the tumor periph-
ery, where tumor infiltration of surrounding brain occurs, CBF
maybe low irrespective of increased 18F-FET uptake. An ongoing
study is investigating the effect of chemotherapy on these obser-
vations.
Key Words: low-grade glioma; fluoro-ethyl-L-tyrosine; blood
flow; positron emission tomography
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Most low-grade gliomas affect adults in their third to
fifth decades of life. According to the classification of the
World Health Organization (WHO), low-grade gliomas
(WHO grade II) comprise diffuse astrocytoma, oligoden-
droglioma, and oligoastrocytoma (1). Although the tumors
are considered slowly progressing, an annual increase in
tumor size of 4.1 mm has been estimated (2). Surgery is the
standard treatment at the time of first presentation. Subse-
quent radiotherapy remains controversial (3,4). Low-grade
gliomas have long been regarded as resistant to chemo-
therapy; however, several studies published over the last few
years showed remarkable responses to regimens such as pro-
carbazine, N-(2-chloroethyl)-N9-cyclo-hexyl-N-nitrosourea,
and vincristine or to the alkylating agent temozolomide
(5,6). There is evidence that loss of heterozygosity on
chromosomes 1p and 19q might be predictive of chemo-
therapy response, but large, prospective randomized studies
on this issue are lacking (6). On the other hand, the ef-
fectiveness of chemotherapy depends on adequate delivery
of drugs to tumor cells, and this delivery is a function of
drug concentration in the blood, blood flow through tumor
microvasculature, and the flux of drugs across tumor
capillaries. Our study aimed at the in vivo characterization
with PET of microvessel distribution and of cerebral blood
flow (CBF) in low-grade gliomas. We used 15O-H2O as a
standard tracer for CBF measurement. To investigate micro-
vessel distribution, we used 18F-fluoro-ethyl-L-tyrosine (FET)
as a tracer for amino acid transport (7). Several PET studies
on human brain tumors showed that the uptake of radiola-
beled amino acids is governed by increased influx across the
blood–brain barrier (8–10). Experimental studies revealed
that this influx is mediated by active transendothelial amino
acid transport (11,12). Accordingly, the signal measured with
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18F-FET PET in tumors reflects the magnitude of amino acid
transport and its distribution over tumors.
MATERIALS AND METHODS
Patients
We enrolled 17 patients with either progressive or recurrent
supratentorial WHO grade II gliomas. At the time of the first
surgery (2–127 mo before the PET study), all tumors were
histologically verified WHO grade II gliomas and included 5
fibrillary astrocytomas, 7 oligoastrocytomas, and 5 oligodendro-
gliomas. Recurrence or progression was defined clinically and on
MRI and occurred at a mean of 30 mo (range, 2–127 mo; Table 1)
after the first tumor surgery. We included only patients who, at the
time of our PET study, did not show any gadolinium enhancement
on MRI, because this finding may indicate the presence of a more
malignant glioma (WHO grade III or IV). The clinical details are
presented in Table 1. PET studies were performed within 2 wk of
the MRI studies. Written informed consent was obtained from all
patients. The study protocol was approved by the local ethics
committee.
Image Acquisition and Processing
MRI included standard procedures on a 1.5-T Siemens Magne-
tom. We obtained digitized pre- and postgadolinium T1- and T2-
weighted, proton-density, and fluid-attenuated inversion recovery
(FLAIR) sequences (slice thickness, 4.8 mm). Following the
methods of recent studies on low-grade gliomas, we used the FLAIR
sequences to calculate the tumor volume, because these sequences
best delineate between the lesion and adjacent brain (6,13).
PET studies were performed on a whole-body PET/CT scanner
(Discovery LS; GE Healthcare) and were acquired in 3-dimensional
mode with a 14.6-cm axial field of view and a reconstructed in-
plane resolution of 7 mm (voxel size, 0.018 cm3; slice thickness,
4.25 mm). Immediately before the CBF PET study, a low-dose
CT scan for attenuation correction was obtained. For the CBF
studies, 600–800 MBq of 15O-H2O were administered using an
automatic injection device that delivers the bolus over 20 s. After
arrival of the bolus in the brain, acquisition of a series of eighteen
10-s frames was initiated. The 15O-H2O PET images were trans-
formed according to a previously described approach yielding
absolute CBF values without arterial blood sampling (14). 18F-
FET studies were performed subsequent to the CBF studies within
the same session. 18F-FET was produced according to the method
of Wester et al. (15). For the 18F-FET studies, 140–250 MBq were
injected intravenously and tracer accumulation was recorded over
60 min as a series of twelve 5-min frames. To avoid movement
of the head during the acquisition, the head was slightly fixed,
and PET images were visually assessed for movement artifacts.
Attenuation-corrected PET images were reconstructed with stan-
dard Fourier rebinning backprojection, including standard cali-
bration factors to receive kBq/mL of tissue and corrections for
randoms, scatters, geometry, decay, and dead time. As in other
reports (16), our patients showed a plateau phase with a relatively
stable tissue radioactivity concentration later than 40 min after
intravenous tracer injection. Therefore, our 18F-FET PET data
were analyzed on averaged activity images acquired 50–60 min
after tracer injection. Dividing these activities by the amount of
injected activity per kilogram of body weight yielded standardized
uptake values.
Data Analysis
PET data were analyzed with PMOD (17). As a standard pro-
cedure in nuclear medicine, tumor uptake values can be normal-
ized to the contralateral normal brain, allowing easy data analysis
TABLE 1
Patients Ranked by WHO Grade II Histologic Subgroups According to Global 18F-FET T/Cb Ratio
Patient
no.
Age
(y) Sex Histology*
Resection
typey Location
Intervalz
(mo)
Lesion volume (cm3) Global T/Cb
ratio
Peak T/Cb
ratioMRI
FLAIR
Active
18F-FET
Active
CBF 18F-FET CBF 18F-FET CBF
1 39 M FIAC b Temporal, R 19 34 — — 0.77 0.77 — —
2 49 F FIAC p Frontoparietal, L 127 46 29 12 1.24 1.25 1.39 1.45
3 46 F FIAC p Temporooccipital, R 9 40 6 1 1.24 1.21 1.40 —
4 51 F FIAC p Frontotemporal, L 79 88 65 9 1.24 1.39 1.38 1.69
5 34 M FIAC p Temporal, L 27 44 6 1 1.25 1.19 1.39 —
6 55 M OA b Temporal, R 12 56 — — 0.70 0.59 — —
7 56 M OA gt Frontal, R 81 91 3 1 1.21 1.31 1.24 —
8 31 F OA p Frontal, L 40 14 11 5 1.32 1.34 1.58 1.61
9 27 M OA p Temporal, L 6 23 18 1 1.42 1.25 1.78 —
10 39 M OA b Temporal, L 9 79 64 16 1.44 1.33 1.93 1.59
11 42 M OA p Frontotemporal, R 50 44 23 10 1.50 1.51 2.18 1.96
12 28 M OA b Parietal, L 5 90 79 28 1.59 1.49 2.17 1.93
13 50 F OD p Frontal, L 26 23 — — 0.61 0.45 — —
14 54 F OD b Temporal, L 2 42 6 1 1.28 1.23 1.46 —
15 37 M OD b Frontal, L, R 13 140 270 41 1.33 1.25 1.62 1.41
16 45 F OD b Frontal, L 2 25 27 3 1.40 1.20 1.75 —
17 34 M OD b Temporal, L 6 23 28 9 1.65 1.35 2.25 1.76
*FIAC 5 fibrillary astrocytoma; OA 5 oligoastrocytoma; OD 5 oligodendroglioma.
yb 5 biopsy; p 5 partial; gt 5 gross total resection.
zBetween surgery and PET.
— 5 no active tumor volume (in those patients, ROIs for calculation of global uptake ratio were drawn from MRI FLAIR images).
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and reliable interindividual comparisons. However, normalization
to contralateral brain depends on the location of the tumor in the
brain and may thus infer substantial variation, particularly as 2
tumors in our series crossed the midline. We therefore chose the
cerebellum as the reference region because it is a large and
homogeneous structure and was distant from the tumor. Regions
of interest (ROIs) were first placed over both sides of the cer-
ebellum on 3 subsequent slides. The mean activity of all cerebellar
ROIs was used to set the threshold for normalization of tumor
tracer uptake (tumor-to-cerebellum [T/Cb] ratio). This thresh-
olding procedure has recently been proposed to provide an
observer-independent evaluation, which is particularly important
for follow-up PET studies during tumor treatment (18). In a first
step, we used thresholds between 100% and 120% of cerebellar
activity. Increasing the threshold produced moderate decreases of
active tumor volumes and small increases of T/Cb ratios. We
finally chose a threshold that gave a volume of active voxels close
to what was the ‘‘visibly increased’’ 18F-FET uptake. For our low-
grade gliomas, we found this threshold to be 110%. This threshold
was also applied for the quantification of CBF. Accordingly, tumor
ROIs were placed covering all voxels with activity values above
110% of the mean activity in the cerebellum, thus yielding the
active tumor volume for CBF and 18F-FET uptake. The activity in
these tumor ROIs was then used for the calculation of global T/Cb
ratios (all active voxels) and peak T/Cb ratios (all voxels that were
75% or more of the maximum radioactivity in the tumor ROI). In
tumors with inactive tumor volumes (below 110% of the mean
activity in the cerebellum), digitized MRI FLAIR images were
coregistered with the PET studies to define the placement of tumor
ROIs according to the FLAIR lesion volume.
To more precisely investigate the spatial relationship between
18F-FET uptake and CBF, we placed linear trace ROIs that
spanned from normal cortex through white matter and tumor
and created CBF and 18F-FET profiles across the brain (Fig. 1,
yellow line). First, trace ROIs were placed on the 3 adjacent
planes that showed the highest tumor tracer uptake. For each of
these planes, 3 adjacent parallel trace ROIs were created per plane
in the 18F-FET study and were then also used at the same position
for the coregistered CBF studies. Depending on the individual
tumor location, a single trace ROI consisted of up to 64 voxels
(voxel size, 0.018 cm3). At this step, 9 single 18F-FET and CBF
profiles per patient were available. Second, the activity of the
spatially corresponding voxels derived from these 9 profiles was
averaged and yielded a mean trace ROI profile for 18F-FET and
CBF activity for each patient. Then, the mean activity for each
voxel was normalized to the cerebellum. Accordingly, the data
points of these profiles represent voxel averages of T/Cb ratios for
CBF and 18F-FET uptake (y-axis) and the distance (mm) across
the brain (x-axis).
Statistics
The Spearman rank test was used to search for correlations
between the active tumor volumes of CBF and 18F-FET uptake,
between tumor uptake of 18F-FET and tumor CBF, and between
these measures and the MRI FLAIR lesion.
RESULTS
The results are summarized in Table 1. Relative to normal
brain, we found increased 18F-FET uptake and CBF in 14 of
17 tumors. 18F-FET uptake and CBF were not homoge-
neously increased across these tumors but rather showed a
variable distribution. The peaks of CBF and 18F-FET uptake
were spatially colocalized. In 3 tumors, both 18F-FET uptake
and CBF were decreased relative to normal brain. The
heterogeneity of 18F-FET uptake and CBF within individual
FIGURE 1. Heterogeneity of 18F-FET
uptake and CBF in 3 low-grade gliomas.
Corresponding axial slices are pre-
sented. Color scale represents T/Cb ratio
of 18F-FET and CBF. (A) Oligoastrocytoma
shows markedly increased 18F-FET up-
take and CBF in right frontoinsular region
(patient 11 in Table 1). 18F-FET and CBF
peak uptake regions coincide; however,
active volume of CBF is smaller than
active 18F-FET volume. (B) Reduced
18F-FET uptake and CBF in fibrillary
astrocytoma (patient 1). (C) Oligoastrocy-
toma (patient 12). Anterior tumor part
involves corpus callosum and shows
substantially reduced CBF and 18F-FET
uptake when compared with posterior
tumor part. This heterogeneity is not
evident from any MRI sequences. Yellow
line through posterior part of brain and
tumor illustrates positioning of trace ROI
(Fig. 4).
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tumors and within our group of low-grade gliomas is illus-
trated in Figure 1.
Tumor tracer uptake was quantified by normalizing the
tumor radioactivity concentration to the activity of the
cerebellum (uptake ratio). Cerebellar 18F-FET uptake and
CBF were calculated as the mean value of both cerebellar
hemispheres. Asymmetry between the hemispheres (‘‘crossed
cerebellar diaschisis’’) was less than 5% for 18F-FETand less
than 9% for CBF. For the cerebellum, the 18F-FET standard-
ized uptake value was 1.22 6 0.32 (mean 6 SD). The
cerebellar CBF was 36.46 8.6 mL/min/100 mL. At a 110%
cutoff of cerebellar tracer uptake, tumor uptake ratios varied
between 0.61 and 1.65 for global 18F-FET uptake and
between 1.24 and 2.25 for peak 18F-FET uptake. For CBF,
these values ranged from 0.45 to 1.50 for the global ratio and
from 1.41 to 1.96 for the peak ratio. At lower 18F-FET uptake
ratios (global), smaller variations in CBF ratios were ob-
served, whereas for higher 18F-FET uptake ratios (peak), the
variation in CBF ratios increased (Fig. 2). Uptake ratios
tended to be higher in oligodendroglial tumors than in
fibrillary astrocytoma. No correlation between MRI lesion
volume and tracer uptake was observed (18F-FET: Spearman
rank r5 0.023, P5 0.931; CBF: Spearman rank r5 0.262,
P 5 0.309) (Table 1). Over the whole study population,
18F-FET uptake and CBF correlated (Fig. 2): For global
uptake ratios, the Spearman rank correlations were r 5
0.771, P , 0.01 (n 5 17). Because of the small number of
pairs, the correlation of peak uptake ratios did not reach
statistical significance (r 5 0.571, P 5 0.139).
In most tumors, the volume of increased 18F-FET uptake
was smaller than the corresponding tumor volume on MRI
FLAIR images. Active tumor volumes of 18F-FET and CBF
were colocalized within 1 tumor (Fig. 1); however, the CBF
volume was always smaller than the 18F-FET uptake vol-
ume. The active tumor volumes ranged from 3 to 270 cm3
for 18F-FET and from 1 to 41 cm3 for CBF. The correlation
between active global tumor volumes is presented in Figure
3 (Spearman rank r 5 0.944, P , 0.01). To address this
spatial relationship between intratumoral tracer uptake, we
created CBF and 18F-FET profiles across tumor and brain.
The positioning of trace ROIs is illustrated for a single
patient (patient 12) in Figure 1. The resulting profile of 18F-
FET and CBF distribution is exemplified in Figure 4. The
presented pattern was observed in all 14 tumors with
increased 18F-FET uptake and CBF—that is, the peak
coincidence of 18F-FET uptake and CBF. Reflective of
our active volume data, the area under the curve in the trace
ROIs was smaller for the tumor CBF than for the tumor
18F-FET uptake profiles. Along the profiles, the mean
distance between increase of intratumoral 18F-FET uptake
and CBF was 6.3 mm (range, 2.2–13.6 mm). At the position
where the CBF ratio in tumors started to exceed 1.0, the
mean 18F-FET ratio was 1.51 (1.01–2.24).
DISCUSSION
Our study demonstrated a substantial heterogeneity in
CBF and 18F-FET uptake over the whole series of low-
grade gliomas that, on MRI, appeared as homogeneous
FIGURE 2. Distribution of global (s) and peak (n) 18F-FET
uptake and CBF. Values represent T/Cb ratios.
FIGURE 3. Correlation of global active tumor volumes of 18F-
FET and CBF (Spearman rank r 5 0.944, P , 0.01). Significant
correlation is maintained if outlier is excluded from analysis (r 5
0.885, P , 0.01).
FIGURE 4. Trace ROI analysis in a single patient (patient 12).
Pixelwise profiles of 18F-FET uptake (n) and CBF ()) span from
normal cortex over white matter and tumor. Vertical dashed
lines represent tumor borders on MRI (patient 12; Fig. 1C).
Increases of tumor CBF (T/Cb ratio . 1.0) are more confined to
tumor center. T/Cb ratio increases in this patient at a ratio of
approximately 2.1 of 18F-FET uptake.
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non–gadolinium-enhancing lesions. In many patients, we
also observed intratumoral heterogeneity on the PET stud-
ies, possibly indicating that subregions of tumors could
behave differentially with respect to tumor evolution and
treatment response. Knowledge of the individual tumor
vasculature is of particular interest with regard to angio-
genetic tumor potential and targeted treatment. The total
intravascular volume, which comprises all sizes of tumor
vessels, can be used as an in vivo marker of angiogenesis
and can be studied by following the changes in the MRI
signal after administration of gadolinium (19,20). If the
point of interest is the distribution of the capillaries them-
selves, where solutes and drugs are exchanged, markers
should exclusively trace mechanisms located at that ana-
tomic level. Such is the case for radiolabeled amino acids
that bind to and are transported by the amino acid carriers
located in the endothelial cells of the blood–brain barrier
(21). In brain tumors of various WHO grades, uptake of
11C-methyl-L-methionine correlates with the microvascular
density (MVD) as validated by immunohistochemistry (22).
18F-FET is a nonmetabolized tyrosine analog and behaves
similarly to methionine (16). 18F-FET was evaluated for the
clinical investigation of gliomas (7,16). We found an 18F-
FET uptake ratio of between 0.61 and 1.65 for the whole
tumor and peak values of between 1.24 and 2.25. These
ratios are in the range of the data presented by Kracht et al.
(22). Taking these findings together, our results provide
evidence that 18F-FET, like methionine, is a surrogate
marker of MVD. To validate this assumption, we initiated a
study on 18F-FET PET–guided biopsies and determination
of MVD in patients with low-grade gliomas.
In our series, 3 of 17 tumors showed neither increased
tyrosine uptake nor increased CBF. In addition, tumor areas
contacting or infiltrating the corpus callosum exhibited
normal or reduced CBF and 18F-FET uptake, whereas in
the same tumor, distant cortical or subcortical areas showed
increases of these measures (Fig. 1). Our finding of reduced
18F-FET uptake in some tumors would be in line with
immunohistochemical results on microvessel counts in as-
trocytomas. In particular, low-grade astrocytomas may show
MVDs below the level of normal cortex or white matter (23).
Studies have shown that microvessels in these tumors are
native cerebral vessels co-opted by tumor cells and that the
formation of new vessels (‘‘neo-angiogenesis’’) and higher
vessel densities occur in more malignant tumors (23,24).
Earlier studies on CBF in gliomas reported a similar range
for tumors (7–102 mL/100 mL/min) and for normal white
matter and cortex (15–59 mL/100 mL/min) (25–27). The
magnitude of CBF in these studies did not discriminate
between glioma types or WHO grade. Across our series,
tumor CBF and 18F-FET uptake correlated (Fig. 2). Our data
therefore suggest a coupling between blood flow and micro-
vascular distribution in low-grade gliomas. This coupling is
different from known perfusion patterns in more malignant
gliomas (WHO grades III and IV), in which, irrespective of
the high vascularity, low CBF is considered to be responsible
for the formation of hypoxia (28). In addition, we found a
significant correlation between active 18F-FET and perfused
tumor volumes (Fig. 3). 18F-FETand CBF volumes showed a
close spatial coincidence and were independent of lesion size
on MRI (Fig. 1). Interestingly, the active CBF volumes were
smaller than the corresponding 18F-FET volumes (Table 1),
as is explained by the characteristic intratumoral rises in 18F-
FET uptake and CBF as presented in the trace ROI analysis
(Fig. 4). Our data revealed that CBF increases occurred when
uptake of 18F-FET exceeded a certain level (mean ratio,
1.50). Assuming that 18F-FET uptake is related to MVD, our
results can be transferred into absolute numbers of tumor
MVD by comparison with the data presented by Kracht et al.
(22). They reported global 11C-methyl-L-methionine uptake
ratios of 1.30 6 0.20 for astrocytic tumors and 2.30 6 0.35
for oligodendroglial tumors (WHO grade II)—values that are
similar to our 18F-FET uptake values (Table 1). Correlating
11C-methyl-L-methionine uptake and histopathologically
proven MVD, an amino acid uptake ratio of 1.50 equals 10
microvessels/0.763 mm2 (22). If we extrapolate a median
18F-FET uptake ratio of 1.50 as calculated from our trace
ROIs, an approximate MVD of 13 microvessels/mm2 would
result. At this level, CBF starts to increase above the level in
normal brain. In view of that fact, we assume that CBF
increases follow the formation of new microvessels and
therefore represent a subsequent phenomenon.
Intratumoral heterogeneity of tumor CBF and amino acid
uptake has been reported in several animal studies. In
opposition to our findings, CBF progressively increased from
the tumor center to the tumor periphery and to brain
surrounding the tumor (29). A corresponding increase in
MVD was reported for large tumors of the same tumor model
(tumor center, 245/mm2, vs. surrounding brain, 689/mm2)
(30). With regard to a cortical or subcortical tumor location,
variable amino acid uptake values were found in more
‘‘malignant’’ tumor models (11). In humans, intratumoral
variations have not been recognized so far. Overall, we
detected in our study no differences in 18F-FET uptake or
CBF with regard to cortical or subcortical tumor location.
However, we noted intratumoral heterogeneity, particularly
in tumor regions infiltrating the corpus callosum. Low CBF
and capillary density may initiate the development of a
mismatch between metabolic demand and energy supply and
may promote hypoxia, possibly making these tumors prone to
behaving more aggressively than tumors with the same histo-
pathologic features located outside the corpus callosum (31).
CONCLUSION
Taking our observations together, we found that tumor
CBF and amino acid uptake varied substantially in non-
enhancing WHO grade II gliomas. This variation was evi-
dent within the whole group of tumors and within individual
tumors and did not depend on lesion size on MRI. All
patients were studied at the time of clinical or radiologic
progression, making tumor therapy necessary after initial
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surgery and observation. Because MVD constitutes a sig-
nificant independent prognostic factor (32,33), it is tempt-
ing to validate whether 18F-FET PET provides a robust
means for the in vivo measurement of MVD. Our results in
this study led us to initiate a prospective PET study that will
address the effect of chemotherapy on regional tumor blood
flow and amino acid uptake, with particular emphasis on
the tumor-to-brain border zone, because this is the area
most critical to tumor cell infiltration of the surrounding
brain and to tumor progression and the prognosis of pa-
tients with low-grade gliomas.
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Abstract Amino acid transport and protein synthesis are
important steps of tumor growth. We investigated the time
course of tumor metabolism in low-grade gliomas (LGG)
during temozolomide chemotherapy, and compared meta-
bolic responses as measured with positron emission
tomography (PET) with volume responses as revealed by
magnetic resonance imaging (MR). A homogeneous pop-
ulation of 11 patients with progressive non-enhancing LGG
was prospectively studied. Imaging was done at 6-months
intervals starting six months, and in a second series starting
three months after treatment initiation. F-18 fluoro-ethyl-L-
tyrosine (FET) uptake was quantified with PET as meta-
bolically active tumor volume, and was compared with the
tumor volume on MR. Response was defined as C10%
reduction of the initial tumor volume. Eight patients
showed metabolic responses. Already 3 months after start
of chemotherapy the active FET volumes decreased in 2
patients to a mean of 44% from baseline. First MR volume
responses were noted at 6 months. Responders showed a
volume reduction to 31 ± 23% (mean ± SD) from base-
line for FET, and to 73 ± 26% for MR. The time to
maximal volume reduction was 8.0 ± 4.4 months for FET,
and 15.0 ± 3.0 months for MR. The initial metabolic
response correlated with the best volume response on MR
(Spearman Rank P = 0.011). Deactivation of amino acid
transport represents an early indicator of chemotherapy
response in LGG. Response assessment based on MR only
has to be reconsidered. The time window obtained from
PET may assist for individual treatment decisions in LGG
patients.
Keywords Low-grade glioma  Chemotherapy 
Temozolomide  Positron emission tomography 
Tyrosine
Introduction
Chemotherapy represents a treatment option in low-grade
glioma patients (LGG) [1]. This may be particularly
important if tumors are not amenable to gross resection or
irradiation. Several retrospective studies have shown that
chemotherapy (either temozolomide or PCV regimen) was
active in LGG. Using magnetic resonance (MR) imaging
chemotherapy yielded response rates up to 61% [2–6]
which were mainly determined by Macdonald’s criteria [7],
although these criteria are not validated for LGG. The
median time to reach a morphological response in the
largest series was 12 months [4]. As many LGG grow very
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slowly the inhibition of tumor metabolism may be detected
earlier than structural volume changes. Early identification
of treatment response by molecular imaging may be
promising. Positron emission tomography (PET) allows to
quantitatively measure several biochemical and physio-
logical alterations in brain tumors. Increased amino acid
transport and protein synthesis represent essential and early
steps of tumor growth [8]. In our present study we used
PET with the radiolabeled amino acid analogue tyrosine
(F-18 fluoro-ethyl-L-tyrosine, FET) to characterize meta-
bolic responses in LGG patients treated with the alkylating
agent temozolomide (TMZ).
Methods
Patients
A homogeneous population of 11 patients (median age
34 years, range 23–49 years, 3 female and 8 male) with
progressive supratentorial LGG WHO II consented to
participate in our study (3 oligodendrogliomas, 4 fibrillary
astrocytomas and 4 oligoastrocytomas [9]). Progression
was defined on MR as an increase in tumor size of [25%
and/or clinical deterioration (according to the EORTC
study protocol on low-grade gliomas, 22033-26033 [10]),
and occurred at a median of 27 months after the first tumor
surgery (range 2–127 months). No patient had received
previous radio- or chemotherapy. We included only
patients which did not show any gadolinium enhancement
on MR as the latter may be suggestive for transformation to
malignant glioma. The clinical data are presented in
Table 1. Patients received 75 mg/m2 TMZ per day over
3 weeks, followed by one week off (21q/28d = one cycle,
according to EORTC protocol 22033-26033 [10]). Patients
were scheduled to receive 12 cycles of chemotherapy.
TMZ chemotherapy was discontinued at the time of tumor
progression or due to inacceptable side effects. Following
the baseline scans the imaging protocol consisted of PET
and MR scans at six-month intervals, starting after six
cycles of chemotherapy in group A (n = 8). Due to the
magnitude of PET responses observed at six months in
group A the first follow-up scans in three subsequent
patients (group B, Table 1) started after three cycles of
chemotherapy. Further follow-up scans in group B patients
were scheduled 9 and 15 months after initiation of treat-
ment. Based on the clinical judgement several patients
received more than 12 cycles (up to 24). The study protocol
was approved by the local Ethical Committee. Written
consent was obtained from all patients.
Imaging
MR imaging included standard sequences on a 1.5 Tesla
Siemens Magnetom. Amino acid imaging with PET was
done with F-18-fluoro-ethyl-L-tyrosine (FET). 3D PET data
were acquired with a whole-body PET/CT Scanner (Dis-
covery LS, GE Medical Systems, Waukesha, WI, USA,
Table 1 Clinical and imaging data
#(group) Histologya,
resection typeb
Gender Age
(years)
Baseline tumor
volume (ccm)
Baseline
T:CBL ratioc
Response
typed
Best volume response
(% from baseline)
Time to best volume
response (months)
MRe FETf FET MR FET MR FET
1 (B) FIAC, pr f 49 46 29 1.24 R 96 49 – 3
2 (A) FIAC, pr m 23 52 52 1.52 R 91 6 – 12
3 (A) OA, b m 28 90 78 1.57 R 65 15 12 12
4 (A) OA, pr f 28 14 11 1.32 R 65 8 18 6
5 (B) OA, pr m 27 23 18 1.45 R 90 38 15 3
6 (A) OD, b m 34 23 29 1.64 R 39 40 12 12
7 (A) OD, pr f 45 25 27 1.40 R 33 18 18 12
8 (A) OD, pr m 36 284 273 1.33 R 102 71 – 6
9 (B) FIAC, pr m 32 44 6 1.25 NR 109 121 – –
10 (A) FIAC, b m 38 66 0 1.10 NR 99 100 – –
11 (A) OA, B m 39 79 69 1.43 NR 99 93 – –
a Histology: FIAC fibrillary astrocytoma, OA oligoastrocytoma, OD oligodendroglioma
b Resection type: b biopsy, pr partial resection
c T:CBL ratio = uptake of the active tumor volume normalized to the mean uptake of the crebellum
d Response type according to FET PET follow up results (see Methods): R responding patients, NR non-responding patients
e MR = FLAIR sequence
f FET = active tumor volume of amino acid uptake
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14.6 cm axial field of view, in-plane resolution 7 mm).
FET was intravenously administered as bolus injection of
140–250 MBq. FET uptake was measured on PET images
acquired from 50 to 60 min after tracer injection [11].
Data analysis
Quantification of PET and MR data was done using PMOD
[12] on digitized images as described in detail in our recent
publication [13]. For calculation of the MR tumor volume
we used the FLAIR sequence which provides the best
delineation between tumor and adjacent brain [3, 14].
Following manual outlining of the tumor boundaries the
areas of all tumor containing MR slices were summed up to
yield the whole tumor volume. For quantification of the
FET PET data the cerebellum was used as reference region.
Regions of interest (ROI) covering the whole cerebellum
were drawn for each slice. The ROI counts of all PET
slices which contained the cerebellum were then averaged
to produce the mean cerebellar FET uptake (counts). For
tumors two measures were calculated. First, the ‘active
volume’ (ccm) was quantified as the tumor volume con-
taining pixels [110% of the mean cerebellar FET uptake.
This threshold corresponds well to the visual impression of
active LGG [13, 15]. Second, the tumor FET uptake
(counts) of the active volume was normalized to the mean
FET uptake of the cerebellum (T:CBL ratio, unit-less).
This uptake ratio is routinely used in nuclear medicine, and
is robust with regard to intra- and inter-individual com-
parisons. For the one patient who showed no active FET
tumor volume (#10) the T:CBL ratio was calculated using
the tumor area derived from the MR FLAIR images. As
TMZ-induced reductions of FET uptake were better
detectable by active volumes than by T:CBL ratios, we
defined treatment response as a C10% reduction of the
initial tumor volume (active PET, MR FLAIR) on at least
two subsequent time points after the initiation of chemo-
therapy. Defining treatment response as a 20% volume
reduction produced the same number of metabolic, but a
lower number of MR responders. The Spearman rank test
(SPSS, version 10.0.7) was applied to test whether baseline
tumor FET uptake, or metabolic responses during treat-
ment, were correlated with treatment response on MR.
Results
In total 172 cycles of TMZ were administered (mean 16,
range 6–24 per patient). The initially scheduled TMZ dose
could be maintained in 9 patients, in the two other patients
the dose had to be reduced by 20% and 30% respectively due
to hematotoxicity (CTCAE v3.0, grade 2 and 3). In group A 3
patients completed 4 follow-up PET-MR scans, 3 patients
completed 3 scans, and 2 patients completed 1 scan. In group
B each 1 patient completed 4, 3, and 2 follow-up scans.
Tumor volumes
At baseline a variable active FET tumor volume was found
in 10/11 patients (range 6–273 ccm). This is line with earlier
reports which describe a lack of increased amino acid uptake
in a proportion of LGG [16]. The absolute numbers of the
baseline active FET and MR volumes are presented in
Table 1. Overall 8/11 patients were metabolic responders.
Among these only five patients also showed a MR volume
response (Table 1). Examples of individual responses are
presented in Figs. 1 and 2. At three months 2/3 patients
(group B, #1, 5) showed a substantially reduced active FET
volume (38% and 49% of baseline volume), whereas no MR
volume change was observed. In one patient the metabolic
response persisted until 15 months (#5, Fig. 1c and bottom
Fig. 2). At that time also a small volume response was noted
on MR (90% of baseline). In group A patients (first follow-
up study at six months) 6/8 patients showed a reduced active
FET volume (range 7–71% of baseline volume). At that time
4/8 MR volume reductions were observed. The delay
Fig. 1 Treatment responses of MR FLAIR (square) are compared with the active FET tumor volume (triangle) in patient #4 a, #3 b, and #5 c. C:
the increase of the active FET volume at 21 months was associated with tumor progression to anaplastic oligoastrocytoma WHO III
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between FET and MR volume reductions is illustrated in
Fig. 3. Whereas the maximal reduction of the active FET
volume was observed between 3 and 12 months (8.0 ± 4.4,
mean ± SD), the delay to maximum MR volume reduction
was 15.0 ± 3.0 months. The best FET response reached a
mean of 31 ± 23% from baseline (Table 1), whereas the
best volume response on MR reached a mean of 73 ± 26%
from baseline.
Uptake ratios
The range of baseline FET T:CBL ratios was 1.10–1.64
(Table 1). In responders the maximal reduction of FET
uptake ratios was 76% from baseline. Similar to the active
volume the maximal response of FET uptake ratios was
reached until 12 months.
Response prediction
Before treatment neither the active tumor volume nor the
uptake ratio predicted the response to TMZ chemotherapy
(Spearman rank P [ 0.68). However, the FET volume
response measured at the time of the first follow up study
correlated with the best MR volume response obtained later
during the course of chemotherapy (Spearman Rank 0.731,
P = 0.01, Fig. 4). Vice versa, patients who did not show a
reduction of the active FET volume in their first follow up
study also did not show PET or MR responses at later time
points. With regard to tumor histology 6/7 oligodendroglial
tumors showed a FET volume response, and 5/7 a MR
Fig. 2 Top: Patient #3
(Fig. 1a). Imaging studies were
done before (left), and 6, 12, 18,
24 months after initiation of
chemotherapy. Bottom: Patient
#5 (Fig. 1c). Imaging studies
were done before (left), and 3,
9, 15, 21 months after initiation
of chemotherapy. At the time of
clear metabolic tumor
progression (21 months) a small
increase of the MR FLAIR
tumor volume was noted
compared to the volume at
15 months (25 vs. 21 ccm). No
tumor gadolinium enhancement
was observed. The increase of
the active FET tumor volume
(27.8 vs. 6.5 ccm) was
paralleled by an increase of the
FET uptake ratio (1.98 vs. 1.51)
which is compatible with
progression from WHO II
towards WHO III. The color
scale represents the
tumor:cerebellum uptake ratio
Fig. 3 The time course of FET (triangle) and MR (square) volumes
in metabolic responders is plotted until tumor progression or study
termination (n = 8, mean ± SEM). Follow up data points: group B at
3, 9, 15 months (n = 2, 2, 1 patients), group A at 6, 12, 18, 24 months
(n = 6, 5, 4, 3 patients)
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volume response. 2/4 fibrillary astrocytomas showed a FET
volume responses in the absence of any MR volume
response. The magnitude of metabolic responses did not
correspond to the duration of chemotherapy.
Clinical follow up, tumor progression
A clinical benefit emerged for two patients which were
seizure-free after four and six months of chemotherapy
respectively. Those patients with PET and MR responses
showed the longest progression-free survival (PFS;
38 ± 3 months). At the time of last follow up 3/8 meta-
bolic responders were still free of progression. In patients
without MR response variable PFS periods were noted
(15 ± 8 months). 5/8 metabolic responders progressed
19 ± 7 months after initiation of chemotherapy. Four
progressive patients underwent re-operation between 6 and
21 months after initiation of chemotherapy, which yielded
unchanged histology (#8), anaplastic oligoastrocytoma
WHO III (#5), anaplastic astrocytoma (#9), and glioblas-
toma WHO IV (#2). In those three patients with progres-
sion towards WHO grade III or IV a prominent increase
particularly of the uptake ratio was observed (1.98, 1.37,
1.69 compared to an uptake ratio of 1.24, 1.24, 1.16 at best
response). Also the active FET volume increased (28, 47,
23 ccm compared to 6, 3, 8 ccm at best response). This is
examplified by Fig. 1c and bottom panel of Fig. 2.
Discussion
LGG tend to grow slowly. A mean tumor diameter increase
of 4.1 mm per year was reported in oligodendrogliomas or
mixed gliomas on serial MR [17]. TMZ chemotherapy
reversed this increase and led to an average tumor diameter
decrease of 9.1 mm per year in one series [18]. The key
finding of our study is that a substantial proportion of
patients initially showing stable MR volumes are ‘early’
metabolic responders during chemotherapy, and that met-
abolic responses are more pronounced than MR volume
responses. Of note none of the patients included in our
series showed blood-brain barrier disruption as revealed by
gadolinium enhanced MR. Interestingly, not only oligo-
dendroglial tumors but also fibrillary astrocytomas showed
metabolic responses, which preceded MR volume reduc-
tions by several months. These responses were particularly
evident from the reduction of the active FET tumor vol-
ume. In contrast, the uptake indices (T:CBL ratios) in
responders decreased only slightly. This suggests a
decrease in tumor cell density, and indicates that the
residual viable tumor has a metabolic activity similar to the
untreated tumor, which is compatible with an unchanged
histology and WHO tumor grade during chemotherapy.
Discrepancies between changes in amino acid uptake
(C-11 methionine) and MR volume reductions were also
reported in pure oligodendrogliomas WHO II [15]. That
study addressed the magnitude of metabolic and MR
volume response after completion of 4–6 cycles of PCV
chemotherapy, and also found that responses are more
pronounced on metabolic compared to MR imaging. Var-
ious other treatment modalities also produced reductions of
amino acid uptake in LGG (radio-chemotherapy [19],
external beam radiotherapy [20], interstitial brachytherapy
with I125-Iodine seeds [21]). Extrapolating our data in
responding patients toward earlier time points (Fig. 3)
suggests that metabolic responses may be observed as early
as one month after treatment initiation. Vice versa we also
found that tumor progression was earlier evident on met-
abolic imaging compared with MR (Fig. 1c and bottom
Fig. 2). Our data therefore underline the role of PET
imaging with amino acids as a sensitive tool for early
response assessment in LGG.
Upregulation of amino acid transporters in human
astrocytomas can be demonstrated by immunohistochem-
istry and correlates with the WHO grade [22, 23]. In
accordance, increased amino acid transport as measured in
vivo with PET also correlates with the WHO grade of
gliomas [24, 25]. The importance of amino acid transport
for tumor growth is illustrated by experiments which show
that specific transport inhibitors produce a rapid suppres-
sion of cell growth, and prolong survival of rats treated
with C6 glioma cells [22]. Also successful chemotherapy
with the alkylating agent TMZ decreases amino acid
transport as shown in our study. As long as amino acid
transport was deactivated no tumor progression was evi-
dent. Moreover, volume expansion on MR as sign of tumor
Fig. 4 The metabolic response at the first FET PET follow up
(DBaseline FET—first FET response (%)) is plotted against the best
MR volume response (DBaseline MR—maximum MR response (%)).
Circles: metabolic responders, triangles: non-responders. In non-
responders the MR volume at the last MR scan is taken
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progression was paralleled by substantially increased
amino acid transport (Fig. 1c and bottom Fig. 2). These
findings suggest that tumor growth in LGG is maintained
by amino acid supply and does not escape towards other
metabolic pathways.
With regard to identify patients who benefit from
treatment the prediction of treatment response in individual
patients would have major impact on patient care. Several
studies suggested that histological features of LGG
(fibrillary astrocytoma versus oligodendroglial tumors) and
molecular profiles (e.g. status of loss-of-heterozygosity,
LOH, on 1p/19q, methylation of O6-methylguanine-
methyltransferase, MGMT) are associated with treatment
response and survival. In individual patients, however,
treatment response cannot be predicted yet [26, 27], and
molecular markers are not implemented into clinical
practice. Actually our data may lead to the concept that
individual patient management should be optimized by
early response identification in addition to response pre-
diction. We clearly demonstrate the advantage of molecu-
lar over structural imaging in LGG particularly with regard
to the time window (Fig. 3). FET PET data may therefore
assist to define the maximal duration of chemotherapy. Due
to our small sample size we cannot draw final conclusions
as to whether the magnitude of PET and MR responses
relate to the subsequent clinical course and to the time until
tumor progression. This has to be addressed in larger
prospective studies. We conclude that the early identifica-
tion of non-responders will help to minimize any negative
impact of chemotherapy on quality of life. Finally, indi-
vidually optimized treatment will also have economical
impact since the costs of PET imaging must be weighted
against the expenses of chemotherapy and the management
of adverse effects.
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